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Herbal formulations claimed to cure several medical conditions including skin 
eruptions, chest pains, wounds, gout, menstrual pains, stress, nervous disorders, 
microbial and viral infections as well as stomach ailments have recently appeared as 
part of South African traditional medicine. The formulations consist of mixtures of 
extracts of different plant parts from several different plant species packaged in 
labelled bottles or boxes. The mixtures are available for sale in herbal shops and 
public places. While there has been widespread use of these herbal mixtures, there 
has been no scientific evidence to support their use. This project was aimed at 
documenting, validating claimed efficacy and testing the safety of fourteen 
unregistered commercial herbal preparations commonly sold in Pietermaritzburg. A 
detailed investigation of the pharmacological effects and safety of the plant 
components of one of the mixtures, Imbiza ephuzwato was also carried out.  
 
Fourteen commercial herbal preparations, Umzimba omubi, Umuthi wekukhwehlela 
ne zilonda, Mvusa ukunzi, Umpatisa inkosi, Imbiza ephuzwato, Vusa umzimba, 
Ingwe® traditional muthi mixture, IbhubeziTM, Supreme one hundred, Sejeso herbal 
mixture Ingwe®, Lion izifozonke Ingwe®, Stameta™ BODicare®, Ingwe® special muti 
and African potato extractTM were evaluated for activities against Gram-positive 
(Bacillus subtilis and Staphylococcus aureus), Gram-negative (Escherichia coli and 
Klebsiella pneumoniae) bacteria and the fungus Candida albicans using the 
microdilution assay to obtain minimum inhibitory concentrations (MIC) and minimum 
fungicidal concentrations (MFC). Imbiza ephuzwato, Ibhubezi™, Sejeso herbal 
mixture and Ingwe® special muthi, which are multipurpose mixtures showed high 
antimicrobial activity ranging from 0.39 to 0.78 mg/ml. The fourteen herbal 
preparations were also evaluated for their ability to inhibit cyclooxygenase (COX-1 
and COX-2), HIV-1 reverse transcriptase (RT) and acetylcholinesterase (AChE) 
enzymes. Imbiza ephuzwato, Sejeso herbal mixture Ingwe®, Lion izifozonke Ingwe®, 
Ingwe® muthi mixture and African potato extractTM showed consistent potent 
activities against the four enzymes. Umzimba omubi, Umuthi wekukhwehlela ne 
zilonda, Mvusa ukunzi, Umpatisa inkosi, Imbiza ephuzwato, Vusa umzimba, 
Supreme one hundred, Sejeso herbal mixture Ingwe® and Ingwe® special muti 
exhibited high antioxidant properties in the DPPH (2,2–diphenyl–1–picryl hydrazyl) 
viii 
 
radical scavenging assay, ferric-reducing power assay and the ability to delay or halt 
the bleaching of β-carotene-linoleic acid in a model system. Phytochemical analysis 
revealed high total phenolic compounds, gallotannins and condensed tannins and 
lower levels of flavonoids in Ingwe® special muti, Ibhubezi™ and Stameta™ 
BODicare®. Imbiza ephuzwato exhibited high flavonoid concentrations and less total 
phenolic compounds, condensed tannin and gallotannin. Thin layer chromatography 
(TLC) was used to investigate the chemical profiles of each of the fourteen herbal 
preparations. It was not surprising to note that Ingwe® muthi mixture, Sejeso herbal 
mixture Ingwe®, Lion izifozonke and Ingwe® special muti showed similar chemical 
profiles as shown by their TLC profiles. The neutral red uptake inhibition bioassay in 
human liver (HepG2) cells was used to assess potential toxicity of the commercial 
herbal preparations. The results revealed that the most toxic herbal mixture was 
Umpatisa inkosi, with a 50% inhibition of neutral red uptake (NI50) value of 0.016 
mg/ml. The least toxic herbal preparation was Stameta™ BODicare® with an NI50 
value of 28.00 mg/ml. The Ames test results revealed that all fourteen herbal 
preparations were non-mutagenic towards the Salmonella typhimurium strains TA98, 
TA100, TA102, TA1535 and TA1537 without metabolic activation. However, five of 
the fourteen herbal mixtures (Umpatisa inkosi, Imbiza ephuzwato, Vusa umzimba, 
Stameta™ BODicare® and African potato extractTM) showed indirect mutagenic effect 
toward the tester strain TA98 after metabolic activation.  
 
A detailed study was done on one of the herbal mixtures, Imbiza ephuzwato which 
had shown consistent activities in the bioassays performed. The petroleum ether 
(PE), dichloromethane (DCM), 80% ethanol (EtOH) and water extracts of the 21 
plants used to make Imbiza ephuzwato herbal mixture were evaluated against two 
Gram-positive and two Gram-negative bacteria, Candida albicans, inhibitory effects 
against COX-1 and -2 as well as AChE enzymes. Gunnera perpensa rhizomes and 
Rubia cordifolia roots were the only plant species used to manufacture Imbiza 
ephuzwato that had water extracts which showed good antimicrobial activity. 
 
The water extracts of Hypericum aethiopicum leaves, Gunnera perpensa rhizomes, 
Drimia robusta bulbs, Vitellariopsis marginate roots, Scadoxus puniceus bulbs and 
Momordica balsamina leaves at a final concentration of 2 mg/ml, had over 70% 
inhibition of COX-1. For COX-2 enzyme, the water extracts of Gunnera perpensa 
ix 
 
rhizomes, Cyrtanthus obliquus bulbs, Momordica balsamina leaves and Tetradenia 
riparia leaves at a final concentration of 2 mg/ml exhibited inhibitory activity above 
70%. Water extracts of Gunnera perpensa rhizomes, Cyrtanthus obliquus bulbs, 
Vitellariopsis marginate roots, Asclepias fruticosa roots and Watsonia densiflora 
corms showed good AChE inhibitory activity (> 80%). 
 
The Ames test results revealed that all the water extracts of the 21 plant species 
used to make Imbiza ephuzwato were non-mutagenic towards the Salmonella 
typhimurium strain TA98 for the assay with and without S9 metabolic activation. The 
results obtained in this study reveal high levels of pharmacological activities by most 
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1.1. Traditional Medicine 
 
Throughout history people had to take measures to cope with health challenges such 
as respiratory ailments, coughs, colds, intestinal disorders, headaches, skin 
infections, wounds, burns, cuts, snakebites and insect bites using available 
resources such as herbs, marine organisms and other animal products. The way 
these communities prepared healing remedies formed an information reservoir that 
was passed from generation to generation (PUJOL, 1990; LIU, 2005). A large 
number of studies have so far been conducted on the traditional usage of plants and 
resulted in the isolation of bioactive compounds for use in western medicine (GILANI 
and RAHMAN, 2005; PATWARDHAN, 2005; VAN VUUREN, 2008). 
 
The emergence of drug-resistant infectious bacteria, viruses and parasites has 
resulted in the growing interests in medicinal plant research to search for new leads 
for modern medicine. The numerous plant extracts that have been and are currently 
used safely by communities throughout the world have become a source of hope in 
the discovery of new and effective remedies (GRAYBILL, 1996; BODEKER, 2004; 
LEUNG, 2004). 
 
Traditional medicine encompasses health practices, approaches, knowledge, and 
beliefs incorporating plant, animal and mineral based medicines, spiritual therapies, 
manual techniques and exercises, applied singly or in combination, to treat, 
diagnose and prevent illnesses or maintain well-being (WHO, 2001).  
 
1.2. African Traditional Medicine in South Africa 
 
In southern Africa, the local communities, mostly those who dwell in communal 
homesteads are truly the masters of nature, deriving most of their medicine, 
nutritional and material resources from indigenous vegetation (PUJOL, 1990). They 
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make sleeping mats and baskets from grass and reeds. They believe strongly that 
plants are powerful sources of healing remedies.  
 
According to the DRAFT NATIONAL POLICY on African Traditional Medicine for 
South Africa (ATMSA) (2008), „African Traditional Medicine (ATM) is a body of 
knowledge that has been developed and accumulated by Africans over tens of 
thousands of years, which is associated with the examination, diagnosis, therapy, 
treatment, prevention of, or promotion and rehabilitation of the physical, mental, 
spiritual or social wellbeing of humans and animals.‟ While Chinese Traditional 
Medicine (CTM) is centred on the „yin-yang‟ theory which states that every human 
being is under three different axes of balance, i.e. balance between „heat and cold‟, 
between the „surface and depth,‟ between „emptiness and fullness‟ (LEUNG, 2004), 
ATM is driven by the spirit of „ungumuthu ngabantu‟ i.e. the essence of being human, 
open and available to others, affirming of others, and not being threatened. 
 
The application and philosophy of ATM in different tribal communities of Africa, 
including South Africa is essentially the same.  Sickness or diseases are believed to 
be caused by supernatural powers through spiritual entities, ancestral spirits, living 
people, animals, plants and „pollutants‟. Ingredients obtained from animals, plants 
and administered by a chosen medium can restore health and therefore have 
medicinal properties (KALE, 1995). In ATM, the term „disease‟ refers more to 
symptoms than a disease entity. The healer controls symptoms with different means 
but not for a specific disease. In most cases, the healer lacks the exact pathology 
and sequence of events in illness. The healer can therefore treat only symptoms 
(LEUNG, 2004). 
 
In Zulu communities, the traditional herbalist (Inyanga), who has the knowledge of 
herbal healing, is the one who takes care of the health of the community. Modern 
herbalists now spend most of their time learning and acquiring knowledge in herbal 
medicines while dealing with both human and livestock ailments. In traditional 
communities, an ill person generally has four options for their health care 
(MARSLAND, 2007). Firstly, they can opt for self care which involves self treatment 
using information that is passed on from generation to generation within families and 
communities. Secondly, they can ask help from family heads where the elders will 
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use their experience in treating several conditions. The third option is to consult a 
traditional healer such as an Inyanga while the fourth option is to go to a modern 
clinic or hospital (PUJOL, 1990). 
 
In these communities, modern clinics and hospitals are in many cases the last option 
when dealing with illness. Most people when they cannot self-treat seek relief from 
an Inyanga and when „bewitchment‟ is suspected, the patient is referred to a spiritual 
healer (Sangoma). Bewitchment is the unusual illness that is believed among black 
African cultures as inflicted by a person who has been offended by a victim‟s 
behaviour and/or success (DOUGLAS, 1999). The Sangoma uses various forms of 
divination to find the root cause and ultimately the cure of the illness. These include 
„throwing of bones‟ or going into a trance and in some cases rituals and sacrifices 
can be performed to appease ancestors (amadlozi) who are also believed to cause 
illness in the case of sexual infidelities, violations of taboos, lack of ritual 
observances, and general breakdown in traditional family life that accompany 
urbanisation (PUJOL, 1990). 
 
This intricate bond shows that traditional medicine is part of African culture, enabling 
the local people to guard themselves against diseases and alleviating them from 
suffering. 
 
1.3. Modernization and commercialization of ATM in South Africa 
 
In the late nineteenth century, during colonialism, the conversion to Christianity and 
the rise in capitalism saw the introduction of modern medicine, which makes use of 
health care systems based on science and technology (PRETORIUS et al., 1993). 
Since then, Inyangas and Sangomas were regarded as „witchdoctors‟ who took 
advantage of the ignorance of the uneducated rural communities (RAPPAPORT, 
1980). Despite this, modern medicine has not managed to completely replace ATM. 
Traditional medicine will continue to be the priority for most African populations 
mainly because it is accessible, affordable, acceptable and dependable (NCHIDA, 
1976; WHO, 2001). Furthermore, modern medicine is in some cases regarded as 
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culturally irrelevant and ill-suited in dealing with some complicated illnesses amongst 
African populations (CHAVUNDUKA, 1994). 
 
In South Africa, there exist about 200 000 practising traditional healers, compared  to 
25 000 certified doctors practicing in modern medicine. About 80% of the black 
population in South Africa use the services of these traditional healers, while 60% of 
babies are delivered by traditional attendants (KARIM et al., 1994). Thus one can 
understand how traditional healers can withstand the competition from modern 
medicine. Traditional healers are enshrined in the minds of the people and respected 
in their community (KALE, 1995). 
 
However, according to the SUPPRESSION OF WITCHCRAFT ACT (1957) 
(amended in 1970), traditional healers were banned in South Africa but this 
represents an example of a law that exists only on the statute books as many 
organizations freely exist. These organizations include: the Southern African 
Traditional Healers Council, the Association of Traditional Healers of Southern Africa, 
the Congress of Traditional Healers of South Africa, the African Dingaka Association, 
and the African Skilled Herbalists Association (ASHFORTH, 2005). 
 
It was expected that the use of traditional healers will diminish as people becomes 
urbanized and the youth become westernised. Instead the influence of traditional 
healers runs deep within the black people‟s cultures (SHERRIFS, 1996). DE JONG, 
(1991) reported that educated black people living in urban areas continue to use 
traditional healers for their primary health care. It is surprising to note that the 
demand for traditional healers could even increase with modernization since they 
become skilled in helping people to cope with the stress associated with current 
globalization (HARDON et al., 2008). Despite western based modernization and 
urbanization, MARSLAND (2007), reported that ATM is not merely a rural 
phenomenon but also an urban phenomenon increasing in frequency in both rural 
and urban black communities.  
 
However, with rapid globalization there have been notable changes in the operation 
of ATM. With education, as people get involved in modern occupations, particularly 
the youth, traditional healers and herbalists are also evolving in order to 
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accommodate such social changes. Furthermore, the widespread use of internet, 
televisions, radios, newspapers and formation of social groups has offered traditional 
healers and herbalist a new platform for commercialization of ATM (BONORA, 
2001).  
 
The evidence of commercialization of ATM is found in the prevalence of medicinal 
plant (muthi) trade in urban areas of South Africa. The ATM being practiced in urban 
areas does not differ with the practices used in rural areas as it also deals with both 
the so-called natural diseases (colds and headaches) and the supernatural diseases 
(witchcraft related and ancestry displeasure) (BONORA, 2001). The term ‘muthi’ 
refers to substances, in most cases plant material, prepared and administered as an 
aid to patients in distress by an experienced or trained traditional healer. Most 
healers or herbalists claim to possess secret knowledge regarding the mixing and 
administering of effective muthi to achieve positive healing powers (ASHFORTH, 
2005). 
 
Several activities in the name of ATM can be identified in almost every town or city in 
South Africa, including traditional medicinal plant gatherers, herbal shops (muthi 
shops), herbal pharmacists, herbal hawkers, herbal wholesalers (DAUSKARDT, 
1990; BONORA, 2001), and recently herbal product processors and distributors. 
Figure 1.1A shows a typical herbal shop commonly found in both rural and urban 
areas; Figure 1.1B represents an urbanised herbal shop with mostly processed 
herbal preparations instead of the plants while Figures 1.1C and D represent a 



























Figure 1.1: (A) Traditional herbal shop with dry plant materials on the shelf, (B) traditional 
urbanized herbal shop with plant material replaced by commercial herbal preparations 
alongside statues of Gods, candles decorated with lucky charms, and other items showing 
the blending of African Traditional Medicine (ATM) and Hinduism in Pietermaritzburg, (C) 
traditional open herbal market, (D) modernized herbal market (Nongoma, Zululand) with 
packaged herbal preparations dominating the products on sale. 
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It is estimated that over half a million people in both rural and urban areas are 
involved in the herbal trade in South Africa resulting in 525 tonnes of plant materials 
valued at 3.4 million USD being traded annually (MANDER, 1998; DOLD and 
COCKS, 2002). In the province of KwaZulu-Natal only, about 6 million people are 
known to be involved in the trade of indigenous medicinal plants either by selling or 
buying (MANDER, 1998). 
 
It can be deduced that for such a huge traditional medicine trade to be present within 
urban areas, there has to be a great demand for such services. Urbanization and 
movements of people to informal settlements has introduced a range of traditional 
activities in the cities which subsequently became informal employment 
(DAUSKART, 1990). Most households in South Africa spend between 4 to 6% of 
their annual income on ATM and services (MANDER, 1998). As a result, the herbal 
trade has become a way of generating an extra income for most households. 
However, this has caused what is now an illegal plant trade and smuggling problem. 
 
Such demand has also brought about competition amongst herbalists. The 
competition is so intense that even in the streets of urban towns, for example 
Pietermaritzburg, the capital of KwaZulu-Natal, different posters and pamphlets 
adverting herbal products and services are handed out to people in the streets. 
Figure 1.2 shows examples of some of the pamphlets. Besides pamphlets, 
advertisements of herbal products in newspapers, television and radio have also 
increased as a result of the competition. The pamphlets advertise services such as 
the protection of houses and cars as well as lucky charms for increasing chances of 
winning gambling games such as lotto and others offered at social establishments 
such as casinos using herbal medicines. Besides lucky charms, the pamphlets 
advertise services such as business attraction, job recovery and even promotion at 
work. There are however, some potentially dangerous and harmful services that are 
also advertised, such as abortion, „short boys for money‟ (tokoloshes- zombie like 
creatures made from dead human beings) and „hiring of magic sticks‟ (Figure 1.2). 
Such services have led to a negative stigma that is now being associated with 
traditional medicine in South Africa.  This is unfortunate as these services are most 
likely the work of a group of money-hungry con-artists (umthakathi) who are 
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responsible for the numerous „muthi-motivated‟ killings (the use of human remains) 
in ATM. The umthakathi’s intention is not to heal but rather to destroy. 
 
The pamphlets have the contact information of the service provider such as the 
address where the consultations are done, business phone and cellular-phone 
numbers and/or street directions. Most of the pamphlets have names of the 
herbalists and in most cases with dubious titles such as ‘Dr’ or ‘Prof.’ (Figure 1.2). 
Some of the names on the pamphlets are not of Zulu origin. For example one of the 
pamphlets in Figure 1.2 has „Dr Shaban and Mama Aminah‟ as the herbalists, both 
of which are not Zulu names. This also shows that ATM is slowly being blended with 
other cultures such as Hinduism and Muslim practices as well as other North African 
cultures. 
 
Figure 1.3 shows a newspaper cutting advertising a special sale of two commercial 
herbal mixtures (Stameta and Uzifozonke) in KwaZulu-Natal. Internet websites also 
offer much information about herbal products, but most are directed toward 








































Figure 1.2: Examples of pamphlets handed to people in the streets of 
Pietermaritzburg, KwaZulu-Natal. The pamphlets advertise a range of services 













Figure 1.3: A newspaper cutting advertising special offers for two popular herbal 
mixtures amongst other products in KwaZulu-Natal: Stameta and Uzifozonke 
(highlighted), both commercialized multipurpose herbal mixtures. Values of products 




1.4. General aims and objectives 
 
This project was aimed at documenting and evaluating claimed efficacy and safety of 
herbal mixtures manufactured by private entrepreneurs and commonly sold in herbal 
shops in KwaZulu-Natal. Commercial herbal mixtures, known locally as muthi 
concoctions provide a new facet and a monumental step in modernization and 
commercialization of ATM in South Africa. The doubtful efficacy, hygiene and safety 
of herbal products used in ATM are a concern as they are manufactured and sold on 
pavements and in open markets where the materials are often exposed to 
contaminants, in contrast with pharmaceutical manufacturing standards which are 
necessary for the production and packaging of such products. However, such 
mixtures may contain considerable amounts of active/lead pharmacological 
compounds. The finding of this study will help in the documentation and the long 
term understanding of traditional herbal mixtures as well as their efficacy and safe 
usage. The project will also offer a stepping stone for policy makers on the way 
towards regulating the manufacturing and selling of herbal mixtures/preparations in 
South African, a country undergoing rapid social changes and trying to keep pace 






Commercial Herbal Mixtures/Preparations 
2.1. Introduction  
 
The evolution of traditional medicines reflects a paradigm shift from using single 
agents (herbs, minerals and animals) to combining them to generate new herbal 
mixtures (KONG et al., 2009). Initially, several centuries ago, traditional remedies 
consisted of only single agents (ZHANG, 1993). With the accumulation of 
therapeutic experience, traditional healers realized that combining diverse natural 
medicines to constitute a mixture could effectively enhance the therapeutic effects 
(KONG et al., 2009). This chapter examines and documents the prevalence of 
commercial herbal mixtures and preparations common in Pietermaritzburg, KwaZulu-
Natal (Table 2.1). Different types of herbal mixtures and their claims will be 
discussed. Methods of preparation, advantages and disadvantages as well as the 
way forward in ensuring safety and efficacy of this new aspect of South African 
traditional medicine will be highlighted. 
 
The use of herbal mixtures as part of traditional medicine has increased over the last 
decade. In 1997, an estimated 12% of the world population used over-the-counter 
herbal products and herbal therapy has since become popular. This has resulted in 
an estimated world market of 10 billion USD in the commercial herbal industry, with 
an annual growth of 6.5% (RATES, 2001; ASHAR and DOBS, 2004). The WHO has 
since incorporated phytotherapy in its health programmes and calls for basic 
procedures for the validation of plant derived products (WHO, 2001). In ATM, many 
healers rely not only on single plant extracts for healing but often combine various 
plant parts and even different species to make herbal mixtures, in the belief that 
efficacy may be increased. 
 
Herbal preparations, in most cases are mixtures of selected medicinal plants or plant 
parts used to treat specific heath conditions including natural and spiritual diseases. 
Plant parts such as leaves, flowers, tubers, bulbs and/or roots from different plant 
species in specific proportions based on the desired function of the herbal product 
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are used. The mixtures could be simple, commonly known home remedies used to 
treat minor illnesses (such as colds, headaches, stomach pains and menstrual 
pains) or could be complex preparations often used for life threatening diseases 
(PUJOL, 1990; RATES, 2001; CANO and VOLPATO, 2004). 
 
2.2. Herbal mixtures in South Africa 
 
Apart from the small scale use of herbal mixtures in ATM, there has recently been 
appearance in shops, pharmaceuticals and supermarket shelves of different 
informally „patented‟ preparations, manufactured by private entrepreneurs making 
numerous claims to the efficacy of their products. The mixtures usually take the form 
of dark brown brews, in 500 ml to 1 litre labelled bottles, coloured solids or capsules. 
The mixtures represent something in-between ATM and western medicine. The 
recipes and preparations are of ATM origin while the packaging and presentations 
are western, but they lack safety and quality controls.  
 
Consumers seek natural therapies mostly with the hope that plant products will 
sustain or restore health, even though health care practitioners and health authorities 
do not always believe in such products (RATES, 2001). The other reasons for 
acceptance of herbal preparations include the perception that natural products 
represent purity, simplicity and safety which in some cases may be far from the truth 
(TANKO et al., 2005).  
 
Some herbal mixtures are manufactured in small quantities by informal street 
traders, market traders or individual traditional healers and are mostly packaged in 
recycled bottles. Most of the herbal mixtures on sale in shops are professionally 
manufactured in large quantities by private entrepreneurs in factories to produce 
packaged and labelled products. Table 2.1 documents some of the common herbal 
mixtures sold in Pietermaritzburg, KwaZulu-Natal including the manufacturer‟s 
details, medicinal uses and other information printed on the labels. Table 2.2, taken 
from MANDER et al. (2007), lists numbers and types of formal as well as informal 
sector role players in the ATM industry in South Africa. Figure 2.1 presents some of 
the common herbal mixtures/preparations sold in shops around Pietermaritzburg. 
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Manufacturer details Medicinal uses and ingredients  
(as listed on the label) 
Directions of use 
Packaging 
Shelf life 
African potato extract- 




Ngwenya quality product 
P.O. Box 747, Germiston 1400 
Used to boost the immune system and treatment of 
HIV/AIDS symptoms. 




Dr  L. Bhayu 
C 188 Umzomusha, Danisa 
Rd, Inanda 4310 
Mobile: 0768026451 
Used to relieve: Blood pressure, period pain, 
HIV/AIDS, swollen body or legs, kidney infections, 
back pain, sores, rash, diarrhoea and chickenpox. 
Also helps to improve appetite. 
4 teaspoons every morning, 
afternoon and evening. 
1L 
Ibhubezi™ Pharmachem 
Pharmaceuticals, Private Bag 
X12, Pretoria West 0117 
Used for wounds, fungal infections, STDs, treatment 
of influenza, to reverse impotence, clean the body 
system and stimulate blood production. 
 
¼ cup twice a week. Not for 
children under 14 years of age 
and pregnant women. Shake 
well before use. 
500 ml 
6 months 
Imbiza ephuzwato Kwa Nyanga Yezizwe, 117 
Retief Street, Pietermaritzburg 
Tel: +2733 3942570 
A detoxifying and energising tonic used to increase 
sexual prowess, relieve constipation, reduce stress, 
reduce high blood pressure, clear skin conditions, 
boost energy, boost vitality, helps to prevent arthritis, 
kidney problems and relieve general body pains. 
¼ cup in the morning after 









Used to relieve: „hangover‟, ulcers, skin eruptions, 
blood pressure, asthma, gout and stress. Also used 
to increase CD4 count, reduce viral load, clean blood 
and increase sex drive. Contains Sutherlandia, Aloe 
extracts, African potato, fortified with vitamin B and 
C. Also contains brewer‟s yeast. 
 
6 teaspoons in the morning 
and afternoon before meals. 
Not for pregnant women. 
Shake well before use. 
1L 
 
Ingwe muthi mixture 
Ingwe® 
AMM 0011 
Guideline Trading, P.O. Box 
136701, Alberton North 1456 
Tel: +2711 9070707 
A traditional African mixture for chest 
Infections, STDs, arthritis, heart burn, relieving 
constipation and increasing sexual prowess. 








Manufacturer details Medicinal uses and ingredients  
(as listed on the label) 





Ingwe special muti 
Ingwe® 
AMM 003 
Guideline Trading, P.O. Box 
136701, Alberton North 1456 
Tel: +2711 9070707 
sales@guidelinetr.com 
www.guidlinetrading.co.za 
Used for alleviating menstrual pain, general pain.   Take one 5 ml teaspoon in hot 
water or with tea every 
morning until the course is 
finished.  Not for children 






Guideline Trading, P.O. Box 
136701, Alberton North 1456 
Tel: +2711 9070707 
sales@guidelinetr.com 
www.guidlinetrading.co.za 
Used for chest infections, STDs,  arthritis, heart burn, 
relieving constipation and increasing sexual prowess. 
¼ cup three times a day after 
meals. Not to be taken by 
children and  pregnant women. 
500 ml 
6 months 
Mvusa ukunzi Kwa Nhlanhla, Indlu Yemithi, 
Pietermaritzburg 
A „man tonic‟ for increasing sexual prowess and can 
be used as an energiser. 
Not on label. 
500 ml 
 




Ngoma Natal, P.O. Box 
11730, Dorpspruit 3200, South 
Africa 
Tel: +27797001370 
Used as an immune booster, against diabetic and 
blood pressure conditions. Ngoma is also used for 
the relief of stomach ailments, arthritis, hypertension, 
stress and influenza. Contains Sutherlandia, 
Echinacea sp., Dandelion sp., Alfalfa sp., Aloe ferox, 
Harpagophytum sp. and 13.5% alcohol. 
1 tablespoon in the morning, 
evening after meals. Shake 
well before use. Not to be 
taken by children under 6 












Used for treatment of HIV Aids symptoms, high blood 
pressure, period pain and cancer. 
5 tablespoons per day for 
persons aged 13 years and 
over. 
500 ml 
Sejeso herbal mixture 
Ingwe ® 
AMM 005 
Guideline Trading, P.O. Box 
136701, Alberton North 1456 
Tel: +2711 9070707 
Used to relieve heartburn, constipation, stomach 
ache, stomach cramps and indigestion. 
¼ cup three times a day after 
meals. Not to be taken by 
children and pregnant women. 






Manufacturer details Medicinal uses and ingredients  
(as listed on the label) 











P.O. Box 2545 
Florida 1710 
South Africa 
Used for nervous disorders, skin conditions, boosts 
sexual performance, poor blood quality, high blood 
pressure. Chest, lung and kidney infections. Fever 
and flu. Heart problems, back pain, persistent 
tiredness. Menstrual pain, cleans out bile, bleeding 
gums, body sores. Strengthens bones and boosts 
the immune system. 
½ or ¼ cup three or four times 
a week. Not for children under 
14 years of age and pregnant 
women. Drink water after 
using Stameta™. 
500 ml 




P.O. Box 2545 
Florida 1710 
South Africa 
Used for nervous disorders, skin conditions, 
stimulates blood production, boost sexual 
performance, treats back pains, fights influenza and 
strengthens the body. 
¼ cup every night before 
sleeping after meals. Not for 
children under 14 years of age 
and pregnant women. 
500 ml 
6 months 
Umpatisa inkosi Kwa Nhlanhla, Indlu Yemithi, 
Pietermaritzburg 
An „adult tonic‟ used for increasing sexual prowess, 
as an energiser also used to treat sexually 
transmitted diseases (STDs), to stop menstrual 
pains, increase appetite, treat high blood pressure 
and fight arthritis. 






Kwa Nhlanhla, Indlu Yemithi, 
Pietermaritzburg 
Used as a cough mixture, to treat chest infections 
and difficulty in breathing. 
Not on label. 
500 ml 
 
Umzimba omubi Kwa Nhlanhla, Indlu Yemithi, 
Pietermaritzburg 
Used to treat wounds, skin rashes, fungal infections 
and boils. 






Herbal solutions, P.O. Box 




Natural sex enhancer for men. The natural herbs 
contained in the mixture have long been used as 
tonics and aphrodisiacs. The mixture is a natural 
testosterone booster and increase sex drive and red 
blood cell production. Contains Aloe ferox, vitamins, 
trace elements, natural tribulus and is preserved in 
½ a cup twice a day before 
meals. Use on regular basis. 
500 ml 
6 months 
Table 1: continued 






Manufacturer details Medicinal uses and ingredients  
(as listed on the label) 
Directions of use 
Packaging 
Shelf life 
sodium benzoate & potassium sorbate. 








Used to treat diabetes, TB, kidney infections, 
arthritis, back pains, influenza, period pains, high 
blood pressure, ulcers, painful eyes, painful ears and 
diarrhoea. Also used for treatment of inflammation 
related conditions. Also used to boost erection and 
purify blood. 
¼ cup every morning and 
evening. Can safely be used 




Guideline Trading, P.O. Box 
136701, Alberton North 1456 
Tel: +2711 9070707 
sales@guidelinetr.com 
www.guidlinetrading.co.za 
Used to treat wounds, rashes, fungal infections, boils 
and chest infections, stop menstrual pains, increase 
stamina and fight against influenza virus. 
4 tablespoons twice a day. Not 
for children under 14 years of 




* Information in the Table was obtained through informal surveys from herbal shops in Pietermaritzburg in order to document the 




















Table 2.2: Formal and informal sectors of herbal product industry in South Africa  
 
Formal/informal producers Number of traders Products sold 
Retail herbal 'muthi ' shops. 
Informal market. 
Between 300 to 
400 in South 
Africa. 
These shops sell similar products to the informal trade: 
plants traded as raw material, chopped or as simple 
mixtures. They also trade quality tested and packaged 
traditional medicines supplied by manufacturers. 
Health shops specializing in 
traditional herbal medicines. 
Formal market. 
Number unknown 
for South Africa, 
but there are at 
least 5 in Durban. 
Popular medicinal plants are sold in various processed 
and packaged forms (creams, mixtures, tablets). Products 
are manufactured by pharmaceutical companies and by 
private entrepreneurs. They also trade a number of non-




5 to 10 in South 
Africa. 
Usually single species products containing safe (non 
toxic) plants. Products include tablets, creams, tinctures 
or mixtures without any claims of efficacy. These products 




50 to 100 in South 
Africa. 
Usually complex mixes of species (with claims of up to 50 
species per single product) in various forms (creams, 
mixtures and tablets), with numerous unproven claims of 
efficacy. The safety of these products is not proven. 
 























Figure 2.1: Examples of some herbal mixtures and preparations common in herbal 
shops and markets in Pietermaritzburg, KwaZulu-Natal. Tokoloshe Salts- protective 
charm against evil spirits and witchcraft; Tshepe- general tonic consisting of herbs 
fortified with vitamin supplements; Impotex forte and Sex sugar- herbal supplements 
for sexual dysfunction. Last insert shows a Pietermaritzburg bulk shopping store with 




The herbal mixtures are in most cases made up of combinations of plant species that 
have been used in ATM for centuries thus they represent a social heritage, and their 
ethnobotanical investigation can add much to the understanding of traditional 
medicine (CANO and VOLPATO, 2004). Despite the obvious differences in the 
degree of „modernization‟ of these herbal preparations, they share a common market 
and their formulation and conception are ATM. These herbal preparations are 
becoming extremely popular in South Africa and are becoming an important 
component of the medicinal plant trade and ATM. Most of the products have African 
names, dosages and indications are mostly written in South African languages, most 
commonly Zulu.  
 
There exist a range of herbal preparations with different traditional uses. These 
include lucky charms, to drive away evil spirits. Such preparations are usually carried 
about on the person in the form of a protective talisman such as the Tokoloshe salts 
(Figure 2.1). The Tokoloshe salts are sprinkled (intelezi) around the homestead, 
added to bathing water or chewed and are often carried around the neck ( imfingo) 
and the waist on ones person to drive away evil spirits. In rural areas, the intelezi is 
usually made of a mixture of bulbous plants. It can also be made using leaves and 
barks that are placed in a container (normally a broken used clay-pot) infused in cold 
water and sprinkled around the homestead or on the person. Plant species used for 
making intelezi and imfingo are mainly strong-smelling or strongly scented plants. 
 
Other products include aphrodisiacs, used to increase sexual prowess, sexual 
appetite or stamina. These products include Fire-BarkTea® (Bangala) (Figure 2.2), 
mainly advertised on the internet as a „love reed‟. Bangalala, also known as ‘African 
Viagra’, is prescribed as an aphrodisiac, notably to enhance male potency. 
Bangalala is a product of a mixture of Corchorus aspleniifolius and Eriosema 
cordatum roots, both plants have a reputation of being powerful sexual tonics 
(HUTCHINGS et al., 1996). Other species that are likely to be used for the same 
purpose includes Securidaca longepeduculata (Polygalaceae). The instructions on 
the packaging states that the roots are either boiled in water and the decoction is 
imbibed, or can be whisked into milk. The packaging of Bangalala (Figure 2.2) 
professes its love powers: “It was once a closely guarded secret of a few Xhosa and 
Zulu witchdoctors but because of its potency and popularity it is now available to all 
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who wish to enjoy its benefits”. The packaging also declares it to be the most 
powerful tonic known to Muthi practitioners, prescribed throughout Africa for 
centuries. Apparently you cannot overdose on it; according to most herbalists, “ if you 
overdo this love drug, it will simply upset your stomach”. „Sex sugar‟ (Figure 2.1) is 
also another popular aphrodisiac product available on the market.  
 
Another important group of herbal mixtures include the „general tonics‟. The names 
of these mixtures mainly mimic the strength of animals, for example „Ingwe (leopard) 
izifozonke‟ and „Lion izifozonke‟ presented in Figure 2.3A and B. The word 
„izifozonke‟ means „all diseases‟, thus the mixtures are used for many conditions. 
General tonics are in most cases administered orally by drinking a warmed portion or 
by adding the mixture to a traditional beer (umcomboti) or the lagers, fermented corn 
(amageu), traditional porridge (uphutu) and/or in tea. Umcomboti is an integral part 
of everyday Zulu life thus it is widely used in administering herbal preparations. 
 
Mixtures used as general tonics may also have names that describe how they are 
administered or what they cure. An example includes a general tonic called „Imbiza 
ephuzwato‟ which literally means „a medicine to drink’. Some names describe the 
use of the tonic for example „Umzimba omubi‟ refers to bad skin, and is used to treat 
skin conditions such as rashes. The general tonics mainly consists of a mixture of up 






















Figure 2.2: Fire-BarkTea® herbal tonic for men. Bangalala is claimed to be the most 
powerful aphrodisiac used in KwaZulu-Natal. It is sometimes referred to as „African 
Viagra‟ and is usually prescribed to men to enhance potency, increase sexual 
appetite and stamina; however women are also known to use the sexual tonic. The 






















Figure 2.3: Multipurpose mixtures „for all diseases‟ with names mimicking strong and 





„Umckaloabo‟ is a multipurpose Zulu herbal remedy widely used as a tonic as well as 
treatment of tuberculosis, fever and cough. The remedy is also used to treat colds, 
influenza, pneumonia and malaria (BRENDLER and VAN WYK, 2008). The term 
umckaloabo is derived from isiZulu, with a rough translation of „a stabbing pain‟ or „a 
stitch in the side‟. It is however, believed that the term may be an invention based on 
the Zulu language, intended to create a mysterious image of the remedy as a market 
strategy. Figure 2.4 shows an antique advertisement of umckaloabo referred to as 
“The Doom of 150 000 People”. 
 
The plant ingredients of Umckaloabo were identified in the 1970s and to date the 
product is supported with data on efficacy and safety, provided through scientific 
research. Umckaloabo consists of the rhizome of Pelagonium sidoides. Various 
metabolites have been isolated and characterized from the rhizome of Pelagonium 
sidoides. These include phenolic compounds such as tannins, flavonoids and 
coumarins as well as essential oils. Antimicrobial activities against pathogens 
involved in infection of the respiratory tract as well as the immunomodulatory 
potential of the product have been conducted. Clinical trials with ethanolic extracts of 
the rhizome referred to as EPs® 7630 (Umcakaloabo®) have confirmed its efficacy 
in conditions such as acute bronchitis. Umcakaloabo is now popular in the EU and is 
fully licensed (BRENDLER and VAN WYK, 2008). 
 
Other types of herbal mixtures include sedatives, herbal teas, resins, snuffs, and 
herbal cigarettes. From personal observation, general sales shows that herbal 
mixtures/preparations for abortion and those used as aphrodisiacs are by far the 























Figure 2.4: An ancient advertisement of Umckaloabo (Pelagonium sidoides) – „The 
Doom of 150 000 People‟ from the Dust jacket of Anonymous (1931). Taken from 




2.3. Preparation of commercial herbal mixtures 
 
Methods of preparing herbal mixtures varies from simple brewing processes to more 
complicated procedures that make use of alcohol and other organic solvents to 
dissolve the “essences” of the plant (PUJOL, 1990). In some cases, addition of 
accepted western medicines, such as aspirin, has been recorded for some herbal 
mixtures (CANO and VOLPATO, 2004). In other cases, clay has been reportedly 
detected in some herbal mixtures (OATES, 1978). Clay binds and neutralizes the 
toxicity of chemical compounds such as alkaloids and tannins as well as heavy 
metals (JOHNS, 1990). Therefore adding clay from termite mounds to herbal 
decoctions could represent a practical attempt to deal with toxic chemicals present in 
some medicinal species at the same time benefiting from their therapeutical 
properties (CANO and VOLPATO, 2004). 
 
Herbal preparations used as stomachic and sedative mixtures mainly contain 
aromatic plant species, rich in therapeutically-active essential oils (PUJOL, 1990), 
which exert their antispasmodic, antibacterial and stomach-soothing properties. 
Mixtures for stomach ulcers and diarrhoea are characterized by plant species with 
high tannin content, popularly used as astringents, antimicrobials and anti-
inflammatory (CANO and VOLPATO, 2004). 
 
Some herbal mixtures are medicinal-food formulae rather than herbal preparations. 
Fruits such as Cocos nucifera L. (Arecaceae) (Coco) and vegetables such as 
Solanum americanum Mill. (Solanaceae) (Yerba mora) are traditionally consumed in 
Cuba as food but are also reported to have specific pharmacological properties such 
as an anthelmintic function. The fruits of Capsicum frutescens L. var. frutescens 
(Solanaceae) (Aji guaguao) and seeds of Myristica fragrans Houtt. (Myristicaceae) 
(Nuez moscada), along with eggs, milk and wine are macerated together and taken 
as a tonic to reverse impotence and sterility (ESQUIVEL et al., 1992).  
 
Ingestion is the preferred means of taking herbal mixtures and topical application as 
a lotion is used to treat skin problems (rashes and boils) and inhaling is often used 
for mental conditions (PUJOL, 1990). Decoctions are sometimes administered as 
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enemas (uchatho in Zulu). In urban areas, they are administered using enema 
syringes or tubes. However in rural areas, a lubricated, truncated cow‟s horn is often 
used (VAN WYK et al., 1997).  
 
There is however, very little regulation and scientific backing of these products in 
South Africa, posing a potential threat to consumer health. Many of these private 
entrepreneurs seem not to conform to industry Good Manufacturing Practice (GMP) 
standards leaving only a few certified pharmaceutical manufacturers producing 
formalized traditional herbal medicines (MANDER et al., 2007). Despite the 
existence of the Medicines and Related Substances Control Act 101 of 1965 and its 
amendments of 2002 (DEPARTMENT OF HEALTH, 1965) it is still difficult to 
regulate commercially labelled medicines, herbal formulations and nutritional 
supplements. Medicine regulation, is in the public interest, and comprises of three 
integral aspects: quality, safety and efficacy. In terms of quality the hygiene and 
potential contamination of herbal products used in traditional medicines are a 
concern as they are sold on pavements and in markets where the materials are often 
exposed to sputum, urine and faeces, contrasting with the pharmaceutical 
manufacturing standards which are necessary for production and packaging of other 
medicines (RATES, 2001; STEENKAMP et al., 2006). It should however be noted 
that in ATM, it still remains a challenge to convince herbalists to reveal their 
ingredients as well as the recipes of their products as it is a guarded secret amongst 
themselves. 
 
The lack of standardization of these commercial products can also be as a result of 
high investment requirements for the development of clinically tested and certified 
medicines especially those derived from medicinal plants. Intellectual property rights 
regarding products from natural resources and the high cost of resolving such issues 
prior to investing in product development can impact directly to the consumer 
through higher prices. An increase in the price of these products will make them 
inaccessible to the majority of current users. Also there are risks associated with 
sustainability of raw plant material supplies, as the majority of indigenous medicinal 




In a country like South Africa, it is difficult to enforce any quality and safety controls 
on natural products that are not listed as registered pharmaceuticals because there 
exist parallel bodies within the government with different views on the use of natural 
products. One group is advocating for the use of ATM and the other putting in 
stringent laws regulating the use of certain plants. The National Policy on African 
Traditional Medicine seeks to address this dichotomy. 
 
2.4. Mode of action of herbal preparations 
 
The use of herbal mixtures presents unique challenges not encountered by western 
single compound medicines. Since these preparations are mostly complex mixtures 
of different plant species with different bioactive compounds, the indications and use 
criteria for western single compound medicines may not be applicable. Compared to 
single compound pharmaceuticals, traditional herbal mixtures may have more than 
one mode of action (YONG and LOH, 2004). 
 
2.4.1. Combinational or additive effects 
 
The healing effects of herbal mixtures could be as a result of the total sum of 
different classes of compounds having diverse mechanisms of action. An example of 
an herbal preparation that could simulate combinational effects is Gingko biloba, 
commercially known as ginkgo. The herbal preparation is used in western countries 
for brain dysfunction, to improve memory and cognition (YONG and LOH, 2004). 
The bioactive compounds in the preparation are known to be flavonoids and 
diterpenes called ginkgolides. These compounds are potent inhibitors of the actions 
of platelet-activating factors, which are important for platelet activation and clotting. 
In addition, ginkgo has also been shown to exhibit antioxidant properties. Platelet 
activating and antioxidant effects could combine to reduce inflammation and 
increase microcirculation of blood flow and improve brain function. Gingko has also 
been reported to have membrane stabilising effects and smooth muscle relaxation 
properties which could also contribute to the total vasodilatation and microvascular 




2.4.2. Synergistic effects 
 
Synergism in drugs occurs when compounds interact in ways that enhance or 
amplify one or more healing effects of mixtures of drugs than when they are 
administered individually (BECKER et al., 2004). Therefore, a partially purified 
extract of a plant offers advantages over a single isolated ingredient. This is the 
concept that underpins the philosophy of herbal mixtures (YONG and LOH, 2004). 
The presence of synergistic properties in medicinal plants is an old concept put forth 
by Hippocrates (an ancient Greek physician) and reinforced by Ibn Sina (the great 
Persian Physician). However, this concept lacks sufficient scientific evidence 
(GILANI and RAHMAN, 2005; VAN VUUREN, 2008). 
 
Apart from the studies on combinational interactions of commercial oils in South 
Africa by VAN VUUREN et al. (2007), the importance of the concept of synergism 
can clearly be reflected in the evolution of traditional Chinese medicine (CTM). The 
history of CTM dates back 4000 years and is still popular and becoming even more 
accepted by western countries. The initial CTM prescriptions consisted of mainly 
single agents. With accumulation of experience, the Chinese traditional healers 
realized that combining diverse natural medicines to form an herbal mixture could 
efficiently enhance the therapeutic effect (KONG et al., 2009). 
 
To help understand the concept of synergism, the CTM compounds within a herbal 
mixture were usually assigned with different roles and names, such as „ master 
(jun)‟, „adviser (chen)‟, „soldier (zuo)‟ and „guide (shi)‟ (KONG et al., 2009). The 
mission of the master compound is to treat the principal symptom of the disease. 
The „adviser‟ compound potentiates the effect of the master compound or treats 
accompanying symptoms. The role of the soldier compound is to enhance and 
modulate the effects of the master and adviser compounds. The task of the guide is 
to lead the active ingredients to specific organs (drug delivery system) and to 
harmonise the actions of these compounds (KONG et al., 2009). 
 
Although at that time, the theory of synergism was not scientifically proven, it was 
justified for a Chinese formula (Fu Fang Qing Dai Pian) created by Dr Huang Shi-Lin 
20 years ago. The mixture consists of Realgar (tetraarsenic tetrasulfide) as the 
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master, Salvia miltiorrhiza as the adviser/guide, Indigo naturalis as the soldier/guide 
and Radix pseudostellariae also as adviser but not essential for the mixture. The 
mixture is used in the treatment of human acute promyelocytic leukaemia (APL). The 
synergistic mechanism of the mixture was recently elucidated (KONG et al., 2009). 
First the tetraarsenic tetrasulfide directly attack the promyelocytic leukaemia (PML)-
retinoic acid receptor α (RAR α) oncoprotein and promotes APL cell differentiation, 
therefore it behaves like a „master‟. Secondly the principal components of Salvia 
miltiorrhiza and Indigo naturalis,  is tanshinnone IIA and indirubin, respectively, which 
increases tetraarsenic tetrasulfide-induced degradation of PML -RAR α, thus serving 
as „adviser‟ and „soldier‟. Finally, indirubin and tanshine IIA which also works as a 
„guide‟ enhances the expression of aquaglyceroporin 9, which helps transport 
tetraarsenic tetrasulfide into APL cells where it carries out its effect (KONG et al., 
2009). 
 
Another theory categorises the components of herbal mixtures into four roles: role of 
an „emperor,‟ of an „adviser,‟ of a „minister‟ and of an „ambassador.‟ The philosophy 
demands a balanced system that includes effectiveness, efficacy, reinforcement, 
moderation and safety. Based on this philosophy, poisonous herbs can be used 
when there is need to forcibly bring about a effective treatment, while toxicity is being 
checked and controlled by other herbs that possess different effects or that act as 
antidotes, low doses on the other hand are supplemented by a variety of other herbs 
present in the mixture (LEUNG, 2004). This clears the mystery that surrounds the 
use of poisonous herbs in herbal mixtures. Most of the mixtures presented in Table 
2.1 contain at least one toxic plant. These includes potentially poisonous herbs such 
as Gomphocarpus fruticosus (Apocynaceae), Scadoxus puniceus (Amaryllidaceae) 
and Drimia robusta (Hyacinthaceae) which forms components of „Imbiza ephuzwato‟, 
a popular Zulu herbal multipurpose mixture. 
 
2.4.3. Dose response relationships 
 
Sometimes dose-dependent effects of combinational medicine are encountered in 
efficacy studies, where higher doses used in traditional medicine have therapeutic 
effects. This has been shown by the extracts of goldenrod (Solidago virgaurea) 
which in low doses have no diuretic effect, whereas in traditional medicine where 
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higher doses (6-12 g dried herb per cup) are prescribed, it has diuretic effects 
(YONG and LOH, 2004). 
 
2.5. Advantages of using herbal mixtures 
 
Western medicine is based on the lock and key theory, which uses one agent to treat 
one disease. However, as the mechanisms of many diseases involve multiple 
factors, a one-agent-one-target approach normally fails. In addition, as the human 
body is a complex network, inhibiting a single target (organ or receptor) usually has 
very little therapeutic effect (KONG et al., 2009). 
 
Furthermore, inhibiting a single target can exert unexpected side effects because of 
the breaking of the balance of the complex body network. It is assumed that herbal 
mixtures modulate the biological networks in a holistic way and in this way may be 
efficient in controlling disease systems (YEH and KISHONY, 2007). 
 
Herbal mixtures containing multiple and complex compounds thus can deal with drug 
resistance that is being observed for most antibiotics, antimalarial, antiviral and 
anticancer drugs (KEITH et al., 2005). 
 
Herbal treatments cost much less than western prescribed drugs. Herbal mixtures 
are also more convenient as they can be purchased over the counter from any 
herbal or food store without the need for a prescription. Herbal mixtures are not yet 
categorized as drugs, they are considered as food and supplements, thus they are 
not subjected to the same strict scientific inspection as prescription medication 
(CANO and VOLPATO, 2004). 
 
In China, hospitals have begun treating the current outbreak of influenza virus 
(H1N1) infected patients with an herbal remedy instead of the WHO-recommended 
Tamiflu. The herbal treatment is a mixture of four locally-used medicinal herbs: Jin 
yin hua (Lonicera japonica), Da qing ye (Lsatis indigodica), Bo he (Mentha 
haplocalyx) and Sheng gan cao (Glycyrrhiza glabra). Doctors in Beijing first began 
using the remedy on May 15, 2009, treating patients with a combination of the herbal 
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remedy and Tamiflu. After successful trials, doctors have since begun prescribing 
only the herbal treatment. Wang Yuguang, head of the Centre of Integrated Chinese 
and Western medicine at Ditan Hospital, said that treatment time for the herbal 
remedy was comparable with that of Tamiflu treatments. The big difference, he said, 
was the cost of the two treatments. The CTM remedy only costs between 10 and 13 
Yuan (between 1.50 and 1.90 USD), while Tamiflu costs 56 Yuan (8.19 USD) 
(KRISHNAN, 2009). 
 
The Chinese Ministry of Public Health has expressed concern about the virus‟ 
increasing resistance to Tamiflu and fears of the drug‟s side-effects. However, the 
Chinese government appears to have given full-backing to promoting the herbal 
remedy (KRISHNAN, 2009). Professor Zhitao Tu, dean of the research and 
education department at the Beijing Administration of CTM confirmed that “in China, 
Tamiflu is not sufficient, and it also weakens the body and has adverse effects on 
body tolerance”. Prof. Tu said the essential difference was that while the CTM 
remedy works to build up the body‟s resistance in a holistic way, the Tamiflu drug 
focuses on attacking the infection (KRISHNAN, 2009).  
 
2.6. Problems associated with use of herbal mixtures 
 
Despite the popularity of botanical supplements, many herbal mixtures on the market 
are of low quality and doubtful efficacy. Researchers and clinicians are usually 
concerned about safety, effectiveness and consistency of herbal mixtures and 
preparations. The low quality of herbal products is usually due to several 
parameters. These include a variety of poorly controlled factors such as collection of 
raw herbs, processing methods and complex heterogeneity of compounds, and 
unpredicted consequences when herbs are mixed with western medicines as well as 
a lack of scientific validation (McINTYRE, 1998).  
 
2.6.1. Problems due to identification, harvesting and manufacturing 
 
Plant species used in herbal preparations often have very similar appearances, 
especially between subspecies or even varieties within the same family. These could 
33 
 
be even harder to separate when the materials are dried. This poses a great threat 
as different plants, even when in the same genus, can have very different chemical 
constituents. Inappropriate use of herbs through misidentification is one of the major 
causes of morbidity and mortality in local communities (RATES, 2001; TANKO et 
al., 2005).  
 
Between 1992 and 1993, an outbreak of a rapidly progressing renal failure was 
recorded in Belgium and was linked to a slimming Chinese herbal mixture containing 
Stephania tetrandra and Magnolia officinalis. Chemical analysis of the herbal mixture 
sold in Belgium at that time pointed to a misidentification between Stephania 
tetrandra and another potentially nephrotoxic Chinese herb, Aristolochia fangchi 
(YONG and LOH, 2004). 
 
Currently, in South Africa, manufacturers are not bound by any law to have good 
manufacturing practices. Therefore, inconsistent methods used by the manufacturers 
can result in different quality levels between batches of a product. Different 
therapeutic potentials in herbal products result from different factors such as the age 
of plants, season of harvesting, geography of plant habitat and post harvest 
handling. Furthermore, herbal mixtures may not be pure and it is possible they may 
contain pollen grains or heavy metal contaminants which could induce sickness. 
Currently, introduction of standardized manufacturing and testing protocols are much 
needed in the herbal industry (MANDER et al., 2007). 
 
2.6.2. Lack of clinical efficacy and safety evidence 
 
The risk and benefits of most herbal mixtures are not supported by scientific or 
clinical testing. Randomised control trials are the standard for clinical efficacy and 
currently they have been done on a handful of herbal products which are now 
acceptable in the European Union (EU) and other western countries. These products 
include gingko, St John‟s wort (Hypericum perforatum), ginseng, saw palmetto and 
kava (YONG and LOH, 2004). Little or no information exists for the vast majority of 





2.6.3. Herb-drug and herb-herb interactions 
 
There is sparse documentation regarding the interaction between western medicines 
and herbal products. However, research on the common herbs indicates that 
significant herb-drug interactions exist. St John‟s wort, a common herbal product is 
known to interfere with cyclosporine, digoxin, warfarin and theophyline and has been 
shown to cause intermenstrual bleeding when used together with oral contraceptives 
(ethinylestradiol/desogestrel). It also causes serotonin syndrome when used together 
with selective serotonin-reuptake inhibitors (sertaline, paroxetine and nefazodone). 
Ginkgo interactions include bleeding when combined with warfarin and raised blood 
pressure when combined with a thiazide diuretic. Garlic (Allium sativa) changes the 
pharmacokinetic variables of paracetamol and produces hypoglycaemia when taken 
with chlorpropamide (YONG and LOH, 2004). Thus interactions between herbal 
products and western synthetic drugs exist and can have fatal consequences (YEH 
and KISHONY, 2007). 
 
2.6.4. Inadequate government regulations 
 
In many countries, including South Africa, herbal remedies are sold for stimulating, 
maintaining, supporting, regulating and promoting health rather than treating 
disease. In South Africa, such supplements are required to carry a label that 
describes the ingredients intended to affect the structure or functions within humans 
in line with Act 101 of 1965 and amendments (2002) (DEPARTMENT OF HEALTH, 
1965). However, this represents another example of a law that exists only on the 
statute books as many herbal mixtures are being sold without ingredient information 
on their labels. It is also regrettable that this law does not require product 
standardization for uniformity between batches. It is an important factor in the future 
to investigate batch to batch pharmacological activities in order to understand the 
effects of storage and other manufacturing practices. Furthermore, the use of 
different processing methods of a particular herb could result in inconsistencies in 






2.6.5. Insufficient consumer education  
 
Many consumers have the belief that herbal mixtures are safe and natural. It is 
however, important for such consumers to be told that even though herbal mixtures 
have been in use for a long time, they still bring with them risks of side effects 
(STEENKAMP et al., 2006). An example of a herbal product that has been used for 
a long time but still have a lot of side effects is ma huang (Ephedra sinica), 
commonly sold as a weight loss product. Ephedra sinica was traditionally used to 
treat a variety of conditions, including asthma, hypotension and depression. The 
traditional communities have, over the years come to recognise that ma huang is not 
a safe herbal product because it has side effects. The side effects include tremors, 
nervousness, insomnia, headache, gastrointestinal distress, high blood pressure, 
irregular heart beat and kidney stones (TINSLEY, 1999). 
 
2.7. When do herbal mixtures become poisonous? 
 
Poisoning due to plant products (herbal poisoning) is not well documented. This is 
mainly because people are unwilling to admit poisoning by herbal products because 
of the fear that their cultural heritage will be put under strong laws and regulations 
(STEENKAMP et al., 2006). 
 
The largest numbers of acute poisoning occur in the age group 1-5 years and 
according to descriptions on most of the labels of the herbal mixtures (Table 1), most 
preparations are not recommended for children under the age of 14 years. In east 
Africa, the widespread use of Crotalaria sp. in the treatment of measles amongst 
children has resulted in a number of cases of liver lesions (STREET et al., 2008). 
 
Adult poisoning occurs usually as a result of mislabelling of products, or products 
which are not stored in their original containers. Occasionally, poisoning is through 
confusing a toxic plant with something that is thought to be edible (VAN WYK et al., 
2002). In some instance, adults could be poisoned by taking incorrect doses thus it is 
also important for the manufacturers to clearly state the directions for use and 




A pharmaceutical product is defined as being stable if it has five basic properties 
which are: physical, chemical, microbial, toxicological and therapeutic stability. Many 
natural products readily oxidise and degrade, giving products with variable 
properties. Carotenoids such as β-carotene and lycopene may have antioxidant 
properties as intact molecules yet their degradation products can be toxic (YEH and 
HU, 2001; HALLIWELL, 2004).  
 
Microbial contamination from soil, during handling of plants and storage is a potential 
threat to the consumer‟s health. Aflatoxins are among the deadly products that are 
generated by bacterial/fungal infections (AMES and GOLD, 2000; HALLIWELL, 
2004). Heavy metal contamination and pesticide and herbicide residues from the soil 
are also a common cause of herbal poisoning. Heavy metal contamination can be 
introduced during sample preparation, for example when extraction of herbal 
products is done in lead containers (ONG et al., 1999). Dry mixtures are often 
coloured with mineral compounds which contain heavy metals such as copper, iron 
and cadmium. 
 
2.8. Research and development in herbal mixtures 
 
Despite the difficulties of quality control on herbal products because of their 
heterogeneous constituents, different mechanisms of action and unusual dose-
response relationships, scientific efficacy and safety evaluation are still possible 
(YONG and LOH, 2004). This is best reflected in the evolution of CTM and of 
traditional medicine native to India (Ayurveda medicine), from which South Africa 
may be able to learn a lot. While CTM has a history of more than 4000 years, it is still 
popular in China and becoming more and more accepted by western countries, 
Ayurveda remains an influential system of medicine in South Asia (KONG et al., 
2009).  
 
The most ancient CTM book of prescriptions for fifty two diseases, compiled around 
300 BC, recorded 247 agents and 150 formulae (herbal mixtures and preparations). 
In another survey published two thousand years later, the number of single CTM 
37 
 
agents had only risen seven-fold, from 247 to 1892, while the quantity of herbal 
mixtures increased more than 400 times, from 150 to 61,739. To date, there are 
about 500 combinational agents used to tackle a wide range of diseases in CTM 
(KONG et al., 2009).  
 
Research into herbal medicine is urgently needed and if this need is to be met, 
dedicated funding will be required to be allocated by the government. Research will 
ensure a rational basis for the use of herbal medicines. Examples of areas that still 
need attention include: 
 Research aimed at the safe and effective production of herbal products. The 
pharmacodynamics, pharmacokinetics, safety and efficacy of bioactive herbal 
mixtures can be examined in animal models; 
 Education and training for both traditional and orthodox medicinal 
practitioners. There is a concurrent need for self-regulation by senior 
traditional health practitioners, focusing on peer supervision and enforcement 
of standards of professional practice and conduct; and 
 Research policies that promotes clinical and quality assurance studies. 
National testing centres are needed and should be appropriately funded. 
 
In South Africa, an initiative has now been made by the formation of research groups 
that are devoted to the research on herbal medicines. ATM and its pharmacopoeia 
form the core business of a new research group formed by the Medical Research 
Council (MRC), the University of Cape Town (UCT) and the University of Western 
Cape (UWC). The Research Group on Traditional Medicine (TRAMED) is based at 
UCT and is headed by Professor Peter Folb of the Department of Pharmacy and 
Professor Peter Eagles of the School of Pharmacy at UWC. The establishment of the 
Indigenous Knowledge Systems (Health) Office (IKS) at the Medical Research 
Council, headed by Dr Motlalepula Matsabisa has contributed greatly in terms of 
research of herbal medicines in South Africa. The IKS office is actively involved with 
the Drugs for Neglected Disease initiative (DNDi) project. The DNDi project aims at 
developing new drugs for neglected diseases such as malaria. Other research 
groups include the Research Centre for Plant Growth and Development (RCPGD), 
headed by Professor van Staden, based at the University of KwaZulu-Natal (UKZN) 
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Pietermaritzburg, University of Pretoria research group headed by Professor J.J.M. 
Meyer, Tshwane University of Technology group headed by Professor A. Viljoen, 
University of Johannesburg group headed by Professor B.E. van Wyk and the 
Pytomedicine programme, University of Pretoria, headed by Professor J.N. Eloff are 
also actively involved in conservation and testing for efficacy of medicinal plants and 
their products. The major aims of all these research groups include documenting 
traditional medicines and herbal products derived from indigenous medicinal plants 
while attempting to identify and isolate their therapeutically active components, 
thereby establishing a database of ATM in South Africa. 
 
Both scientific and political will are needed to support the development of a data 
base of ATM. In poor countries, the search for effective and affordable treatments for 
epidemics such as malaria and opportunistic infections associated with HIV/AIDS is 
driving renewed policy interests in herbal medicine research. Substantial increases 
in research funding are therefore needed and new directions in clinical evaluation 
must be forged by researchers who are able to transcend limitations in research 
orthodox in the interests of providing sound information to the public on what 
constitute good health care (BODEKER, 2004).  
 
A vital requirement in ensuring that policies such as the National Policy on ATMSA 
(2008) which is still at a draft level and the Medicines and Related Substances 
Control Act 101 of 1965 become enacted is an adequate level of development. Most 
South African policies only exist in the statutory books and are never enacted or are 
not adequately policed/enforced. This trend suggests that the way forward in policy 
development should be via a combination of concerted local consultation with all 
relevant interest groups, matched by an exchange of information and experience 
with international partners who have developed some perspective or have 
experience in one or more areas of herbal medicines such as in China and 
Germany.  
 
Some recipes and validation of claimed properties of herbal mixtures have been 
reported in China, Japan, Cuba and Syria (CANO and VOLPATO, 2004; 
CARMONA et al., 2005; LEE et al., 2006). In China, there exists a number of 
government supported groups responsible for quality and safety of CTM. In 
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Germany, The Ministry of Health runs a commission (Commission E) comprising of 
doctors, pharmacists, scientists and herbalists to evaluate quality, safety and efficacy 
of herbal products (VALLI and GIARDINA, 2002). The regulations are designed so 
that manufacturers have to provide proof of quality according to pharmaceutical 
standards for herbal medicines. This includes statutory declarations for herbal 
ingredients, dosages, application/administering instructions and intended use. On 
the other hand, safety and effectiveness are relegated to monographs published by 
Commission E (YONG and LOH, 2004).  
 
The setting up of government supported groups responsible for quality and safety of 
CTM has led to the advancement in their traditional medical systems so much that 
the Chinese government has sanctioned hospitals to launch CTM-based treatments 
for H1N1 on a large scale. The herbal mixture is now undergoing clinical trials “to 
show concrete evidence that the treatment is scientific.” The Chinese government 
has invested 10 million Yuan (6.83 million USD) in conducting a comparative study 
of herbal and Tamiflu treatments. Mao Yue, president of the Ditan Hospital, said, 
“There was a serious possibility of a large-scale outbreak of the flu in the autumn 
and winter of this year, and that the government has already begun procuring 




Due to the relatively recent development of herbal preparations very little is known 
by the scientific community about the epistemology influencing herbal preparation 
design, the production process as a whole and knowledge management. Are there 
quality assurance measures in place (i.e. why and how quality is ensured; are there 
tests for quality, validation of standards and specifications)? Can we observe an 
„experimental process‟ that has lead to the development of these herbal formulae 
from single component remedies? 
 
It cannot be denied that herbal mixtures harbour many potential lifesaving bioactive 
compounds. The isolation of many microbial compounds including antiplasmodial 
diterpenoids, sesquiterpene lactones, antibacterial anthraquinones, anti-
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inflammatory isoeugenitols and (S)-naringenin from different plant species observed 
to be the commonly used in commercial herbal mixtures and preparations in South 
Africa is a case in point (CHUKWUJEKWU et al., 2005; ELGORASHI et al., 2007; 
STAFFORD et al., 2007; PEDERSEN et al., 2009). The modernization and 
acceptance of herbal mixtures into mainstream medical practice will depend on the 
outputs of scientific research aimed at providing the rational for their usage. In this 





Pharmacological, Phytochemical and Safety 
Evaluation of Fourteen Commercial Herbal 




As herbal products become popular, their safety and efficacy become an important 
issue (YEH and KISHONY, 2007). The study of ethnobotanical systems as 
therapeutic agents is of paramount importance to addressing health problems of 
traditional communities. A large number of studies have been conducted in the past 
few decades on the traditional pharmacopoeia of indigenous peoples and rural 
communities throughout the world (CANO and VOLPATO, 2004). Nevertheless, 
these studies are rarely focused on commercial herbal preparations and mixtures. 
The botanical and pharmacological aspects of such complex preparations have often 
been overlooked and very little attention has been paid to them.  
 
In this study, in vitro tests, frequently known as „bioassays‟ were used as 
ethnopharmacological research, to measure biological activity in undefined 
substances, determination of toxicity and measurement of the concentration of 
known substances in herbal products. The bioassays most commonly utilize 
microbial cells and enzymes as targets for the substances under test. In some 
cases, nematodes can be used, for example, the use of the Caenorhabditis elegans 
for anthelmintic studies (HOUGHTON et al., 2007). This chapter will answer several 
questions relating to the efficacy and safety of fourteen commercial herbal 
preparations currently sold in KwaZulu-Natal, South Africa. 
 
3.1.1. Aims and objectives  
 
The project was aimed at investigating the pharmacological properties of fourteen 
commercial herbal preparations common in KwaZulu-Natal. The bioassays used for 
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the evaluation of the pharmacological properties included the antibacterial, 
antifungal, anthelmintic assays, the inhibition of the cyclooxygenase (COX-1 and 
COX-2), HIV-1 reverse transcriptase (RT) and the acetylcholinesterase (AChE) 
enzymes and antioxidant assays, as well as the cytotoxicity and mutagenicity 
assays. 
 
3.1.2. Sample procurement 
 
Fourteen commercial herbal preparations, Umzimba omubi, Umuthi wekukhwehlela 
ne zilonda, Mvusa ukunzi, Umpatisa inkosi, Imbiza ephuzwato, Vusa umzimba, 
Ingwe® traditional muthi mixture, IbhubeziTM, Supreme one hundred, Sejeso herbal 
mixture Ingwe®, Lion izifozonke Ingwe®, Stameta™ BODicare®, Ingwe® special muti 
and African potato extractTM were bought from herbal shops around 
Pietermaritzburg, KwaZulu-Natal. Figure 3.1 presents the pictures of the fourteen 
herbal preparations. The information of the commercial herbal preparations including 
the manufacturers‟ details, claims and directions of use are presented in Table 2.1 
(Chapter 2). 
 
3.1.3. Sample preparation 
 
The herbal preparations (200 ml) were filtered through Whatman No. 1 filter paper 
and freeze dried. The dried material was weighed and resuspended in water and 
filtered through a sterile 0.22 µm filter unit (Millex® GV, Molsheim, France) to obtain 
a sterile 50 mg/ml starting concentration, subsequently diluted to lower concentration 
depending on the assay. Ingwe® special muti was obtained from the herbal shop as 
a powdered material, therefore the extract was prepared following the directions on 
the packaging. The powdered sample (5 g) was extracted in boiling water (200 ml) 
with stirring for five minutes (obtaining a tea-like solution) and left to stand until cold. 
The solution was filtered through Whatman No. 1 and the filtrate was treated as 
described for the other herbal preparations.  
 
The resuspended extracts of the herbal preparations, were evaluated for 
antibacterial, antifungal, anthelmintic properties and the inhibitory activities against 
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the cyclooxygenase (COX-1 and COX-2), the HIV-1 reverse transcriptase (RT), 
acetylcholinesterase (AChE) enzymes. The herbal preparations were also evaluated 
for cytotoxicity and mutagenicity using the neutral red uptake assay (NRU) and the 
Ames test. The antioxidant potentials as well as the phytochemical constituents of 
































































Figure 3.1: Commercial herbal preparations commonly found in traditional herbal 
shops, pharmacies and supermarkets in KwaZulu-Natal, South Africa. (1) Umzimba 
omubi, (2) Umuthi wekukhwehlela ne zilonda, (3) Mvusa ukunzi, (4) Umpatisa inkosi, 
(5) Imbiza ephuzwato, (6) Vusa umzimba, (7) Ingwe® muthi mixture, (8) Ibhubezi™, 
(9) Supreme one hundred™, (10) Sejeso herbal mixture Ingwe®, (11) Lion izifozonke 








Bacteria form a heterogeneous and the most abundant group of unicellular 
organisms on earth and are able to adapt to almost any living condition. They are 
both useful and harmful to humans. Bacterial infections are very common and are 
amongst the leading causes of death worldwide (SLEIGH and TIMBURY, 1998). 
The clinical efficacy of many existing antibiotics is being threatened by the 
emergence of multidrug-resistant microorganisms (PAGE et al., 1997). 
 
The cellular organisation of bacteria is prokaryotic with rigid cell walls, which 
determines their shape. Bacteria may be spherical (cocci), cylindrical (bacilli or rods) 
or helical (spirochaetes). Besides conferring rigidity upon bacteria, the rigid cell wall 
protects the cell against osmotic damage. It is porous and permeable to substances 
of lower molecular weight (SLEIGH and TIMBURY, 1998). 
 
Gram‟s staining technique is used to divide bacteria into two different classes, the 
Gram-positive and the Gram-negative. Bacterial cells are stained with crystal violet 
(CV) and after being decolourized with alcohol and treated with safranine and 
washed in water, bacterial cells that retain the crystal violet complex are Gram-
positive and those that do not retain it are Gram-negative. The Gram-negative 
bacterium consists of an outer membrane which contains lipopolysaccharide, a 
reduced layer of peptidoglycan separated from the cytoplasm by a periplasm or a 
periplasmic space. The cell wall also contains specific proteins which include pore-
forming proteins through which hydrophilic molecules are transported. The other 
proteins include the receptor sites for phages and bacteriocins. The peptidoglycan 
layer of the cell wall of Gram-positive bacteria is much thicker than in Gram-negative 
bacteria. Gram-positive bacteria lack periplasmic space.  
 
The Gram-staining reaction reflects the structure of the cell wall. In aqueous 
solutions, CV dissociates into CV+ and chloride (Cl–) ions. The CV+ and Cl- ions can 
penetrate through the cell walls and cell membranes of both Gram-positive and 
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Gram-negative cells. The CV+ ion interacts with negatively charged components of 
bacterial cells and stains the cells purple. Addition of Iodine (I) ions to the stained 
cells results in the interaction in the formation of large complexes of crystal violet and 
iodine (CV–I) within the inner and outer layers of the cell. When alcohol or acetone is 
added, as a decolourizer, it destabilises the lipids of the cell membrane. A Gram-
negative cell will lose its outer membrane and the peptidoglycan layer is left 
exposed. Washing with water removes CV–I complexes from the Gram-negative cell 
along with the outer membrane. In contrast, a Gram-positive cell becomes 
dehydrated by an ethanol treatment. The large CV–I complexes become trapped 
within the Gram-positive cell due to the multilayered nature of its peptidoglycan. 
Therefore, Gram-positive cells remain purple and the Gram-negative cells lose their 
purple colour (BEVERIDGE and DAVIES, 1983; DAVIES et al., 1983). 
 
Some of the medically important bacteria that are known to cause infections include 
Bacillus subtilis, Escherichia coli, Klebsiella pneumonia and Staphylococcus aureus. 
Bacillus subtilis is a Gram-positive aerobic rod-shaped spore-producing bacterium. 
Bacillus subtilis often occurs in chainlike formations, found primarily in soil and 
causes food poisoning (RYAN and RAY 2004). Staphylococcus aureus is a 
spherical Gram-positive pyogenic bacterium that causes illnesses such as boils, 
conjunctivitis, pneumonia, skin infections, meningitis and septicaemia as well as 
worsening conditions such as wound infections and food poisoning (FRANKLIN and 
LOWY, 1998). Staphylococcus aureus exists in multiple resistant forms, especially in 
hospitals (SLEIGH and TIMBURY, 1998). Escherichia coli is a Gram-negative 
bacterium normally present as part of the normal flora of the gut and within the 
intestinal tract of humans and other warm-blooded organisms. The bacterium 
benefits its hosts by producing vitamin K2, and prevents the establishment of 
pathogenic bacteria within the intestinal tract. Most Escherichia coli strains are 
harmless, but sometimes they can cause serious food poisoning in humans, and are 
occasionally responsible for costly product recalls. Strains of Escherichia coli are 
also responsible for wound and urinary tract infections (SLEIGH and TIMBURY, 
1998). Klebsiella pneumonia is a genus of non-motile rod-shaped Gram-negative 
enterobacteria which cause urinary tract infections, septicaemia, meningitis and 




Besides bacterial infections, humans are constantly fighting fungal invasions, 
especially from Candida albicans. Candida albicans is a member of the yeast family 
and sub-group fungi or moulds (CHAITOW, 1996). Candida albicans forms part of 
the flora living in the gastrointestinal tract, including the mouth and the gut. The 
fungus lives in 80% of the human population with no harmful effects but sometimes it 
is a causal agent of opportunistic oral and genital infections in humans (WOLSKI 
and GLOWNIAK, 2003). Overgrowth of Candida albicans results in candidiasis. 
Candidiasis is often a common case in immunocompromised individuals such as 
HIV-AIDS patients. Candidiasis, also known as „thrush‟, is a common condition which 
is usually observed in people who are not immunocompromised. To infect host 
tissue, the usual unicellular yeast-like form of Candida albicans reacts to 
environmental cues and switches into invasive, multicellular filamentous forms 
(ZACCHINO et al., 2003). “The introduction of broad-spectrum antibiotics, the use of 
the contraceptive pill and the widespread proliferation of steroid medication, have 
played their part in Candida’s growth. In addition, the increase in the use of sugar 
and sugar rich foods has provided the yeast with just the sustenance it loves. This is 
the unfortunate combination of factors that is the root cause of the problem for many 
people” (CHAITOW, 1996). 
 
Intestinal nematodes are also important pathogens of humans. The WHO estimates 
that 2 billion people harbour worm infections. Helminthic infections are mostly 
controlled by treatment with synthetic drugs but there is evidence of drug resistance 
(BEHNKE et al., 2008). Anthemintics are grouped into three classes. The first group 
includes the benzimidazoles, introduced in the early 1960s but resistance was 
detected after 4 years of usage. The second group, the nicotinic acetylcholine 
agonists such as levamisol was introduced in the 1970s and resistance was first 
reported in 1977. The third group, macrocyclic lactones includes ivermectin, were 
first introduced in the early 1980s and resistance was first reported in South Africa 
within seven years of use (BEHNKE et al., 2008). 
 
Nematodes are not considered ideal for laboratory use because they have complex 
life-cycles. Activity of the extracts is rated based on the viability or mobility of the 
worms after incubation thus the method is subjective, often unreliable and time 
consuming. For this study, a new colourimetric technique was used which utilizes the 
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metabolic activity of p-iodonitrotetrazolium chloride (INT) as a measure of biological 
activity. Caenorhabditis elegans is very different to the other nematodes, because it 
is easy to culture, making the assay cheap and rapid, thus it has been used in the 
search for anathematic drugs. Caenorhabditis elegans is sensitive to the majority of 
anthelmintic drugs that are used for the treatment of parasitic worm infections 
(BEHNKE et al., 2008).  
 
Although it appears that many drugs are available for the treatment of microbial and 
worm infections, there are in fact, a limited number of efficacious microbial drugs 
(ZACCHINO et al., 2003). Many of the drugs currently available lead to the 
development of resistance or have undesirable side effects as well as being toxic 
(LERNER, 1998). Therefore, development of antimicrobial and anthelmintic agents 
for clinical use from natural products could play a crucial role in meeting the demand 
for new drugs against microbial infections. 
 
Several screening methods have been described for antimicrobial evaluation of 
botanical extracts. These could be classified into three groups, disc-diffusion, 
microdilution and bioautographic assays (RIOS et al., 1988). Microdilution 
techniques are used to determine more precisely the antimicrobial activity of the 
extracts by determining the minimum inhibitory concentration (MIC) or minimum 
bactericidal/fungal concentration of test extracts for a given microorganism (ELOFF, 
1998).The disc-diffusion assay is also a common form of testing for antimicrobial 
activity, and does not require homogenous dispersion of the extract and has an 
advantage of allowing multiple screening of plant extracts at the same time. The 
bioautographic assays allows for rapid detection of bioactive constituents of plant 
extracts and it is mainly utilised for bioassay-guided fractionation of antibacterial 
compounds (FENNELL et al., 2004). 
 
In order to test for antimicrobial and anthelmintic activities of the herbal preparations, 
antibacterial, antifungal and anthelmintic evaluation was carried using microdilution 
techniques against two Gram-positive (Bacillus subtilis and Staphylococcus aureus) 
and two Gram-negative (Escherichia coli and Klebsiella pneumoniae) bacterial 




3.2.2. Materials and methods 
 
3.2.2.1. Antibacterial microdilution bioassay 
 
Minimum inhibitory concentration (MIC) values for antibacterial activity of the 
fourteen herbal preparations were determined using the microdilution bioassay in a 
96-well (Greiner Bio-one GmbH, Germany) microtitre plates (ELOFF, 1998). One 
hundred microlitres of each resuspended herbal mixture (in water to a concentration 
of 50 mg/ml) obtained by the process explained in Section 3.1.3 was two-fold serially 
diluted with sterile distilled water, in duplicate down the microtitre plate for each of 
the four bacteria used. A similar two-fold serial dilution of neomycin (Sigma) (0.1 
mg/ml) was used as a positive control against each bacterium. Water was included 
as a negative/solvent control. Overnight Mueller-Hinton (MH) broth cultures 
(incubated at 37 °C in a water bath with shaking) of four bacterial strains: two Gram-
positive (Bacillus subtilis American type culture collection (ATCC) 6051 and 
Staphylococcus aureus ATCC 12600) and two Gram-negative (Escherichia coli 
ATCC 11775 and Klebsiella pneumoniae ATCC 13883) were diluted with sterile MH 
broth (1 ml bacteria/50 ml MH) resulting in a final inoculum of approximately 106 
cfu/ml. One hundred microlitres of each bacterial culture were added to each well. 
The plates were covered with parafilm and incubated overnight at 37 °C. Bacterial 
growth was tested by adding 50 µl of 0.2 mg/ml p-iodonitrotetrazolium chloride (INT) 
to each well and the plates incubated at 37 °C for 1 h. Bacterial growth in the wells 
was indicated by a red-pink colour, whereas clear wells indicated inhibition of growth 
by the tested sample. MIC values were recorded as the lowest concentration of 
extract showing a clear well. Each assay was repeated twice with two replicates. 
 
3.2.2.2. Antifungal microdilution bioassay 
 
The antifungal activity of the herbal preparations was evaluated against Candida 
albicans (ATCC 10231) using the micro-dilution assay (ELOFF, 1998) modified for 
an antifungal assay (MASOKO et al., 2007). An overnight fungal culture was 
prepared in 10 ml yeast malt (YM) broth. Four hundred microliters of the overnight 
Candida culture were added to 4 ml of sterile saline solution. The absorbance was 
read at 530 nm and adjusted with sterile saline solution to match that of a 0.5 M 
51 
 
McFarland standard solution. From this prepared stock, a 1:1000 dilution with sterile 
YM broth was prepared to give an approximately 106 cfu/ml culture. 
 
One hundred microlitres of each herbal mixture obtained by the process explained in 
Section 3.1.3 were resuspended in water to a concentration of 50 mg/ml and two-fold 
serially diluted with sterile distilled water, in duplicate down a 96-well microtitre plate. 
A similar 2-fold serial dilution of Amphotericin B (Sigma) (2.5 mg/ml) was used as a 
positive control. Water and fungal free broth were included as negative controls. To 
each of the wells containing the test and control solutions, 100 µl of the dilute 
Candida cultures were added and incubated for 24 h at 37 °C. To indicate fungal 
growth, 50 µl of 0.2 mg/ml INT were added to each well, and the plates were 
incubated for a further 24 h. The wells which displayed no change in colour 
represented antifungal activity. The MIC was taken as the lowest concentration of 
plant extract to inhibit growth of the tested fungus after 48 h. After noting the MIC, 50 
µl YM broth was added to the clear wells to determine whether the inhibition was 
fungicidal. The microplates were re-covered with parafilm and incubated for a further 
24 h after which new MFC (minimum fungicidal concentrations) were noted. In the 
case where there was no growth of fungus in the last clear well even after addition of 
YM broth to clear wells, the MIC was taken as the MFC. 
 
3.2.2.3. Anthelmintic microdilution bioassay 
 
The anthelmintic activity of the herbal preparations was evaluated against 
Caenorhabditis elegans var. Bristol (N2) using a rapid colourimetric microdilution 
assay (JAMES and DAVEY, 2007) with modifications to obtain minimum lethal 
concentration (MLC) values. 
 
A nematode growth (NG) agar plate containing 7-day-old Caenorhabditis elegans 
culture was washed with 5 ml M9 (6 g Na2HPO4, 3 g KH2PO4, 5 g NaCl and 0.25 g 
MgSO4∙7H2O per litre) buffer and the liquid part with suspended worms, was 
transferred into a sterile McCartney bottle. The optical density (OD) at a wavelength 
of 530 nm of the M9 buffer with the nematodes was measured using a UV-visible 
spectrophotometer (Varian Cary 50, Australia). Thereafter, 5 ml M9 buffer was 
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diluted with appropriate volume of the prepared Caenorhabditis elegans culture to 
obtain a mixture with an OD530 range of 0.4 - 0.6 (100 worms/50 µl). 
 
One hundred microlitres of each resuspended herbal mixture (in water to a 
concentration of 50 mg/ml) obtained by the process explained in Section 3.1.3 were 
two-fold serially diluted with sterile distilled water, in duplicate down the microtitre 
plate. A similar two-fold serial dilution of levamisole (Sigma) (5 mg/ml) was used as a 
positive control. 50 µl of the prepared Caenorhabditis elegans culture were added to 
each well. The microtitre plates were covered with parafilm and incubated at 20 ºC 
for 48 h. After the incubation period, 50 µl of 1.25 mg/ml p-iodonitrotetrazolium 
chloride (INT) (Sigma, Germany) was added to each well and further incubated at  
20 ºC for 24 h. Active organisms biologically reduce the colourless INT to a red-pink 
colour. Nematode survival in the wells was indicated by a red-pink colour, whereas 
clear wells indicated inhibition of survival by the tested sample. MLC values were 
recorded as the lowest concentration of extract showing a clear well. Each assay 
was repeated in duplicate, two times. 
 
3.2.3. Antimicrobial and anthelmintic: Results and discussion  
 
The antibacterial MIC values for the 14 herbal preparations are presented in Table 
3.1. Antibacterial MIC values less than or equal to 1 mg/ml (ALIGIANNIS et al., 
2001) is considered to be good activity. Umzimba omubi, Umuthi wekukhwehlela ne 
zilonda, Mvusa ukunzi and Umpatisa inkosi had low activities against the bacterial 
strains tested with MIC values above 12.5 mg/ml. High antibacterial activity was 
expected from Umzimba omubi and Umuthi wekukhwehlela ne zilonda which are 
herbal preparations for wounds, boils, chest infections including tuberculosis and 
general coughs. Wounds are mostly polymicrobial, involving numerous 
microorganisms that are potentially pathogenic (LUSEBA et al., 2007). Mvusa 
ukunzi is a tonic/aphrodisiac that has less to do with microbial infections and 
accordingly low antimicrobial activity was observed. 
 
The MIC values for Vusa umzimba, Ingwe® muthi mixture, Lion izifozonke Ingwe®, 
Stameta™ BODicare®, Ingwe® special muti and Supreme one hundred were 
between 12.5 mg/ml and 1.56 mg/ml. Vusa umzimba and Lion izifozonke Ingwe®, 
53 
 
however, showed exceptional activity against Staphylococcus aureus with MIC of 
0.39 and 0.78 mg/ml respectively. Ingwe® muthi mixture, Vusa umzimba and 
Supreme one hundred are frequently used for wounds and boils. However, Ingwe® 
muthi mixture showed low activity against the tested bacterial strains. The herbal 
preparations are prepared by extraction with water. Water extracts have frequently 
been reported to have low antimicrobial activity (RABE and VAN STADEN, 1997; 
LUSEBA et al., 2007).  
 
Imbiza ephuzwato, IbhubeziTM and Sejeso herbal mixture Ingwe® showed good 
activity against the Bacillus subtilis, Staphylococcus aureus, Escherichia coli and 
Klebsiella pneumoniae strains tested. Imbiza ephuzwato is a complex multipurpose 
mixture of 21 plant species consisting of bulbs, leaves and roots. Most of the 21 
plant species that constitute Imbiza ephuzwato are used by traditional people to treat 
various conditions. Bioactive compounds with utero-active properties have been 
isolated from one of the plant species Gunnera perpensa or Ugobo in Zulu 
(BROOKES and DUTTON, 2007). Mixing plant extracts can result in synergistic 
effects and sometimes antagonistic effects which could result in either a more potent 
and/or less toxic product. 
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Table 3.1: Antibacterial activity (MIC) of herbal preparations sold in 
Pietermaritzburg, KwaZulu-Natal 
Herbal preparations 
MIC value (mg/ml) 
Bacteria 
B.s. E.c. K.p. S.a. 
Umzimba omubi >12.50 >12.50 >12.50 >12.50 
Umuthi wekukhwehlela ne zilonda >12.50 >12.50 >12.50 >12.50 
Mvusa ukunzi >12.50 >12.50 >12.50 >12.50 
Umpatisa inkosi >12.50 >12.50 >12.50 >12.50 
Imbiza ephuzwato     0.78     0.78     1.56     0.78 
Vusa umzimba     1.56     3.13     3.13     0.39 
Ingwe® muthi mixture     6.25     6.25   12.50 >12.50 
Ibhubezi™     0.78     1.56     0.78     0.78 
Supreme one hundred >12.50   12.50   12.50     6.25 
Sejeso herbal mixture Ingwe®     0.78     0.78     0.78     0.39 
Lion izifozonke Ingwe®     1.56     1.56     3.13     0.78 
Stameta™ BODicare®   12.50     6.25     3.13   12.50 
Ingwe® special muti     1.56     1.56     1.56     1.56 
African potato extractTM 1.56 3.125 1.56   0.78 
Neomycin 1.6 ×10-3 0.8×10-3 0.8×10-3 1.6×10-3 
 
B.s.=Bacillus subtilis; E.c.=Escherichia coli; K.p.=Klebsiella pneumoniae; 
S.a.=Staphylococcus aureus. 
 
Herbal extracts with MIC values written in bold font are considered to be very active 




The results for the antifungal activity (MIC) of the herbal concoctions are shown in 
Table 3.2. Umuthi wekukhwehlela ne zilonda, Mvusa ukunzi and Umpatisa inkosi 
had low antifungal activity against Candida albicans with MIC and MFC values above 
12.5 mg/ml. Umzimba omubi, Ingwe® muthi mixture and Stameta™ BODicare® had 
moderate antifungal activity. Imbiza ephuzwato, Ingwe® special muti, Vusa umzimba 
and Supreme one hundred had good antifungal activities with MIC values of 0.78 
mg/ml and MFC values of 1.56 mg/ml. IbhubeziTM, Sejeso herbal mixture and Lion 
izifozonke exhibited the best antifungal activities against Candida albicans each with 
an MIC value of 0.39 mg/ml and MFC values of 0.78, 3.125 and 6.25 mg/ml 
respectively. 
 
It is interesting to note that seven products (Lion izifozonke, Imbiza ephuzwato, 
Ingwe® special muti, Sejeso herbal mixture, Vusa umzimba, IbhubeziTM and 
Supreme one hundred) sold for treating fungal infections and skin conditions showed 
good activity against Candida albicans. However, these seven products also 
exhibited a fungistatic characteristic which is undesirable for good antifungal drugs. 
This was shown by the re-growth of the Candida albicans after the addition of YM 
broth to clear wells (MIC). There are certain conditions ideal for a herbal product or 
compound to be a good antifungal drug. The compound should be fungicidal other 
than fungistatic and should have a selective mechanism of action (ZACCHINO et al., 
2003). According to POLAK (1999), “ideal antifungal drugs are not yet discovered”. It 
is important to carry out further research on the herbal preparations which showed 




Table 3.2: Antifungal activity (MIC and MFC) of fourteen herbal preparations 
sold in Pietermaritzburg, KwaZulu-Natal 
Herbal preparations 
Candida albicans 
MIC (mg/ml) MFC (mg/ml) 
Umzimba omubi     1.56     6.25 
Umuthi wekukhwehlela ne zilonda >12.50 >12.50 
Mvusa ukunzi >12.50 >12.50 
Umpatisa inkosi >12.50 >12.50 
Imbiza ephuzwato     0.78     1.56 
Vusa umzimba     0.78     1.56 
Ingwe® muthi mixture     1.56     6.25 
Ibhubezi™     0.39     0.78 
Supreme one hundred     0.78     1.56 
Sejeso herbal mixture Ingwe®     0.39     3.125 
Lion izifozonke Ingwe®     0.39     6.25 
Stameta™ BODicare®     6.25     6.25 
Ingwe® special muti     0.78     1.56 
African potato extractTM     0.39     1.56 
Amphotericin B 9.77 × 10-3 7.81 × 10-2 
 
Herbal preparations with MIC values written in bold font are considered to have good 




The anthelmintic MLC values for the 14 herbal preparations are presented in Table 
3.3. In this study, anthelmintic MLC values equal to or less than 1 mg/ml 
(ALIGIANNIS et al., 2001) was considered to be good activity. Sejeso herbal mixture 
Ingwe®, Imbiza ephuzwato, Ingwe® muthi mixture, Lion izifozonke Ingwe® and 
African potato extractTM exhibited good anthelmintic activity. The rest of the herbal 
preparations showed low activity.  
 
Most anthelmintic drugs are taken as hot decoctions, exerting their therapeutic 
effects by cleansing the blood, promoting circulation, clearing toxins and killing the 
worms as well as their eggs. Hot decoctions can be combined with several other cold 
infusions to strengthen the detoxification power, thus herbal preparations still remain 
a hope for the discovery of anthelmintic drugs. Even though Ingwe® special muti did 
not show a good anthelmintic activity, it is administered as a hot tea thus may be 
active in that form.  
 
Moreover, because of the blood cleansing effect of anthelmintic herbs, excessive 
use or misuse have emaciating effects upon body tissues. In this regard, 
anthelmintic herbs may reduce sperm count and deplete vitality (FRAWLEY and 
LAD, 1986). It is therefore, not desirable to have prolonged use of herbal 
preparations with high anthelmintic activity such as Sejeso herbal mixture Ingwe®, 
Imbiza ephuzwato, Ingwe® muthi mixture, Lion izifozonke Ingwe® and African potato 
extractTM, as such products should be used with care. However, herbal preparations 
with high anthelminitic activity can be used synergistically or rather include nutritive 









Umzimba omubi 2.34 
Umuthi wekukhwehlela ne zilonda 1.17 
Mvusa ukunzi 4.66 
Umpatisa inkosi 4.66 
Imbiza ephuzwato 0.59 
Vusa umzimba 9.38 
Ingwe® muthi mixture 0.59 
Ibhubezi™ 4.66 
Supreme one hundred 2.34 
Sejeso herbal mixture Ingwe® 0.29 
Lion izifozonke Ingwe® 0.59 
Stameta™ BODicare® 9.38 
Ingwe® special muti 1.17 
African potato extractTM 0.59 
Levamisole 0.042 
 
Herbal extracts with minimum lethal concentration (MLC) values written in bold font 
are considered to have good activity (MIC < 1 mg/ml). 
59 
 
As expected, Lion izifozonke, Imbiza ephuzwato, Ingwe® special muti, Sejeso herbal 
mixture and Vusa umzimba herbal preparations used as multipurpose remedies 
showed moderate to higher activity against the bacterial and fungal strains used. 
Supreme one hundred exhibited selective activity against the fungus Candida 
albicans. However, this was not the case for Stameta™, a multipurpose mixture, 
fortified with vitamins, as it consistently showed lower activities against both the 
bacteria and the fungus. Activity cannot be ruled out as there are many mechanisms 
by which natural products can act when combating microbial and helminthic 
infections, including immune boosting which will in turn deal with the infection. 
 
Apart from the absence of active compounds within the herbal preparations, other 
reasons explaining the lack of antimicrobial and anthelmintic activity, includes the 
parts of the plants used, the solvent used for extraction. Water extracts have often 
been reported to have poor activity in many bioassays (LUSEBA et al., 2007). The 
location where the plants were collected, and possibly the time of collection as well 
as the storage of the material can result in lower compounds with antimicrobial 
activities. Another grave concern is the storage of the manufactured herbal 
preparations. The herbal preparations are kept in non-refrigerated places. Higher 
temperatures may lead to rapid degradation of unstable active compounds. It is also 
possible that the preparatory process of these mixtures for the assays which 
includes freeze drying and filtration could possibly inactivate or remove active 
compounds from the extracts. 
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Enzymes are the most attractive targets for drug intervention in the treatment of a 
number of human diseases. This is because of their involvement in essential 
catalytic roles in many physiological processes that may be altered during disease 
progression. The structures of enzymes have lent them well to inhibition by small 
molecular weight drugs. As a result there is a large and growing interest in the 
discovery of compounds that may serve as enzyme inhibitors. Enzyme inhibitors 
represent almost half the drugs in clinical use at the moment (COPELAND, 2005).  
 
Prostaglandins are known to be involved in many physiological processes such as 
the regulation of blood flow to organs, stimulation of protective mucosal linings in the 
gastrointestinal tract as well as the participation in the initiation of platelet 
aggregation in blood clotting, bone resorption, ovulation and the mediation of the 
classic symptoms of inflammation such as pain, swelling and fever (MORITA, 2002; 
COPELAND, 2005). Prostaglandins are derived from arachidonic acid by an 
enzymic reaction catalysed by a single class of enzyme referred to as 
cyclooxygenase (COX) or prostaglandin synthase. Research studies in the 1990s led 
to the conclusion that there exist two isoforms of the COX enzymes, having distinct 
functions in the tissues and organs. This raised a possibility that selective inhibition 
of either COX isoenzyme may have useful therapeutic outcomes (HANSEN et al., 
1999). The two isoenzymes are referred to as COX-1 and COX-2.  
 
COX-1 is consistently expressed in a wide variety of tissues while COX-2 is induced 
in response to pro-inflammatory stimuli. Nonsteriodal anti-inflammatory drugs 
(NSAID) are used for the treatment of inflammation. Aspirin and Ibuprofen (Brufen) 
are the mostly used examples of NSAIDs for pain and fever. All the NSAIDs exert 
their therapeutic function by blocking or inhibiting the two COX isoenzymes. 
Unfortunately, the use of NSAIDs results in side effects including gastric and renal 
ulceration from long term usage. It was later elaborated that these side effects were 
associated with inhibition of COX-1 while the anti-inflammatory activity was due to 
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inhibition of COX-2 (COPELAND, 2005). It is therefore important to have natural 
products with COX-2 selective inhibition, in the hope that such products will exhibit 
good anti-inflammatory efficacy with or without reduced side effects that are common 
with inhibition of COX-1 as with NSAIDs usage. 
 
HIV-1 reverse transcriptase (RT) is a DNA dependent polymerase that catalyses the 
synthesis of a double stranded DNA copy from a single stranded HIV-RNA. The 
enzyme is for that reason, essential for the life cycle of HIV-1 and hence, a target for 
anti-HIV therapy (SPALLAROSSA et al., 2009). The current therapeutic drugs 
against HIV infections include the inhibitors of RT and protease enzymes. These 
include the nucleoside RT inhibitors, nucleotide RT inhibitors and the non-nucleoside 
RT inhibitors. All non-nucleoside RT inhibitors bind to an allosteric binding pocket 
(i.e. a site other than the enzyme‟s active site) (DE CLERCQ, 2009). The formation 
of a RT-non-nucleoside RT inhibitor complex results in short and long range 
structural changes that make the enzyme inactive (SPALLAROSSA et al., 2009).  
 
Presently, the oral prodrug forms of nucleoside RT inhibitors have been approved for 
the treatment of HIV infections. A prodrug is a substance that is prescribed and 
taken orally in an inactive or less active form. Once administered, the prodrug is 
metabolized in vivo into an active form. The use of prodrugs generally increases 
absorption, distribution and metabolism of most oral pharmaceuticals. The prodrugs 
include zidovudine, didanosine, lamivudine, stavudine, zalcitabine, abacavir, 
nevirapine, ritonavir and emtricitabine (DE CLERCQ, 2009). 
 
Although anti-retroviral drugs have resulted in an improvement of the quality of life 
amongst HIV infected humans (i.e. eating and sleeping well, and keeping a positive 
outlook on life), the development of resistance, appreciable levels of toxicity, high 
cost, unavailability and lack of curative effect are their major short-comings 
(BESSONG et al., 2005). These short-comings, especially the appearance of drug 
resistant virus strains have resulted in increased efforts for the search of better anti-
HIV agents and much attention is now being directed towards natural products 




The prevalence of HIV in South Africa is a prominent health concern because South 
Africa is believed to have more people infected than in any other country. HIV/AIDS 
prevalence in South Africa is an epidemic of shattering dimensions with more than 5 
million people infected by 2002 (BESSONG et al., 2005). The high prevalence of 
HIV among poor people in South Africa has resulted in the increase in usage of 
medicinal plants and herbal products. The beneficial effects of herbal preparations 
and remedies could be due to direct inhibition of HIV replication by blocking RT, 
boosting of the immune system or curative effects on the opportunistic infections 
(MILLS et al., 2005). 
 
Besides the COX and RT enzymes, another pharmacologically important enzyme 
used in drug development is acetylcholinesterase (AChE), that catalyses the 
hydrolytic degradation of the neurotransmitter acetylcholine, resulting in choline and 
an acetate group. AChE is found at neuromuscular junctions and cholinergic 
synapses in the central nervous system (CNS), where its activity serves to terminate 
synaptic transmission (VOET and VOET, 1995). Alzheimer‟s disease (AD) that 
occurs frequently in elderly people is caused by malfunctioning of biochemical 
pathways associated with the production of the neurotransmitter acetylcholine 
resulting in progressive memory loss and cognitive impairment (LIN et al., 2008). 
Treatment of AD takes advantage of AChE inhibition. Galanthamine, an alkaloid 
isolated from snowdrop (Galanthus nivalis, in the family Amaryllidaceae), is a well 
known AChE inhibitor and is widely used for AD treatments (FERREIRA et al., 2006; 
STAFFORD et al., 2008). 
 
Apart from the use in treatment of AD, AChE inhibitors are also used in the control of 
Myasthenia gravis, an autoimmune disorder, in which there is severe muscle 
weakness caused by circulating antibodies that block acetylcholine receptors at the 
post-synaptic neuromuscular junction, inhibiting the stimulative effect of acetylcholine 
(RAJ et al., 2005). 
 
There is a wide usage of herbal preparations for pain related conditions, which could 
involve inflammation responses. The high prevalence of HIV infection has also left a 
number of patients to rely on herbal products to counteract the infection. Herbal 
preparations are also widely used for reviving memory loss and stress related 
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problems amongst the depressed and old people. The fourteen commercial herbal 
preparations were evaluated for their inhibitory activities against COX-1 and COX-2, 
HIV-1 RT and AChE. 
 
3.3.2. Materials and methods 
 
3.3.2.1. Cyclooxygenase 1 (COX-1) inhibitory bioassay 
 
The COX-1 bioassay was performed as described by JÄGER et al., (1996). The 
COX-1 enzyme isolated from ram seminal vesicles was obtained from Sigma-
Aldrich. A stock solution of COX-1 enzyme was stored at -70 °C until use. The 
enzyme was activated with 1250 µl of co-factor solution (0.3 mg/ml L-adrenaline and 
0.3 mg/ml reduced glutathione in 0.1 M Tris buffer, at pH 8.0) and pre-incubated on 
ice for 5 min. In 1.5 ml Eppendorf tubes, 60 µl of the enzyme solutions were added to 
each sample solution (20 µl of 10 mg/ml sample giving a final assay concentration of 
2 mg/ml) in duplicate and the mixture was incubated at room temperature for 5 min. 
Two separate sets of Eppendorf tubes, labelled the background (the enzyme was 
inactivated with HCl before incubation), solvent blank (containing water instead of 
sample) and positive control (containing 5 µM indomethacin obtained from Sigma) 
were included in the test. After 5 min of incubation, the reaction was started by 
adding 20 µl 14C-arachidonic acid (16 Ci/mol, 30 µM) to each Eppendorf tube. The 
preparations were incubated in a water bath at 37 ºC for 10 min and afterwards the 
reaction was stopped by adding 10 µl 2N HCl except in the background tubes. Glass 
columns were packed with silica gel (silica gel 60, 0.063-0.200 mm, Merck) to a 
height of 3 cm in Pasteur pipettes. Four microlitres (0.2 mg/ml) of unlabeled 
prostaglandins (PGE2: PGF2α 1:1) (Sigma-Aldrich) were added to each Eppendorf 
tube as a carrier solution.  
 
The test solutions were applied to the columns with 1 ml of eluent 1 [hexane: 1, 4-
dioxane: glacial acetic acid (70:30:0.2 v:v:v)]. This was done to separate the 
prostaglandins and unmetabolized arachidonic acid. The arachidonic acid was eluted 
first with 4 ml eluent 1. The prostaglandin products were eluted with 3 ml of eluent 2 
[ethyl acetate: methanol (85:15 v:v)] and collected in scintillation vials. To each vial, 
4 ml of scintillation fluid were added and the disintegration per minute of the 
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radioactive material was counted using a scintillation counter (Beckman LS 6000LL 
scintillation counter). The assay was repeated twice. Inhibition percentage was 
calculated using the equation below: 
 
COX inhibition  %  =  1 –  
 DPMextract   –  DPMbackground   
 DPMsolvent blank   – DPMbackground  
   × 100 
 
where DPMsample is the disintegrations per minute for plant extract, 
DPMbackground is the disintegrations per minute in which the enzyme was 
inactivated and DPMblank is the disintegrations per minute for the reaction mixture 
containing water. Results are presented as means ± standard errors of two 
independent experiments, each experiment in duplicate. The IC50 values of herbal 
preparations were calculated using Graph Pad Prism (version 4.0) statistical 
software programme for Windows (GraphPad Software Inc.). 
 
3.3.2.2. Cyclooxygenase 2 (COX-2) inhibitory bioassay 
 
The COX-2 activity was assessed using a method described by NOREEN et al. 
(1998), with slight modifications (ZSCHOCKE and VAN STADEN, 2000). Human 
recombinant COX-2 enzyme containing a six histidine sequence near the N-terminus 
isolated from a Baculovirus over expression system in Sf 21 cells was used (Sigma-
Aldrich). Ten microlitre of the enzyme containing 3 units were prepared and stored at 
-70 ºC until use. The enzyme was activated with 1450 µl co-factor solution (0.6 
mg/ml L-adrenaline, 0.3 mg/ml reduced glutathione and 1 µM hematin in 0.1 M Tris 
buffer, pH 8.0) and pre-incubated on ice for 5 min. In 1.5 ml Eppendorf tube, 60 µl of 
the enzyme solution were added to each sample solution (20 µl of 10 mg/ml sample 
giving a final assay concentration of 2 mg/ml) in duplicate and the mixture was 
incubated at room temperature for 5 min. Two separate sets of Eppendorf tubes, 
labelled the background (the enzyme was inactivated with HCl before incubation), 
solvent blank (containing water instead of sample) and positive control (containing 
200 µM indomethacin obtained from Sigma) were included in the test. After 5 min of 
incubation, the reaction was started by adding 20 µl 14C-arachidonic acid (16 Ci/mol, 
30 µM) to each Eppendorf tube. The reaction preparations were incubated in a water 
bath at 37 ºC for 10 min and afterwards the reaction was stopped by adding 10 µl 2N 
HCl except in the background tubes. Glass columns were packed with silica gel 
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(silica gel 60, 0.063-0.200 mm, Merck) to a height of 3 cm in Pasteur pipettes. Four 
microlitres (0.2 mg/ml) of unlabeled prostaglandins (PGE2: PGF2α 1:1) (Sigma-
Aldrich) were added to each Eppendorf tube as a carrier solution.  
 
The test solution was applied to the column with 1 ml of eluent 1 [hexane: 1, 4-
dioxan: glacial acetic acid (70:30:0.2)]. This was done to separate the prostaglandins 
and unmetabolized arachidonic acid. The arachidonic acid was eluted first with 4 ml 
eluent 1. The prostaglandin products were eluted with 3 ml of eluent 2 [ethyl acetate: 
methanol (85:15)] and collected in scintillation vials. To each vial 4 ml of scintillation 
fluid were added and the disintegration per minute of the radioactive material was 
counted using a scintillation counter (Beckman LS 6000LL scintillation counter). 
Inhibition percentage was calculated using the equation below: 
 
COX inhibition  %  =  1 –  
 DPMextract   –  DPMbackground   
 DPMsolvent blank   – DPMbackground  
   × 100 
 
Where DPMsample is the disintegrations per minute for herbal preparations, 
DPMbackground is the disintegrations per minute in which the enzyme was 
inactivated and DPMblank is the disintegrations per minute for the reaction mixture 
containing water. Results are presented as means ± standard errors of two 
independent experiments, with each herbal preparation being tested in duplicate. 
The IC50 values of herbal preparations were calculated using Graph Pad Prism 
(version 4.0) statistical software programme for Windows (GraphPad Software Inc.). 
 
3.3.2.3. HIV-1 reverse transcriptase (RT) inhibitory bioassay 
 
The effect of the herbal preparations on reverse transcription was evaluated using a 
non-radioactive HIV-RT colourimetric ELISA kit obtained from Roche Diagnostics, 
Germany. The protocol supplied together with the kit was followed, under nuclease-
free conditions. The reverse transcriptase colourimetric assay, takes advantage of 
the ability of RT to synthesize DNA, starting from the template/primer hybrid poly  
(A) × oligo (dT)15. The kit avoids the use of [3H]- or [32P]-labelled nucleotides which 
are used for the other classical RT assays. In place of radio-labelled nucleotides, 
digoxigenin- and biotin-labelled nucleotides are incorporated into one and the same 
DNA molecule, which is freshly synthesized by the RT. The detection and 
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quantification of synthesized DNA as a parameter for RT activity is followed in a 
sandwich ELISA protocol: Biotin-labelled DNA freshly synthesized by the RT, binds 
to the surface of microtitre plate modules (MPM) with wells that were precoated with 
streptavidin. In the next step, an antibody to digoxigenin, conjugated to peroxidase 
(anti-DIG-POD), binds to the digoxigenin-labelled DNA. In the final step, the 
peroxidase substrate ABTS (2, 2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]- 
diammonium salt) is added. The peroxidase enzyme catalyzes the cleavage of the 
substrate, producing a coloured reaction product which is measured 
spectrophotometrically.  
 
The following solutions, provided with the kit were prepared according to the 
manufacturer; Solution 1, HIV-1 reverse transcriptase (final concentration 2 ng/μl, 
corresponding to 10 mU/μl) stored at -70 ºC. Solution 2, incubation buffer. Solution 3, 
reaction mixture containing poly (A) x oligo (dT)15 (46 mM Tris-HCl, 266 mM 
potassium chloride, 27.5 mM magnesium chloride, 9.2mM DDT, 10 μM dUTP/dTTP, 
template/primer hybrid, 750 mA260 nm/ml). Solution 4, lysis buffer. Solution 5,  
anti-digoxigenin-peroxidase (anti-DIG-POD) (200 mU/ml). Solution 6, washing buffer 
and solution 7, ABTS substrate solution. 
 
In sterile Eppendorf tubes, 20 µl of resuspended herbal preparations (with final assay 
concentrations of 0.25, 2.5, 25, 250, 2500 µg/ml) or controls were mixed with 20 µl of 
recombinant HIV-1-RT (4 ng in lysis buffer) and 20 µl reaction mixture (solution 3) 
and the tubes were incubated for 1 h at 37 °C. After the 1 h incubation period, the 
contents of the tubes (60 µl) were transferred into a MPM wells. The MPM were 
covered with foil and incubated for 1 h at 37 °C after which the contents were 
removed from the MPM wells completely. The wells were rinsed 5 times with 250 μl 
of washing buffer (solution 6) per well for 30 s, the washing buffer being removed 
carefully after each wash. After the wash, 200 μl of anti-DIG-POD (solution 5) was 
added to each well and the MPM were recovered with foil and incubated for 1 h at  
37 °C. After the incubation period, the solution was removed completely from the 
MPM wells. The MPM wells were rinsed 5 times with 250 μl of washing buffer 
(solution 6) per well for 30 s, the washing buffer being removed carefully after each 
wash. After washing, 200 μl of ABTS substrate solution (solution 7) was added to 
each well and the MPM were incubated at room temperature for 5 minutes (a green 
67 
 
colour appeared in the wells). The absorbance of the reaction mixture was then 
measured at 405 nm (reference wavelength: 490 nm) using a microplate reader 
(Opsys MRTM, Dynex Technologies Inc.). Percentage of inhibition was calculated by 
comparing the absorbance of the sample to the negative control using the equation 
below: 
HIV-1 RT inhibition  %  =  1 –  
 Abs405 nm     Sample  
 Abs405 nm     Neg Control 
   × 100 
 
where Abs405nm Sample is the absorbance of the reaction with herbal preparations or 
positive control at 405 nm and Abs405nm Neg Control is the absorbance of reaction 
with water instead of sample at 405 nm. 
 
Three tubes containing water instead of sample were used as a negative controls. 
Another set of three tubes containing lysis buffer and no HIV-1-RT added were 
included. Combivir® (GlaxoSmithKline) [lamivudine (1.0 mg/ml) + zidovudine (2.0 
mg/ml)] and Kaletra® (Abbott) [lopinavir (8.9 mg/ml) + ritonavir (2.2 mg/ml)]. Results 
were presented as means ± standard errors of two independent experiments; each 
experiment was done in duplicate. The IC50 values of herbal preparations were 
calculated using Graph Pad Prism (version 4.0) statistical software programme for 
Windows (GraphPad Software Inc.). 
 
3.3.2.4. Acetylcholinesterase (AChE) enzyme inhibitory bioassay 
 
Inhibition of AChE by the herbal preparations was done as described by ELLMAN et 
al. (1961) with some modifications. The acetylcholinesterase enzyme activity was 
measured by spectrophotometric observation of the increase in a yellow colour 
produced from thiocholine when it reacts with the dithiobisnitrobenzoate ion. The 
following buffers were used; Buffer A: 50 mM Tris-HCl, pH 8; Buffer B: 50 mM Tris-
HCl, pH 8, containing 0.1% bovine serum albumin (BSA); Buffer C: 50 mM Tris-HCl, 
pH 8, containing 0.1 M NaCl and 0.02 M MgCl2·6H2O. Acetylthiocholine iodide 
(ATCI), galanthamine, 5,5-dithiobis-2-nitrobenzoic acid (DTNB) and AChE (isolated 




In a 96-well plate, 25 µl of herbal preparations at an initial concentration of 10 mg/ml 
were added to the first well and serially diluted two-fold down the plate. To the 
diluted sample, 25 µl of 15 mM ATCI in water, and 125 µl of 3 mM DTNB in buffer C 
were added, followed by 50 µl of buffer B. The absorbance of the reaction mixture 
was then measured three times at 405 nm every 45 s using a microplate reader 
(Opsys MRTM, Dynex Technologies Inc.). After the third reading, 25 µl of 0.2 U/ml 
AChE in buffer A was added. The absorbance was measured again every 45 s for a 
further five times. The final concentration of the herbal preparations in the first well 
containing the highest concentration was 1.0 mg/ml. Galanthamine at 0.12, 0.23, 
0.46, 0.92, 1.84, 3.68 and 7.37 µg/ml concentrations and water were used as 
positive and negative controls respectively. The increase in absorbance due to the 
spontaneous hydrolysis of the substrate was corrected by subtracting the ratio of 
reaction before adding the enzyme from the rate after adding the enzyme. 
Percentage of inhibition was calculated by comparing the reaction rates for the 
sample to the negative control. Results were presented as means ± standard errors 
of the experiment in duplicate. The IC50 values of herbal preparations were 
calculated using Graph Pad Prism (version 4.0) statistical software programme for 
Windows (GraphPad Software Inc.). 
 
3.3.3. Enzyme inhibition: Results and discussion  
 
Figure 3.2 represents the percentage inhibition of COX-1 and COX-2 enzymes by 
the fourteen herbal preparations. Four levels of activity are defined in the COX assay 
with activity below 20% being considered insignificant, 20–40% low, 40–70% 
moderate, and 70–100% high (TAYLOR and VAN STADEN, 2001). The level to 
which the herbal preparations could inhibit the COX-1 enzyme can consequently be 
considered high for Imbiza ephuzwato, Vusa umzimba, Ingwe® muthi mixture, 
Ibhubezi™, Lion izifozonke Ingwe®, Stameta™ and African potato extractTM and 
moderate for Umzimba omubi, Mvusa ukunzi, Umpatisa inkosi, Sejeso herbal 
mixture Ingwe®, and Ingwe® special muti. COX-1 inhibitory activity was insignificant 
for Umuthi wekukhwehlela ne zilonda and Supreme one hundred although both 




Imbiza ephuzwato, Vusa umzimba, Ingwe® muthi mixture, Ibhubezi™, Sejeso herbal 
mixture Ingwe® and African potato extractTM showed high COX-2 inhibitory activity 
while Lion izifozonke Ingwe® and Ingwe® special muti exhibited moderated activity. 
The rest of the preparations showed low activity and none had insignificant activity. 
 
The lower doses of herbal preparations assayed for COX-1 and COX-2 were used to 
calculate IC50 values (concentration effective to cause a 50% enzyme inhibition) The 
IC50 values are presented in Table 3.4. IC50 values less than 1 mg/ml were 
considered to represent good COX inhibitory activity. The order of the active herbal 
preparations with respect to the IC50 values for COX-2 were Imbiza ephuzwato > 
African potato extractTM > Vusa umzimba > Sejeso herbal mixture > Ibhubezi™. For 
COX-1, the order was as follows; Imbiza ephuzwato > Lion izifozonke Ingwe® > 
African potato extractTM > Ingwe® special muti > Sejeso herbal mixture. The IC50 
value for Sejeso herbal mixture was lower in COX-2 compared to COX-1, suggesting 
the mixture could be a COX-2 selective inhibitor. Lion izifozonke and Ingwe® special 
muti showed lower IC50 values for COX-1 than COX-2 thus the preparations are 
COX-1 selective inhibitor. 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) that exert their therapeutic effects 
by blocking the COX enzymes are still being used in the treatment of inflammation, 
fever, pain and thrombosis although they have a tendency to cause significant 
damage in the gastrointestinal tract, resulting in ulcers (KIM et al., 2005). Therefore, 
plant remedies are becoming popular and are now often preferred to synthetically 
derived drugs. COX-1 catalyses the production of prostaglandins involved in 
prostanoid-mediated physiological functions such as gastric cytoprotection, 
maintenance of renal homeostasis, and normal platelet functions and its inhibition 
could is associated with serious side effects. Because of the side effects such as the 
damage to the gastrointestinal tract, it is undesirable to have a remedy that has high 
COX-1 activity (LUSEBA et al., 2007). Prolonged use of products with high COX-1 
inhibitory activity such as Lion izifozonke and Ingwe® special muti, Imbiza 
ephuzwato, Vusa umzimba, Ingwe® muthi mixture, Ibhubezi™ may be associated 
with damage in the gastrointestinal tract. It is therefore important to develop 





























Figure 3.2: Percentage inhibition of COX-1 (■) and COX-2 (□) by commercial herbal 
preparations at the highest concentration (2 mg/ml); (1) Umzimba omubi, (2) Umuthi 
wekukhwehlela ne zilonda, (3) Mvusa ukunzi, (4) Umpatisa inkosi, (5) Imbiza 
ephuzwato, (6) Vusa umzimba, (7) Ingwe® muthi mixture, (8) Ibhubezi™, (9) 
Supreme one hundred, (10) Sejeso herbal mixture Ingwe®, (11) Lion izifozonke 
Ingwe®, (12) Stameta™ BODicare®, (13) Ingwe® special muti and (14) African potato 
extractTM. Herbal preparations with inhibitory activity above 70% were considered to 
be highly active. Percentage inhibition by indomethacin was 64.18 ± 3.10 and 68.50 
± 2.57 for COX-1 and COX-2 respectively. Indomethacin® concentrations were 5 µM 
and 200 µM for COX-1 and COX-2 respectively. 
 






















Table 3.4: IC50 values for the inhibition of COX-1 and COX-2 enzymes by the 
fourteen herbal preparations sold in Pietermaritzburg, KwaZulu-Natal 
Herbal preparations 
IC50 Values (mg/ml) 
COX-1 COX-2 
Umzimba omubi 2.14 ± 0.02 4.44 ± 0.06 
Umuthi wekukhwehlela ne zilonda 4.23 ± 0.06 2.89 ± 0.05 
Mvusa ukunzi 1.99 ± 0.21 4.74 ± 0.14 
Umpatisa inkosi 2.33 ± 0.05 3.41 ± 0.09 
Imbiza ephuzwato 0.41 ± 0.03 0.43 ± 0.02 
Vusa umzimba 0.64 ± 0.02 0.61 ± 0.01 
Ingwe® muthi mixture 1.53 ± 0.08 1.43 ± 0.12 
Ibhubezi™ 0.87 ± 0.13 0.66 ± 0.04 
Supreme one hundred 4.51 ± 0.05 2.55 ± 0.01 
Sejeso herbal mixture Ingwe® 0.89 ± 0.01 0.65 ± 0.04 
Lion izifozonke Ingwe® 0.65 ± 0.04 1.81 ± 0.04 
Stameta™ BODicare® 1.91 ± 0.04 4.71 ± 0.79 
Ingwe® special muti 0.87 ± 0.08 1.54 ± 0.05 
African potato extractTM 0.66 ± 0.06 0.55 ± 0.12 
 







The HIV-1 RT inhibitory activity of the herbal preparations is shown in Figure 3.3. 
Only four of the fourteen herbal preparations (Imbiza ephuzwato, Ingwe® muthi 
mixture, Sejeso herbal mixture Ingwe® and African potato extractTM) showed good 
activity (> 50%) at 2.5 mg/ml. The rest of the preparations showed moderate to low 
activity. 
 
The IC50 values presented in Table 3.5 show that Ingwe
® muthi mixture > Imbiza 
ephuzwato > African potato extractTM > Sejeso herbal mixture Ingwe®, in that order, 
are potent inhibitors of the HIV-1 RT. The mechanisms of action of these four herbal 
preparations could be through a conformational change on the HIV-1 RT thereby 
rendering it inactive. It is also possible that the herbal preparations may contain 
compounds that may act as competitive inhibitors of the HIV-1 RT. Since these 
preparations are made of a mixture of plant species, there is a possibility that the 
compounds may be novel. It is therefore important to carry out bioassay guided 
fractionation in order to isolate the active principles. 
 
In South Africa, there is a rapid proliferation of the consumption of plant based 
decoctions and herbal preparations by HIV infected people (BESSONG et al., 2005), 
and this is likely to increase as more people become infected and are desperate to 
get well. The preparation of herbal preparations is cheap and simple; hence they 
remain a hope for the infected people who cannot access the government sponsored 
antiretroviral (ARV) programmes. 
 
Basing on the results presented in Figure 3.3 and Table 3.5, herbal mixtures such as 
Imbiza ephuzwato, Ingwe® muthi mixture, Sejeso herbal mixture Ingwe® and African 
potato extractTM have great potential for use as anti-HIV-1 RT inhibitors. However, 
more studies are still required to confirm such activity both in vitro and in vivo. It is 
therefore, important to determine the plant species used to make these four herbal 
preparations as well as to isolate the active compounds from the mixture. Upon 
isolation of active compounds, the mechanisms of action of the herbal mixture as 





















Figure 3.3: Percentage inhibition of HIV-1 RT by commercial herbal preparations 
(2.5 mg/ml); (1) Umzimba omubi, (2) Umuthi wekukhwehlela ne zilonda, (3) Mvusa 
ukunzi, (4) Umpatisa inkosi, (5) Imbiza ephuzwato, (6) Vusa umzimba, (7) Ingwe® 
muthi mixture, (8) Ibhubezi™, (9) Supreme one hundred, (10) Sejeso herbal mixture 
Ingwe®, (11) Lion izifozonke Ingwe®, (12) Stameta™ BODicare®, (13) Ingwe® special 
muti and (14) African potato extractTM. Herbal preparations with inhibitory activity 
above 70% were considered to be highly active. Percentage inhibition by Combivir®  




























Table 3.5: HIV-1 RT inhibitory activity (IC50 mg/ml) of fourteen herbal 
preparations sold in Pietermaritzburg, KwaZulu-Natal 
Herbal preparations 
HIV-1 RT inhibitory activity 
IC50 (mg/ml) 
Umzimba omubi            2.628 ± 0.645 
Umuthi wekukhwehlela ne zilonda            2.762 ± 0.400 
Mvusa ukunzi            3.500 ± 1.605 
Umpatisa inkosi            2.177 ± 0.100 
Imbiza ephuzwato            0.152 ± 0.001 
Vusa umzimba            3.493 ± 1.008 
Ingwe® muthi mixture            0.095 ± 0.008 
Ibhubezi™            3.983 ± 0.100 
Supreme one hundred            4.320 ± 0.336 
Sejeso herbal mixture Ingwe®            0.367 ± 0.083 
Lion izifozonke Ingwe®            2.389 ± 0.309 
Stameta™ BODicare®            3.025 ± 0.026 
Ingwe® special muti            2.332 ± 0.764 
African potato extractTM            0.364 ± 0.022 
Combivir®            0.065 ± 0.003   
Kaletra®            0.330 ± 0.105 
 





The results of AChE inhibitory activity are presented in Figure 3.4. Nine out of 
fourteen herbal preparations showed inhibitory activity above 50%. Imbiza 
ephuzwato, Umpatisa inkosi, African potato extractTM, Sejeso herbal mixture Ingwe® 
and Vusa umzimba showed good AChE inhibitory activity (> 80%). Ingwe® muthi 
mixture, Ibhubezi™, Lion izifozonke Ingwe® and Ingwe® special muti exhibited 
moderate AChE inhibitory activity (between 50% and 70%). The rest of the herbal 
preparations exhibited very low activity (< 20%). 
 
The IC50 values for herbal preparations with dose dependent activity are shown in 
Table 3.6. Five of the herbal preparations (Umzimba omubi, Umuthi wekukhwehlela 
ne zilonda, Mvusa ukunzi, Supreme one hundred and Stameta™ BODicare®) did not 
show dose dependant activity, making it impossible to calculate IC50 values. The 
order of potent activity with respect to IC50 values was: Imbiza ephuzwato > Sejeso 
herbal mixture Ingwe® > African potato extractTM > Vusa umzimba > Umpatisa inkosi 
> Ibhubezi™ > Ingwe® special muti > Ingwe® muthi mixture > Lion izifozonke Ingwe®.  
 
Umpatisa inkosi, a male tonic used as an aphrodisiac and lucky charm showed good 
activity against AChE, as expected. Herbal preparations used as lucky charms 
(Umpatisa inkosi) are likely to contain plants with psychoactive effects, exerting their 
therapeutic effects by blocking AChE. This is also possible for the rest of the herbal 
preparations which showed activity against AChE as they are multipurpose products. 
Such herbal preparations are likely to contain high levels of alkaloids, known potent 
inhibitors of AChE. The results of this study indicate that nine out of fourteen herbal 






















Figure 3.4: Percentage inhibition of AChE by commercial herbal preparations  
(1 mg/ml); (1) Umzimba omubi, (2) Umuthi wekukhwehlela ne zilonda, (3) Mvusa 
ukunzi, (4) Umpatisa inkosi, (5) Imbiza ephuzwato, (6) Vusa umzimba, (7) Ingwe® 
muthi mixture, (8) Ibhubezi™, (9) Supreme one hundred, (10) Sejeso herbal mixture 
Ingwe®, (11) Lion izifozonke Ingwe®, (12) Stameta™ BODicare®, (13) Ingwe® special 
muti and (14) African potato extractTM. Herbal preparations with inhibitory activity 
above 70% were considered to be highly active. Percentage inhibition by 
galanthamine (20 µM) was 89.90 ± 0.32. 
 
 























Table 3.6: AChE inhibitory activity (IC50 mg/ml) of fourteen herbal preparations 
sold in Pietermaritzburg, KwaZulu-Natal 
Herbal preparations 
AChE inhibitory activity 
IC50 (mg/ml) 
Umzimba omubi             NC 
Umuthi wekukhwehlela ne zilonda             NC 
Mvusa ukunzi             NC 
Umpatisa inkosi     297.00 ± 5.00 
Imbiza ephuzwato         0.48 ± 0.01 
Vusa umzimba       26.50 ± 0.10 
Ingwe® muthi mixture          950 ± 30.00 
Ibhubezi™     367.35 ± 35.85 
Supreme one hundred             NC 
Sejeso herbal mixture Ingwe®       21.50 ± 9.50 
Lion izifozonke Ingwe®         0.96 ± 0.01 
Stameta™ BODicare®             NC 
Ingwe® special muti             NC 
African potato extractTM      0.023 ± 0.01 
Galanthamine          1.6 ± 06 (µM) 
 
Herbal preparations with IC50 values in bold are considered potent inhibitors of AChE. 
 




The use of enzymes in drug discovery is on the increase, and it coincides with the 
widespread use of commercialized herbal products that still need quality control 
(COPELAND, 2005). Based on IC50 values, Imbiza ephuzwato, Sejeso herbal 
mixture Ingwe®, Lion izifozonke Ingwe®, Ingwe® muthi mixture and African potato 
extractTM showed consistent potent activities against the three enzymes (COX, RT 
and AChE) used in this study. The observed activities validate the use of these 
herbal preparations in treating pain related conditions, eradicating HIV/AIDS 
symptoms and mental conditions. 
 
Poor or lower inhibition of enzymes in these bioassays by some herbal preparations 
does not rule out activities as some plant compounds exert their therapeutic effects 
through other pathways, resulting also in relief of symptoms. During the anti-
inflammation process, some compounds act as inhibitors of the nuclear factor κB 
(NF κB) mediated signalling pathways in immune cells that leads to the production of 
the inducible COX enzymes themselves and other pro-inflammatory cytokines 
(POLYA, 2003). Thus, such compounds will not inhibit COX enzymes but would 
rather suppress its production, achieving the same anti-inflammatory activity as 









Free radicals produced from oxygen to form reactive oxygen species such as the 
singlet oxygen, superoxide, peroxyl, hydroxyl and peroxynitrite radicals, are 
constantly produced within living cells for specific metabolic purposes (WAFFO-
TÉGUO et al., 2008). Living cells have complex mechanisms that act as antioxidant 
systems to counteract the damaging effects of reactive species. These antioxidant 
systems include enzymes such as superoxide dismutase, catalase, and glutathione 
peroxidase. Apart from enzyme systems, macromolecules such as albumin, 
ceruloplasmin, and ferritin; and an array of small molecules, including ascorbic acid, 
alpha-tocopherol, carotenoids, polyphenols, ubiquinol, reduced glutathione (GSH), 
methionine, uric acid, and bilirubin also act as protective systems of living cells 
against oxidation (KATALINIC et al., 2005).  
 
Overproduction of free radicals (Oxidative stress), which occurs when the cell‟s 
natural antioxidant systems are overwhelmed, results in severe damage to biological 
molecules, especially to DNA, proteins and lipids. Oxidative stress has been 
associated with the progression of chronic conditions such as cancer, aging, 
atherosclerosis, inflammation, cardiovascular disease, diabetes, and 
neurodegenerative diseases such as Parkinson‟s and Alzheimer‟s diseases 
(ORHAN et al., 2009). 
 
Natural compounds, which are present in herbal products, vegetables, fruits and 
grains, possess the ability to reduce oxidative damage by acting as antioxidants 
(SIDDHURAJU and BECKER, 2007). An antioxidant is a substance that, even in 
small quantities is able to prevent, or greatly delay, the oxidation of an oxidizable 
substance (BECKER et al., 2004). The oxidation process proceeds as a chemical 
reaction that transfers electrons from a reducing substance to an oxidizing agent, 
forming chain reactions that can be difficult to contain. Antioxidants terminate these 
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chain reactions by removing free radical intermediates, and inhibit other oxidation 
reactions by getting themselves oxidized (BECKER et al., 2004). 
 
The consumption of herbal products, vegetables, fruits and grains has been linked to 
reduced risk of several conditions, including cancer and cardiovascular diseases. 
The fourteen commercial herbal preparations were evaluated for their antioxidant 
potentials including the DPPH (2,2–diphenyl–1–picryl hydrazyl) radical scavenging 
activity, ferric-reducing power (FRAP) and the ability to delay or halt the bleaching of 
β-carotene-linoleic acid in a model system. 
 
3.4.2. Materials and methods 
 
3.4.2.1. Diphenyl–1–picryl hydrazyl (DPPH) radical scavenging activity 
 
The DPPH radical scavenging assay was done as described by KARIOTI et al. 
(2004) with modifications. Fifteen microlitres of each resuspended herbal preparation 
(0.065, 0.26,0.52, 1.04, 6.25, 12.5, 25 and 50 mg/ml, in triplicate), was diluted in 
methanol (735 µl) and added to freshly prepared methanolic DPPH solution (750 µl, 
50 µM) to give a final volume of 1.5 ml in the reaction mixture. The reaction 
preparations were prepared under dim light and incubated at room temperature for 
30 min in the dark. Absorbance was read at 517 nm using a UV-vis 
spectrophotometer (Varian Cary 50, Australia), with methanol as the blank solution. 
A standard antioxidant, ascorbic acid (5, 10, 20, 40, 80 µM) was used as a positive 
control. A solution with the same chemicals without the herbal preparations or 
standard antioxidants served as the negative control. The assay was repeated twice. 
The free radical scavenging activity (RSA) as determined by the decolouration of the 
DPPH solution was calculated according to the formula: 
 
RSA  %  =  1 –  
 Abs517 nm    Sample  
 Abs517 nm    Neg Control 
   × 100 
 
where Abs517 sample is the absorbance of the reaction mixture containing the 
resuspended herbal preparation or positive control solution, and Abs517 Neg control  
is the absorbance of the negative control. The EC50 values, representing the amount 
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of extract required to decrease the absorbance of DPPH by 50% was calculated 
from the percentage radical scavenging activity. 
 
3.4.2.2. Ferric-reducing power (FRAP) assay 
 
The ferric reducing power of the commercial herbal preparations was determined 
based on the method by LIM et al. (2009) with modifications. The ferric-reducing 
power assay involves the reduction of the Fe3+/ferricyanide complex to the ferrous 
(Fe2+) form. Thirty microlitres of each resuspended herbal preparation (6.25 mg/ml) 
or the positive control, ascorbic acid dissolved in methanol was added to a 96 well 
microtitre plate in triplicate and two-fold serially diluted down the wells of the plate. 
To each well, 40 µl potassium phosphate buffer (0.2M, pH 7.2) and 40 µl potassium 
ferricyanide (1% in phosphate buffer, w/v) were added. The microtitre plate was 
covered with foil and incubated at 50 °C for 20 min. After the incubation period, 40 µl 
trichloroacetic acid (10% in phosphate buffer, w/v), 150 µl distilled water and 500 µl 
FeCl3 (0.1% in phosphate buffer, w/v) were added. The microtitre plate was re-
covered with foil and incubated at room temperature for 30 min. Absorbance was 
measured at 630 nm using a microtitre plate reader (Opsys MRTM, Dynex 
Technologies Inc.). The ferric-reducing power of the commercial herbal preparations 
and ascorbic acid were expressed graphically by plotting absorbance against 
concentration. The assay was repeated twice. 
 
3.4.2.3. β-Carotene-linoleic acid model system (CLAMS) 
 
The delay or inhibition of β-carotene and linoleic acid oxidation was measured 
according to the method described by AMAROWICZ et al. (2004) with modifications. 
The antioxidant assay measures the ability of a test solution to prevent or minimize 
the coupled oxidation of β-carotene and linoleic acid in an emulsified aqueous 
system. In the reaction, the emulsion loses its orange colour due to the reaction with 
radicals, but this process can be inhibited by antioxidants.  
 
β-carotene (10 mg) was dissolved in 10 ml chloroform in a brown Schott bottle. The 
excess chloroform was evaporated under vacuum, leaving a thin film of β-carotene 
near to dryness. Linoleic acid (200 µl) and Tween 20 (2 ml) were immediately added 
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to the thin film of β-carotene and mixed with aerated distilled water (497.8 ml), giving 
a final β-carotene concentration of 20 µg/ml. The mixture was further saturated with 
oxygen by vigorous agitation to form an orange coloured emulsion. The emulsion 
(4.8 ml) was dispensed into test tubes to which the resuspended herbal preparation 
or butylated hydroxytoulene (BHT) (200 µl, 6.25 mg/ml) were added, giving a final 
concentration of 250 µg/ml in the reaction mixtures. Absorbance for each reaction 
was immediately (t = 0) measured at 470 nm and incubated at 50 °C, with 
absorbance of each reaction mixture being measured every 30 min for 180 min. 
Tween 20 solution was used to blank the spectrophotometer. The negative control 
consisted of 50% methanol in place of the sample. The rate of β-carotene bleaching 
was calculated using the following formula: 
 
Rate of bleaching (R)  =  ln 
 A t=0   
 A t=t   





where At=0 is the absorbance of the emulsion at 0 min; and At=t is the absorbance at 
time t (90 min). The calculated average rates were used to determine the antioxidant 
activity (ANT) of the respective herbal preparations, and expressed as percent 
inhibition of the rate of β-carotene bleaching using the formula: 
 
% ANT  =  
 R control  −  R sample    
R control  
  × 100 
 
where Rcontrol and Rsample represent the respective average β-carotene bleaching 
rates for the control and herbal preparation, respectively. Antioxidant activity was 
further expressed as the oxidation rate ratio (ORR) based on the equation: 
 
ORR =  
R sample  
R control  
 
 
3.4.3. Antioxidant: Results and discussion 
 
Figure 3.5 demonstrates the percentage DPPH radical scavenging activity of the 
fourteen herbal preparations commonly sold in Pietermaritzburg, KwaZulu-Natal. 
Only one of the herbal preparations (Ibhubezi™) had DPPH radical scavenging 
activity above 70% while eleven (Umzimba omubi, Mvusa ukunzi, Umpatisa inkosi, 
Imbiza ephuzwato, Vusa umzimba, Ingwe® muthi mixture, Supreme one hundred, 
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Sejeso herbal mixture Ingwe®, Lion izifozonke Ingwe®, Stameta™ BODicare®, 
Ingwe® special muti and African potato extractTM) had moderate activity between 
40% and 70%. One of the preparations (Umuthi wekukhwehlela ne zilonda) had poor 
activity, lower than 25%. 
 
For this study EC50 values less than or equal to 2 mg/ml was considered good 
activity. The radical scavenging activity of the herbal preparations against DPPH 
radicals according to the respective EC50 values (Table 3.7) that were less than  
2 mg/ml was in the following order: Ibhubezi™ > Lion izifozonke Ingwe® > Umzimba 
omubi > African potato extractTM > Stameta™ BODicare® > Sejeso herbal mixture 
Ingwe® > Vusa umzimba > Umpatisa inkosi > Imbiza ephuzwato.  
 
It was interesting to note that some herbal preparations that showed poor activities in 
the antibacterial, antifungal, HIV-1 RT, AChE and COX assays, i.e. Umzimba omubi 
and Umpatisa inkosi showed good potentials as antioxidants by having higher DPPH 
radical scavenging percentages as well as lower EC50 values. This would validate 
the use of such herbal preparations as antioxidants in traditional medicine.  
 
A fresh preparation of DPPH radical solution has a deep purple colour which 
disappears when an antioxidant is added to the medium. Thus, the DPPH radical 
scavenging assay detects the ability of substances to transfer hydrogen (H) atoms or 
electron donation via a radical attack (on the DPPH radicals) and convert them to 
colourless products (ROMANO et al., 2009). Therefore, Ibhubezi™, izifozonke 
Ingwe®, Umzimba omubi, African potato extractTM, Stameta™ BODicare®, Sejeso 
herbal mixture Ingwe®, Vusa umzimba, Umpatisa inkosi and Imbiza ephuzwato may 






















Figure 3.5: Percentage DPPH radical scavenging activity by commercial herbal 
preparations (1 mg/ml); (1) Umzimba omubi, (2) Umuthi wekukhwehlela ne zilonda, 
(3) Mvusa ukunzi, (4) Umpatisa inkosi, (5) Imbiza ephuzwato, (6) Vusa umzimba,  
(7) Ingwe® muthi mixture, (8) Ibhubezi™, (9) Supreme one hundred, (10) Sejeso 
herbal mixture Ingwe®, (11) Lion izifozonke Ingwe®, (12) Stameta™ BODicare®,  
(13) Ingwe® special muti and (14) African potato extractTM. Herbal preparations with 
scavenging activity above 70% were considered to be highly active. Percentage 
inhibition by ascorbic acid (0.6 mg/ml) was 62.4 ± 1.42. 
 
 
































Table 3.7: DPPH radical scavenging activity (EC50 mg/ml) of fourteen herbal 
preparations sold in Pietermaritzburg, KwaZulu-Natal 
Herbal preparations 
DPPH scavenging activity 
EC50 (mg/ml) 
Umzimba omubi                1.24 ± 0.2 
Umuthi wekukhwehlela ne zilonda              13.22 ± 0.72 
Mvusa ukunzi                4.52 ± 1.12 
Umpatisa inkosi                1.86 ± 0.66 
Imbiza ephuzwato                1.89 ± 0.90 
Vusa umzimba                1.86 ± 0.06 
Ingwe® muthi mixture                5.48 ± 1.02 
Ibhubezi™                0.40 ± 0.03 
Supreme one hundred              21.76 ± 5.46 
Sejeso herbal mixture Ingwe®                1.58 ± 0.08 
Lion izifozonke Ingwe®                0.94 ± 0.05 
Stameta™ BODicare®                1.41 ± 0.09 
Ingwe® special muti                4.38 ± 0.02 
African potato extractTM                1.38 ± 0.02 
Ascorbic acid                0.07 ± 0.01 
 
Herbal preparations with EC50 values (< 2 mg/ml) in bold are considered potent 
DPPH radical scavengers. 
 
The lower the EC50, the more rapidly the colour of DPPH radical was being bleached 




Figure 3.6 depicts the reducing powers of the fourteen herbal preparations at varying 
concentrations. The ability of the herbal preparations to reduce the Fe3+ solution 
increased with an increase in concentration of the preparation. Depending on the 
reducing power of the herbal preparation, the initial yellow colour of the reaction 
mixture changes to various shades of green and blue. A strong antioxidant 
(reductant) reduces the Fe3+/ferrcyanide complex to a green/blue ferrous form, 
exhibited by higher absorbance values at λ 630 nm. At the highest concentration  
(6.5 mg/ml) of the herbal preparations, the reducing powers of Umuthi 
wekukhwehlela ne zilonda, Umpatisa inkosi and Mvusa ukunzi were higher than that 
of all the other preparations while Umzimba omubi, Vusa umzimba and Ingwe® 
special muti were weaker than the rest. 
 
As with the DPPH radical scavenging results, herbal preparations which had 
previously showed poor activities, exhibited higher reduction powers towards the 
Fe3+/ferrcyanide complex, i.e. Umuthi wekukhwehlela ne zilonda, Umpatisa inkosi 
and Mvusa ukunzi. Another interesting observation was that at all concentrations 
tested, Imbiza ephuzwato, which was consistently showing higher activities in all the 






















































































Figure 3.6: Ferric reducing activity of commercial herbal preparations (A; 1-7 and  
B; 8-14); (1) Umzimba omubi, (2) Umuthi wekukhwehlela ne zilonda, (3) Mvusa 
ukunzi, (4) Umpatisa inkosi, (5) Imbiza ephuzwato, (6) Vusa umzimba, (7) Ingwe® 
muthi mixture, (8) Ibhubezi™, (9) Supreme one hundred, (10) Sejeso herbal mixture 
Ingwe®, (11) Lion izifozonke Ingwe®, (12) Stameta™ BODicare®, (13) Ingwe® special 
muti, (14) African potato extractTM and (BHT) butylated hydroxytoulene. Increase in 
absorbance of the reaction mixture indicates the increase in reducing power. 
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The results of the prevention of the heat-induced oxidation of β-carotene and linoleic 
acid in a model system by the herbal preparations are presented in Figure 3.7. In the 
presence of an active antioxidant, the rate of β-carotene bleaching is reduced. Heat 
(50 °C) induced oxidation involves the subtraction of a H-atom from an active 
methylene group of linoleic acid, forming a linoleate free radical. The linoleate radical 
then viciously attack the highly unsaturated β-carotene in an effort to regain lost 
H-atoms. As the β-carotene is attacked, it loses its orange colour. The presence of a 
good antioxidant can prevent the attack on β-carotene by neutralizing the linoleate 
radical. 
 
Nine herbal preparations (Umzimba omubi, Umuthi wekukhwehlela ne zilonda, 
Mvusa ukunzi, Imbiza ephuzwato, Vusa umzimba, Ibhubezi™, Sejeso herbal mixture 
Ingwe® and Stameta™ BODicare®) exhibited the best potentials to delay the 
oxidation of β-carotene throughout the incubation period. Umpatisa inkosi, Ingwe® 
muthi mixture and African potato extractTM exhibited the poorest potentials to delay 
the oxidation of β-carotene.  
 
Variable antioxidant percentages (ANT), shown in Table 3.8, were observed for the 
herbal preparations with Umzimba omubi, Umuthi wekukhwehlela ne zilonda, Mvusa 
ukunzi, Umpatisa inkosi, Imbiza ephuzwato, Vusa umzimba, Supreme one hundred, 
Sejeso herbal mixture Ingwe® and Ingwe® special muti showing moderate activity, 
between 35% and 70%. Stameta™ BODicare® and African potato extractTM exhibited 
low activity (15% to 35%) while Ibhubezi™ and Lion izifozonke Ingwe® showed poor 
activity (< 15%). 
 
The lower oxidation rate ratio (ORR) values, just like EC50 values, denote better 
antioxidant potentials. Based on ORR, the order of antioxidant capacity with respect 
to the protection of β-carotene against bleaching was as follows; Mvusa ukunzi > 
Ingwe® special muti > Umzimba omubi > Umuthi wekukhwehlela ne zilonda > Imbiza 
ephuzwato > Sejeso herbal mixture Ingwe® > Vusa umzimba > Supreme one 
hundred > Stameta™ BODicare® > Ingwe® muthi mixture > Lion izifozonke Ingwe® > 




















































Figure 3.7: Antioxidant activity of commercial herbal preparations (A; 1-7 and B; 8-
14) as determined by the β-carotene-linoleic acid coupled oxidation model system; 
(1) Umzimba omubi, (2) Umuthi wekukhwehlela ne zilonda, (3) Mvusa ukunzi, (4) 
Umpatisa inkosi, (5) Imbiza ephuzwato, (6) Vusa umzimba, (7) Ingwe® muthi 
mixture, (8) Ibhubezi™, (9) Supreme one hundred, (10) Sejeso herbal mixture 
Ingwe®, (11) Lion izifozonke Ingwe®, (12) Stameta™ BODicare®, (13) Ingwe® special 
muti, (14) African potato extractTM, (N) negative control (water) and (BHT) butylated 
hydroxytoulene. Slow decrease in absorbance signifies protection of β-carotene; 
hence the test preparation is a potent antioxidant. 

























Table 3.8: Antioxidant activity as determined by the β-carotene-linoleic acid 




ANT (%) ORR 
Umzimba omubi 57.14 ± 6.77 0.43 ± 0.07 
Umuthi wekukhwehlela ne zilonda 55.90 ± 4.19 0.44 ± 0.04 
Mvusa ukunzi 60.90 ± 3.62 0.39 ± 0.04 
Umpatisa inkosi 39.16 ± 1.24 1.39 ± 0.10 
Imbiza ephuzwato 51.33 ± 5.79 0.48 ± 0.06 
Vusa umzimba 48.41 ± 5.31 0.52 ± 0.05 
Ingwe® muthi mixture 21.53 ± 8.80 0.78 ± 0.09 
Ibhubezi™   1.69 ± 0.41 1.02 ± 0.39 
Supreme one hundred 39.13 ± 7.40 0.61 ± 0.07 
Sejeso herbal mixture Ingwe® 50.31 ± 6.01 0.49 ± 0.06 
Lion izifozonke Ingwe®   9.04 ± 2.40 0.91 ± 0.02 
Stameta™ BODicare® 29.08 ± 6.67 0.71 ± 0.07 
Ingwe® special muti 61.15 ± 4.58 0.39 ± 0.05 
African potato extractTM   19.4 ± 2.26 1.19 ± 0.02 
 
ANT (%) - Antioxidant activity calculated on the basis of the rate of β-carotene 
bleaching at t = 30, 60 and 90 min. 
 
ORR - Oxidation Rate Ratio at t = 90. The lower the ORR value, the more protective 




Many plant secondary metabolites are known to possess antioxidant activity 
(STEENKAMP et al., 2006). Flavonoids, one of the largest groups of plant 
secondary metabolites have been given much credit as being responsible for the 
antioxidant properties of most plant extracts. Herbal preparations with plant species 
that are known to contain flavonoids will therefore show high antioxidant potentials. 
Flavonoids reduce free radicals by quenching, up-regulating or protecting antioxidant 
defences and chelating radical intermediate compounds. Flavonoids have also been 
shown to inhibit the enzymes responsible for free radical production, for instance 
xanthine oxidase, cyclooxygenase, lipoxygenase, microsomal monooxygenase, 
glutathione S-transferase, mitochondrial succinoxidase, NADH oxidase and protein 
kinase C (JOVANOVIC et al., 1994). 
 
However, some compounds could behave as both antioxidants and prooxidants, 
depending on the specific set of conditions such as concentration of the antioxidant 
and whether oxygen or transition metals are present. In the presence of transition 
metals, in aqueous medium, flavonoids autooxidize to form highly reactive hydroxyl  
radicals. Also, some phenolic compounds may act as substrates for xenobiotic 
metabolizing enzymes such as the cytochrome P450s (CYP450) and peroxidases 
and other metallo-enzymes, yielding quinone- or quinomethide-type prooxidant and 
alkylating products (SERGEDIENE et al., 1999). 
 
Therefore, it is important to use herbal products that exhibit high antioxidant 
properties such as Umzimba omubi, Umuthi wekukhwehlela ne zilonda, Mvusa 
ukunzi, Umpatisa inkosi, Imbiza ephuzwato, Vusa umzimba, Supreme one hundred, 
Sejeso herbal mixture Ingwe® and Ingwe® special muti at correct doses and with a 
controlled diet, without a lot of transition metals. There are so many compounds that 
are responsible for antioxidant properties displayed by the plant extracts, that it 




3.5. Determination of the phenolic compounds of the fourteen 




Plants produce a wide variety of secondary metabolites which form a large and 
heterogeneous group of biologically active non-nutrients (HARBORNE, 1998). Plant 
secondary metabolites are mainly involved in the adaptation of plants to their 
environments; ultra violet ray protectants, defence against herbivores and pathogens 
as well as regulators of seed germination (MAKKAR et al., 2007). Common plant 
secondary metabolites, often referred to as phytochemicals, include alkaloids, 
saponins, tannins, protease inhibitors, lectins and glycosides (MAKKAR, 2003).  
 
Phytochemical compounds are attracting interest among researchers because of 
their use as natural drugs, antibiotics, insecticides, herbicides, oils, waxes and dyes 
(CROZIER et al., 2006). Depending on their biochemical synthesis, phytochemical 
compounds are grouped into three major groups: (i) the phenolic compounds 
including flavonoids and tannins, (ii) the terpenoids, and (iii) the alkaloids (MITHEN, 
2006). 
 
Most phytochemical compounds exhibit bioactivity. Many bioactive compounds with 
known effects on human physiology and diseases have been isolated and identified 
mainly from traditional medicines (MUELLER-HARVEY, 2001; CHRISTENSEN and 
BRANDT, 2006). Plant phenolic compounds are hydroxylated derivatives of benzoic 
acid and cinnamic acids. Phenolic compounds are of possible pharmacological value 
and have been reported to have antioxidative and anti-carcinogenic effects. 
Flavonoids make up the largest group of phenolic compounds. The group include 
flavonols, flavones, catechins, proanthocyanidins, anthocyanidins and isoflavonoids. 
They have long been recognised to possess anti-inflammatory, antiallergenic, 
antiviral and anti-proliferative activities (HARBORNE, 1994; KUDA et al., 2005). 
 
Tannins are tentatively separated into two classes: condensed tannin and 
hydrolysable tannin. Tannins are known to have both beneficiary and diverse effects, 
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depending on their concentration and nature. Although research on tannins has been 
carried out for a long time, additional studies must be carried out to investigate the 
benefits of incorporating plant species with high tannin levels into herbal 
preparations and/or agro-industrial products such as animal feed (MAKKAR, 2003). 
 
A number of methods are available for quantification of phytochemical compounds. 
The mostly utilized methods are the Folin-Ciocalteu, Folin-Denis or Prussian blue 
methods, the vanillin-HCl assay, the acid butanol method, high performance liquid 
chromatography (HPLC) and thin layer chromatography (TLC) (MUELLER-
HARVEY, 2001). 
 
The fourteen herbal preparations were evaluated for their phenolic constituents 
including total phenolic compounds, condensed tannin, hydrolysable tannin and 
flavonoids using colourimetric methods. TLC profiles were obtained to demonstrate 
the characteristic constituents of each herbal preparation. The TLC profiles can be 
used for monitoring the identity and purity of the preparations as well as detecting 
adulterations and substitutions of plant materials initially used. 
 
3.5.2. Materials and methods 
 
3.5.2.1. Determination of total phenolics 
 
The Folin Ciocalteu (Folin C.) assay for determination of total phenolic compounds 
was done as described by MAKKAR et al., (2007) with modification (NDHLALA et 
al., 2008). In triplicate, 50 µl of herbal preparations were transferred into test tubes 
and were made up to 1 ml with distilled water (950 µl). Folin C. reagent (500 µl, 1 N) 
and 2% sodium carbonate (2.5 ml) were added to the dilute sample. Similarly, a 
blank that contained 50% aqueous methanol instead of the herbal preparation was 
also prepared. The test mixtures were incubated for 40 min at room temperature and 
the absorbance was measured at 725 nm using a spectrophotometer (Varian Cary 
50, Australia). Total phenolic concentrations were expressed as gallic acid (GAE) 





3.5.2.2. Determination of condensed tannins (proanthocyanidins) 
 
The butanol-HCl assay for the determination of condensed tannin was done as 
described by PORTER et al. (1985). In triplicate, 3 ml of butanol-HCl reagent (95:5 
v/v) was added to 500 µl of the herbal preparation, followed by 100 µl ferric reagent 
(2% ferric ammonium sulphate in 2 N HCl). The test tube contents were mixed using 
a vortex. The tubes were transferred into a water bath set at 100 ºC for 60 min. A 
blank test was prepared for each herbal preparation by mixing the herbal preparation 
(500 µl) with butanol-HCl reagent (3 ml) and ferric reagent (100 µl), but without 
heating. Absorbance was then read at 550 nm using a spectrophotometer (Varian 
Cary 50, Australia) against a suitable blank. Condensed tannin (% in dry matter) was 
calculated as equivalent amount of leucocyanidins using the formula:  
 
Condensed tannin (%)  =  




where A550 nm is the absorbance of the herbal preparation at 550 nm and 78.26 is the 
molecular weight of leucocyanidin. 
 
3.5.2.3. Determination of hydrolysable tannin 
 
The determination of hydrolysable tannin as gallotannins was done according to 
MAKKAR (1999) with modifications (NDHLALA et al., 2007). In triplicate, herbal 
preparations (50 µl) were made up to 1 ml with distilled water. Sulphuric acid (0.4 N, 
100 µl) and 600 µl rhodanine were added to the diluted extracts. After 5 min 
incubation at room temperature, 200 µl of potassium hydroxide (0.5 N) was added 
followed by the addition of distilled water (4 ml) after a further 2.5 min. The mixtures 
were incubated for an additional 15 min at room temperature, after which the 
absorbance at 520 nm was read using a spectrophotometer (Varian Cary 50, 
Australia) against a blank that contained 50% aqueous methanol instead of the 
herbal mixture. Gallotannin concentrations were expressed as gallic acid (GAE) 






3.5.2.4. Determination of flavonoids 
 
The assay was performed as described HAGERMAN (2002) with modifications. In 
triplicate, 50 µl of herbal preparation was made up to 1 ml with methanol in a test 
tube before adding 2.5 ml of 8% HCl in methanol and 2.5 ml of 1% vanillin reagent in 
methanol. A blank that contained methanol instead of the herbal preparation was 
made. After 20 min of incubation at 30 °C, absorbance at 500 nm was read using a 
spectrophotometer (Varian Cary 50, Australia). The amounts of flavonoids in the 
herbal preparations were expressed as catechin equivalents (CTE), derived from a 
standard curve. 
 
3.5.2.5. Thin Layer Chromatography 
 
The crude herbal preparations (10 µl, 50 mg/ml) were applied to Silica gel 60 on 
polyester plates, 10 x 20 cm, (Merck, Germany) and developed with ethyl 
acetate:methanol:water (100:16.5:13.5 v:v:v) in a pre-saturated chromatographic 
chamber (SHEN et al., 2001). Several other solvent systems that include 
chloroform:ethyl acetate:formic acid (6:3:1), benzene:acetone (1:1), 
chloroform:acetone:diethylamine (5:4:1), benzene:1,4-dioxane:acetic acid (90:25:4) 
and ethyl acetate:propan-2-ol (9:1) were run but with poor compound separation. 
The developed plates were dried under a stream of cold air and visualized under 
visible (VIS) and ultraviolet (UV) light (λ = 254 and 366 nm). Photographic pictures 
were taken at both wavelengths. The plates were then sprayed with a universal 
anisaldehyde spray reagent, Folin C. phenol reagent and Dragendorff reagent.  
 
3.5.3. Determination of phenolic compounds: Results and discussion 
 
Plants with high phenolic composition, including tannins have been regularly used as 
astringents, antimicrobials, anti-inflammatory and antioxidants (POLYA, 2003; 
CANO and VOLPATO, 2004). Such plants are usually used in making herbal 
preparation for stomach ailments, infectious diseases and general pain. The herbal 
preparations were therefore, subjected to quantitative phytochemical analysis for 
identification of the major classes of active phenolic constituents. The phytochemical 
analysis carried out included colourimetric reactions for detection of total phenolic 
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compounds, condensed tannins, gallotannins and flavonoids. Table 3.9 presents the 
phenolic composition of the fourteen herbal preparations. 
 
Phytochemical analysis revealed high total phenolic compounds, gallotannins and 
condensed tannins and less flavonoids in Ingwe® special muti, Ibhubezi™ and 
Stameta™ BODicare®. Surprisingly, these three herbal preparations were not active 
in most bioassays except for Ingwe® special muti which showed moderate activity 
against COX-1 and AChE. On the other hand, Imbiza ephuzwato exhibited high 
flavonoid concentrations and less total phenolic compounds, condensed tannin and 
gallotannin. Generally, Supreme one hundred, Sejeso herbal mixture Ingwe®, Mvusa 
ukunzi and African potato extractTM showed lesser amounts of total phenolic 
compounds, gallotannin, condensed tannin and flavonoids.  
 
At lower concentrations, phytochemical compounds have beneficiary effects such as 
antioxidant effects. Condensed tannin levels of up 4% in dry matter have been 
shown to contribute positively in diet. However, the beneficiary effects still depend on 
the nature and type of phenolic compound. This explains why Ingwe® special muti, 
Ibhubezi™ and Stameta™ BODicare® showed no activities in the bioassays 
evaluated even though they contain high amounts of phenolic compounds.  
 
In some instances, depending on the chemistry of the phenolic compounds, 
phytochemicals at higher concentrations (> 4% in dry mater) may have negative 
physiological effects such as neurological problems, reproductive failure, goiter, 
gangrene and in lower animals may lead to death (MAKKAR et al., 2007). In this 
case, all the herbal preparations had condensed tannin far less than 4% (Table 3.9). 
“Poisoning from the consumption of oak (Quercus sp.) leaves and yellow-wood 
toxicity from the leaves of Terminalia sp., Clidemia sp., and Ventilago sp. has been 
attributed to the presence of hydrolysable tannins, in particular gallotannins” 
(MAKKAR et al., 2007). The toxicity is due to higher levels of hydrolysable tannins 
and other phenolic compounds in the blood stream, which will be beyond the levels 
of the liver to detoxify. 
 
However, tannins isolated from various other plants have been shown to have anti-
carcinogenic activity and also protect some ruminates from bloat and have 
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anthelmintic effects (KAHN and DIAZ-HERNANDEZ, 2000). The use of herbal 
preparations with beneficiary effects provides cheaper alternatives than synthesized 
compounds. 
 
The challenge that still remains is the bioavailability of the phytochemical 
compounds. However, some studies have recently reported on the absorption of 
flavonoids like catechin, quecetin and isoflavones (MAKKAR et al., 2007). The 
bioavailability of flavonoids has been reported to be about 10 to 50% (KING, 2000). 
Consumption of herbal preparations with higher levels of tannins may lead to 





Table 3.9: Total phenolics, gallotannin, flavonoid and condensed tannin contents of fourteen herbal 











Umzimba omubi 228.80 ± 4.13   1.59 ± 0.61 0.01 ± 0.00 0.25 ± 0.06 
Umuthi wekukhwehlela ne zilonda   73.35 ± 1.41   1.82 ± 0.05 0.01 ± 0.00 0.10 ± 0.01 
Mvusa ukunzi 303.40 ± 9.34   6.53 ± 2.27 0.23 ± 0.02 0.27 ± 0.01 
Umpatisa inkosi 158.00 ± 1.60   8.41 ± 2.21 0.02 ± 0.018 0.37 ± 0.01 
Imbiza ephuzwato 155.90 ± 13.95 14.13 ± 1.55 0.01 ± 0.01 1.03 ± 0.14 
Vusa umzimba   55.30 ± 1.35   6.23 ± 0.88 0.01 ± 0.00 0.22 ± 0.01 
Ingwe® muthi mixture 189.60 ± 41.79 2.918 ± 0.85 0.14 ± 0.06 0.39 ± 0.17 
Ibhubezi™ 629.10 ± 30.37 16.12 ± 0.17 0.45 ± 0.02 0.99 ± 0.02 
Supreme one hundred 141.50 ± 6.02   2.24 ± 0.81 0.05 ± 0.04 0.08 ± 0.01 
Sejeso herbal mixture Ingwe®   87.49 ± 4.07   1.10 ± 0.05 0.01 ± 0.01 0.25 ± 0.01 
Lion izifozonke Ingwe® 115.00 ± 8.72   7.54 ± 0.12 0.05 ± 0.00 0.87 ± 0.01 
Stameta™ BODicare® 658.30 ± 3.11   6.82 ± 0.80 0.43 ± 0.01 0.19 ± 0.01 
Ingwe® special muti 832.90 ± 2.23 16.14 ±  0.41 0.48 ± 0.01 0.10 ± 0.03 
African potato extractTM   56.44 ± 0.5   7.66 ± 0.33 0.01 ± 0.01 0.08 ± 0.01 
aValues expressed as gallic acid equivalent ( GAE) per 1 ml of commercial herbal preparation.  
b Values expressed as percentage leucocyanidin equivalents (LCE) per 1 ml of commercial herbal preparation.  
c Values expressed as catechin equivalents (CTE) per 1 ml of commercial herbal preparation. 
All data represented as mean ± SE of three separate measurements.  
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Thin layer chromatography (TLC) profiles were performed to investigate the chemical 
profiles of the fourteen herbal preparations and the chromatograms are presented in 
Figure 3.8. It was not surprising to note that Ingwe® muthi mixture, Sejeso herbal 
mixture Ingwe®, Lion izifozonke and Ingwe® special muti showed similar chemical 
profiles as exhibited in their TLC profiles. The four herbal preparations are 
manufactured by the same company (Guideline Trading) but are sold in different 
packaging and under different names. This is also confirmed by the almost similar 
activities observed for Lion izifozonke Ingwe® and Ingwe® special muti in all the 
bioassays. Despite similarities in the TLC profiles of Ingwe® muthi mixture, Sejeso 
herbal mixture Ingwe®, Lion izifozonke and Ingwe® special muti, there were variation 
in their phenolic contents. Ingwe® special muti, had almost ten-fold amounts of total 
phenolic compounds when compared with Sejeso herbal mixture Ingwe® (Table 3.9). 
Therefore, the similarities in the TLC profiles could be due to some common plant 
species and/or additives that make up the four herbal preparations. 
 
Under UV (λ = 254 nm), all compounds containing at least two conjugated double 
bonds appear as dark bands/zones against a green fluorescent background of the 
TLC plate (Figure 3.8B). Phenol (C6H5OH, benzene with hydroxyl group) derivatives 
have this property (WAGNER et al., 1984). Other examples of compounds with 
conjugated double bonds include vitamins A and D. However, with the rigorous 
processing methods used to make these preparations, it is highly unlikely that 
vitamins A and D could be responsible for the dark bands observed on the TLC 
plates. However, some other stable compounds such as anthraquinone derivatives, 
anethole, eugenol, cinnamic aldehydes and thymol also contain conjugated double 
bonds (WAGNER et al., 1984) thus, could be the quenching compounds. 
 
Under UV (λ = 366 nm), intense blue fluorescence is observed (Figure 3.8C), 
characteristic of alkaloids, flavonoids and terpene alcohols. Anisaldehyde spray 
result in strong red and brown colouration to detect terpenoids, propylpropanoids, 
and saponins (SPANGENBURG, 2008). Figure 3.9 represents a TLC chromatogram 
produced in an attempt to separate the compounds that makes up the herbal 
mixtures using a combination of ethyl acetate:propan-2-ol (9:1 v/v) and spraying with 
anisaldehyde universal spray. The pencil marks represent fluorescence observed 
under UV light. After spraying with anisaldehyde, no useful bands were detected as 
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the compounds remained stationed at the spotting point. Several other solvent 
systems including chloroform:ethyl acetate:formic acid (6:3:1), benzene:acetone 
(1:1), chloroform:acetone:diethylamine (5:4:1) and ethyl acetate:propan-2-ol (9:1) 
were run but with poor compound separation. Figure 3.10A represent TLC profiles 
after spraying with Folin C. phenol reagent. Distinct amounts of phenolic compounds 
were detected for the mixtures tested. Figure 3.10B represents TLC profiles after 
spraying with Dragendorff reagent to detect alkaloids. Supreme one hundred and 
Sejeso herbal mixture Ingwe® showed some trace amounts of compounds that can 
be suspected to be alkaloids. Further confirmatory tests using quantitative methods 
needs to be carried out for a more solid conclusion.  
 
Further research needs to be done, aimed at identifying the chemicals shown on the 
TLC profiles. These TLC profile profiles recorded here, forms an important 
component of quality control for the herbal mixtures. Besides quality control, the TLC 
































Figure 3.8: TLC profiles of the fourteen commercial herbal preparations commonly 
found in herbal shops, pharmacies and supermarkets in Pietermaritzburg, KwaZulu-
Natal; (1) Umzimba omubi, (2) Umuthi wekukhwehlela ne zilonda, (3) Mvusa ukunzi, 
(4) Umpatisa inkosi, (5) Imbiza ephuzwato, (6) Vusa umzimba, (7) Ingwe® muthi 
mixture, (8) Ibhubezi™, (9) Supreme one hundred, (10) Sejeso herbal mixture 
Ingwe®, (11) Lion izifozonke Ingwe®, (12) Stameta™ BODicare®, (13) Ingwe® special 
muti and (14) African potato extractTM. (A) Anisaldehyde universal spray, (B) UV  
λ = 254 nm and (C) UV λ = 366 nm fluorescence. The solvent system used 













Figure 3.9: TLC profiles of herbal preparations commonly found in herbal shops 
herbal mixtures in Pietermaritzburg, KwaZulu-Natal; The solvent system used 
consisted of ethyl acetate:propan-2-ol (9:1) after spraying with anisaldehyde 
universal spray. (1) Umzimba omubi, (2) Umuthi wekukhwehlela ne zilonda, (3) 
Mvusa ukunzi, (4) Umpatisa inkosi, (5) Imbiza ephuzwato, (6) Vusa umzimba, (7) 
Ingwe® muthi mixture, (8) Ibhubezi™, (9) Supreme one hundred, (10) Sejeso herbal 
mixture Ingwe®, (11) Lion izifozonke Ingwe®, (12) Stameta™ BODicare®. Dotted 
pencil marks represents bands observed at UV λ = 366 nm and solid lines 






















Figure 3.10: TLC profiles of herbal preparations commonly found in herbal shops 
herbal mixtures in Pietermaritzburg, KwaZulu-Natal; (A) after spraying with Folin C. 
phenol reagent and (B) Dragendorff reagent. (1) Umzimba omubi, (2) Umuthi 
wekukhwehlela ne zilonda, (3) Mvusa ukunzi, (4) Umpatisa inkosi, (5) Imbiza 
ephuzwato, (6) Vusa umzimba, (7) Ingwe® muthi mixture, (8) Ibhubezi™, (9) 
Supreme one hundred, (10) Sejeso herbal mixture Ingwe®, (11) Lion izifozonke 
Ingwe®, (12) Stameta™ BODicare®. The solvent system used for plate (A) consisted 
of benzene:1,4-dioxane:acetic acid (90:25:4) while for plate (B) the system consisted 
of chloroform:acetone:diethylamine (5:4:1). Dotted pencil marks represents bands 
observed at UV λ = 366 nm and solid lines represents UV λ = 254 nm fluorescence. 
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3.6. In vitro cytotoxic and mutagenic evaluation of fourteen 





Techniques involving in vitro tests are increasingly used as alternatives to whole 
animal toxicity tests due to their reduced use of experimental animals, their lower 
cost, higher specificity and rapidity of performance (ASENSIO et al, 2007). Cell line 
methods such as the neutral red uptake (NRU) assay are used as screening tests for 
new therapeutic products to assess acute and chronic toxicity (CASTELL and 
GÓMEZ-LECHÓN, 1996). The NRU cytotoxicity assay procedure is a cell 
survival/viability chemosensitivity assay based on the ability of viable cells to 
incorporate and bind neutral red (NR), a supravital dye. NR is a weak cationic dye 
that readily penetrates cell membranes by non-ionic diffusion and accumulates 
intracellularly in lysosomes. Alterations of the cell surface or the sensitive lysosomal 
membrane leads to lysosomal fragility and other changes that gradually becomes 
irreversible. Such changes brought about by the action of xenobiotics result in 
decreased uptake and binding of NR. It is thus possible to distinguish between 
viable, damaged, or dead cells, which form the basis of this assay (BARILE, 1994; 
REPETTO et al., 2008). 
 
Healthy mammalian cells, when maintained in culture, continuously divide and 
multiply over time. A toxic chemical, regardless of site or mechanism of action, will 
interfere with this process and result in a reduction of the growth rate as reflected by 
cell number. Cytotoxicity is expressed as a concentration dependent reduction of the 
uptake of the NR after chemical exposure thus providing a sensitive, integrated 
signal of both cell integrity and growth inhibition (REPETTO et al., 2008). 
 
Damage of the genetic material by environmental mutagens can lead to mutations in 
many organisms, including humans. Mutations are associated with the development 
of most cancers and various degenerative disorders and genetic defects in offspring 
(CARIÑO-CORTÉS et al., 2007). To prevent mutagenic risk, it is important to identify 
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the involved environmental mutagens and minimize human exposure to them. Short-
term genetic bioassays like the Ames assay have been used as important tools in 
mutagenic studies because of their simplicity, sensitivity to genetic damage, speed, 
low cost of experimentation and small amount of sample required (MATHUR et al., 
2007). 
 
Poisoning due to plant products (herbal poisoning) is not well documented because 
of the unwillingness of people to admit using traditional medicine derived from plant 
material and because of the fear that the cultural heritage of the people will be put 
under strong laws and regulations (STEENKAMP et al., 2006). To date several 
studies have looked at the mutagenic effects of individual medicinal plants from 
South Africa (ELGORASHI et al., 2003; VERSCHAEVE et al., 2004; REID et al., 
2006; VERSCHAEVE and VAN STADEN, 2008), but not at the toxicity and 
mutagenic potential of commercial herbal preparations. This study was undertaken 
to evaluate cytotoxic and mutagenic effects of fourteen herbal preparations that are 
commonly sold in herbal shops in Pietermaritzburg, KwaZulu-Natal. 
 
3.6.2. Materials and methods 
 
3.6.2.1. The neutral red uptake (NRU) assay 
 
The NRU test was done by Professor L. Verschaeve at the Toxicology, Scientific 
Institute of Public Health (Brussels, Belgium) according to BORENFREUND and 
PUERNER (1985). Cell suspensions of human hepatocellular liver carcinoma cell 
line 2 (HepG2) in Dulbecco's modified Eagle's culture medium (DMEM) 
supplemented with 10% foetal calf serum was seeded into each well of a 96-well 
microtitre plate such that the cell density was forty thousand cells/well. Plates were 
incubated overnight at 37 ºC, 5% CO2 and humidity was maintained using a water 
bath (milli-q water) inside the incubator. After the 24 h incubation, the cells were 
treated with dilutions of the herbal preparations and a positive control sodium 
dodecyl sulphate (SDS). Cells were kept in the presence of the test mixture (0, 
0.0005, 0.005, 0.05, 0.5, 5 and 50 mg/ml of each herbal mixture initially and 
thereafter suitable concentrations were used depending on the preliminary toxicity 
results) for another 24 h. At this point the medium was removed and cells were 
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washed with PBS solution. Medium (200 µl) containing 0.05 mg/ml neutral red dye 
(NR) was added to each well using a multichannel pipette. The microtiter plates were 
incubated for 3 h in a humidified 5% CO2 incubator at 37 °C. The medium was 
removed and the cells were rapidly washed with 0.2 ml of PBS solution. An acetic 
acid-ethanol mixture (0.2 ml) was used to extract the dye from the cells. The plates 
were agitated on a microtiter plate shaker for at least 1 h (or until a homogeneous 
stained medium was obtained) and then absorbance against a blank reference was 
measured at 540 nm using a micro plate spectrophotometer. 
 
For all wells optical density (OD) values were calculated as the measured value 
minus the control value (Vc). Results were expressed as percentage of the OD 
determined from the average of the blank control culture read at 540 nm and set at 
100%. The NI50, (50% inhibition of NRU) was determined from the dose response 
curve of the mean OD values of the seven concentrations as indicated. 
 
For the positive control a separate plate was used where cells were treated with 
different concentrations of SDS and the NI50 was determined as for the herbal 
extracts described above. The NI50 was kept within limits that were determined from 
10 independent experiments from which the average NI50 values and standard 
deviations were calculated. The calculated NI50 for the positive control in an 
experiment should be within ± 2.5 SD of the historical data for SDS. If this is not the 
case the results cannot be accepted and the test should be repeated. 
 
3.6.2.2. Ames test 
 
Mutagenicity was tested using the Salmonella microsome assay based on the plate-
incorporation procedure with Salmonella typhimurium tester strains TA98, TA100, 
TA102, TA1535 and TA1537 with and without metabolic activation (MARON and 
AMES, 1983; MORTELMANS and ZEIGER, 2000). TA98 strain has a -1 frameshift 
mutation at hisD3052 which affects the reading frame of a repetitive base pair –C-G-
C-G-C-G-C-G- sequence, TA100 and TA1535 has a hisG46 marker resulting from 
the substitution of a leucine (GAG/CTC) by a proline (GGG/CCC). The hisG46 
mutation can be reverted to a wild type by mutations that cause base pair 
substitution at the GC site. TA102 contains AT base pairs at the hisG428 mutant 
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site. The hisG428 can be reverted by mutagens that cause oxidative damage. 
TA1537 carries a +1 frameshift mutation hisC3076 located near the repetitive site –
C-C-C- sequence and can be reverted by frameshift mutagens that are not readily 
detected by the hisD3052 (TA98). 
 
Overnight bacterial tester strains were grown in  10 ml Oxoid nutrient broth No. 2 for 
16 h at 37 °C to obtain a density of 1-2 x 109 colony forming units (cfu/ml). The 
metabolic activation mixture (S9 mix) was prepared freshly before the assay and 
kept on ice throughout the assay procedure. The S9 mix consisted of 5% (v/v) S9 
fraction (Sigma-Aldrich, Co., St Louis) pooled from Sprague-Dawley male rats in 
mixed enzymic cofactors containing NADP. At the beginning of the assay, top agar 
supplemented with 0.5 mM histidine and biotin was melted and kept in a 50 °C water 
bath. To sterile glass tubes, in triplicate, 100 µl of  three dilutions (50, 500, 5000 
µg/ml) per sample were added, followed by 500 µl phosphate buffer (0.1 mM, pH 
7.4) or S9 mix. To the mixture, 100 µl of the overnight bacterial culture were added 
followed by 2 ml of the melted top agar. The contents of the tubes were then mixed 
and poured onto labelled minimal agar plates. As soon as the top agar had hardened 
(2-3 min), the plates were inverted and incubated at 37 °C for 48 h. The colonies 
were then counted with the aid of a binocular microscope. The assay was repeated 
twice for each bacterial strain and the results were expressed as the mean  
(± standard error) number of revertant colonies per plate. 4-Nitroquinoline-N-oxide 
(4NQO) (2 µg/plate) was used as a positive control for the assay without metabolic 
activation while 2-aminoanthracene (2-AA) (2 µg/plate) was used where the assay 
was carried out with S9 metabolic activation. Sterile distilled water was used as a 
negative control in both assays. The test herbal mixture/compound was classified as 
a „mutagen‟ if the results satisfied two criteria (1) a dose dependent increase in the 
number of revertants is observed and (2) the number of histidine (His+) revertants is 
equal to or greater than two times that of the negative control. 
 
3.6.3. Neutral red uptake (NRU) and Ames test: Results and discussion 
 
The neutral red uptake inhibition in human liver (HepG2) cells was used to assess 
potential toxicity of the fourteen commercial herbal preparation sold in South Africa. 
The NRU assay is important for ranking of toxic components according to their 
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potencies and structure-toxicity relationship studies. The NI50 values of the fourteen 
preparations are summarised in Table 3.10. The results revealed that the most toxic 
herbal preparation was Umpatisa inkosi, with an NI50 value of 0.016 mg/ml and a 
yield of 2.2 X 10 10-4 mg/ml residue which implies that 72.72 ml of the herbal 
preparation will result in the stated NI50 value (Table 3.10). The least toxic herbal 
preparation was Stameta™ BODicare® with an NI50 value of 28.00 mg/ml and a yield 
of 1.8 x 10-4 mg/ml which implies that 115.56 litres of the mixture is required to reach 
the NI50 value of the mixture. The rest of the preparations exhibited moderate toxicity 
with NI50 values ranging within the two highlighted values. 
 
Umpatisa inkosi showed consistently low IC50 values in the other assays but showed 
a potent NI50 value in the NRU assay. Stameta™ BODicare
® had the least toxic 
value in terms of NI50 as well as in the other assays where it did not perform well, 
basing on its IC50 values for COX assays and HIV-1 RT assay. 
 
HepG2 cells used were from a highly differentiated human hepatoma cell line that 
retains many of the cellular functions often lost by cells in culture. This cell line also 
has the enzymes involved in phase I (mixed function oxidases) and phase II 
(glucuronic acid and sulphate conjugation) metabolism of xenobiotics, and it has 
been used as an in vitro system instead of human normal hepatocytes to study drug 
metabolism and toxicity (NAKAMA et al., 1995). 
 
The standard plate incorporation test methods for the Ames test using Salmonella 
typhimurium tester strains TA98, TA100, TA102, TA1535 and TA1537 exposed to 
three dilutions with and without S9 metabolic activation of the herbal preparations 
was performed. Ames test without S9 metabolic activation can only detect direct 
mutagens while with S9 metabolic activation allows the detection of indirect 
mutagens, often caused by conjugation reactions of metabolic oxidation systems. 
Table 3.11 presents the spontaneous reversion response of the Salmonella 
typhimurium tester strain to the different dilutions of the herbal preparations. The 
results revealed that all fourteen herbal preparations were non-mutagenic towards 
the Salmonella typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 for 
the assay without metabolic activation. The average His+ revertants observed for all 
the tester strains caused by the herbal preparations at all the concentrations without 
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metabolic activation did not satisfy the criteria for mutagenicity. There were no 
notable dose dependent increase in the number of revertants and the numbers of 
revertants were all not equal to or greater than two times that of the negative control 
(BULMER et al., 2007). There was also no decrease in the number of revertant 
colonies to levels far below the negative control (spontaneous reversion) which could 
also be classified as toxic. 
 
The Ames test with metabolic activation was carried out by addition of the S9 mix so 
as to detect indirect mutagenic effects caused by metabolites of the test herbal 
preparations. The S9 fraction contains a mixture of xenobiotic metabolizing enzymes 
such as the cytochrome P450s and sulfotransferase. Five of the fourteen herbal 
preparations (Umpatisa inkosi, Imbiza ephuzwato, African potato extractTM, Vusa 
umzimba and Stameta™ BODicare®) showed indirect mutagenic effects towards the 
tester strain TA98 after metabolic activation but not in the other tester strains 
(TA100, TA102, TA1535 and TA1537). Umpatisa inkosi, induced 219.6, 70.6 and 
32.3 TA98 revertant colonies from the highest to the lowest concentration, with 
colonies increasing as the concentration of the mixture increases. However, the 
revertant colonies (32.3) induced at the lowest concentration (50 µg/ml) by Umpatisa 
inkosi did not satisfy the criteria for mutagenicity. Imbiza ephuzwato, a multipurpose 
Zulu herbal tonic induced a high number of TA98 revertant colonies (227.7, 71.5 and 
45.3) while Vusa umzimba, also a multipurpose herbal mixture induced 217.0, 106.0 
and 52.7 TA98 revertant colonies with decreasing concentration. The number of 
revertant colonies for Imbiza ephuzwato and Vusa umzimba satisfy the criteria of 
mutagenicity. Stameta™ BODicare® exhibited a weak mutagenicity potential against 
TA98. At the highest concentration (5000 µg/ml), Stameta™ BODicare®, induced 
131.1 revertant colonies and 48.0 at 500 µg/ml. African potato extractTM also 
exhibited a weak mutagenic potential against TA98 with about 174, 65 and 40 
revertant colonies at 5000, 500, and 50 µg/ml. The rest of the preparations did not 
show any mutagenic potential against all tester strains after metabolic activation. 
 
TA98 has a -1 frameshift mutation hisD3052 which affects the reading frame of a 
repetitive -C-G-C-G-C-G-C-G- sequence (MORTELMANS and ZEIGER, 2000). 
Therefore, the five herbal preparations (Umpatisa inkosi, Imbiza ephuzwato, Vusa 
umzimba African potato extractTM, and Stameta™ BODicare®) cause a reversion of 
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the hisD3052 mutation back to the wild-type state. The herbal preparations could 
contain various aromatic nitroso-derivatives of amine carcinogens that have been 
shown to cause such a reversion of hisD3052 mutation back to the wild-type state. 
 
Some carcinogenic compounds such as aromatic amines or polycyclic aromatic 
hydrocarbons like benzo-[a]-pyrene are biologically inactive unless they are 
metabolized to active forms. In humans, xenobiotic metabolizing enzymes present in 
the liver, lungs and kidneys, are constantly carrying out conjugation reactions and in 
some cases the compounds result in bioactive metabolites capable of damaging 
DNA (MORTELMANS and ZEIGER, 2000).  
 
Imbiza ephuzwato contains plants that are known from previous investigations to 
possess mutagenic and toxic constituents (VERSCHAEVE and VAN STADEN, 
2008). Imbiza ephuzwato, consists of a mixture of 21 plant species consisting of 
bulbs, leaves and roots. Most of the 21 plant species that constitute Imbiza 
ephuzwato are used by traditional people to treat various conditions. For example, 
Gunnera perpensa or Ugobo in Zulu, one of the plant constituents of Imbiza 
ephuzwato contains bioactive compounds with uteroactive properties (BROOKES 
and DUTTON, 2007). Other plant species in the same mixture include toxic plants 
species such as Scadoxus puniceus, Gomphocarpus fruticosa, Gnidia kraussiana 
and Drimia robusta (VAN WYK et al., 2002). Gnidia kraussiana contains 
diterpenoids which causes fatalities in both humans and livestock in various parts of 
Africa including South Africa. The plant has been used as a fish poison. However, 
diterpenoids also have antitumor and antileukaemic activities (VAN WYK et al., 
2002).  
 
A great deal of research has already been done on the curative effects of African 
potato extracts, „South Africa’s miracle muthi‟ which originates from the plant 
Hypoxis hemerocallidea (formerly Hypoxis rooperi) and locally known in Zulu as 
„inkomfe‟."A study on the safety and efficacy of the Hypoxis plant (African potato) 
extract in HIV-positive patients was terminated prematurely, and reported to the 
Medicines Control Council, because most of the patients who received the extract 
showed severe bone marrow suppression after eight weeks," and as such "At best, 
therefore, HIV/Aids patients should avoid any such supplements, until such time as 
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their safety and efficacy, or otherwise, has been fully documented" 
(TERREBLANCHE, 2003). 
 
The evaluation of bacterial mutagenicity is important as an initial test for complex 
mixtures because of the possibility that one or more of their components can be a 
mutagen (LEE et al., 2005; DÉCIGA-CAMPOS et al., 2007). The fact that some of 
the tested herbal preparations showed no mutagenic effects against all the tester 
strains could be due to antagonism on potential toxic compounds which could be a 
result of mixing a number of herbs (LEUNG, 2004). 
 
Recently, there have been reports on increased global demands for herbal products 
that act as energy boosters, detoxifiers, immune boosters and aphrodisiacs 
(CHERDSHEWASART et al., 2008). The result of this study provides evidence to 
support the safe consumption of some herbal preparations at low and medium doses 




Table 3.10: NI50 values (mg/ml) after 24 h treatment of HepG2 with thirteen 
commercial herbal preparations 
Herbal preparations *Yield (mg/ml) NI50 (mg/ml) 
Umzimba omubi 2.4  X 10-6 1.220 
Umuthi wekukhwehlela ne zilonda 2.3  X 10-6 1.010 
Mvusa ukunzi 2.9  X 10-6 1.680 
Umpatisa inkosi 2.2  X 10-4 0.016 
Imbiza ephuzwato 2.1  X 10-5 1.150 
Vusa umzimba  5.5  X 10-6 5.890 
Ingwe®  muthi mixture 5.5  X 10-6 3.610 
IbhubeziTM 1.1  X 10-4 15.200 
Supreme one hundred  9.2  X 10
-5 17.900 
Sejeso herbal mixture Ingwe®  0.5  X 10
-5 2.630 
Lion izifozonke Ingwe®  5.3  X 10
-6 4.280 
StametaTM BODicare® 1.8  X 10-4 28.000 
Ingwe® special muti  6.2  X 10-6 2.080 
African potato extractTM NT NT 
SDS (positive control)  0.082 
 
* Yield was obtained by filtering and freeze drying 100 ml portions and the residue 
was weighed and expressed as yield (mg/ml). 
 




Table 3.11: Number of His+ revertants in Salmonella typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 produced by 
fourteen commercial herbal preparations with and without S9 metabolic activation 
    Number of His+ revertants             























5000 22.3 ± 0.9 29.0 ± 1.7 157.0 ± 12.6 183.3 ±10.1 349.3 ± 20.7 277.0 ± 5.8 13.3 ± 1.2 21.3 ± 1.8  6.0 ± 1.7  9.3 ± 0.3 
500 21.7 ± 1.7 24.3 ± 3.8 195.0 ± 2.9 234.3 ± 15.7 374.0 ± 26.4 269.0 ± 9.1 14.3 ± 4.5 18.0 ± 0.5  6.7 ±0.6  8.0 ± 0.5  




5000 26.0 ± 0.6 21.3 ± 0.7  168.7 ± 4.4 209.7 ± 5.9 331.7 ± 12.8 284.7 ± 6.8 17.0 ± 1.2 33.0 ± 0.5  9.0 ± 0.5  7.7 ± 1.4  
500 25.0 ± 1.5 23.0 ± 1.0 173.3 ± 8.9 187.7 ± 5.5 321.6 ± 17.1 275.0 ± 6.1 16.3 ± 0.3 21.7 ± 1.8  8.3 ± 0.3  7.0 ± 0.5  
50 23.3 ± 0.9 19.3 ± 0.9 183.0 ± 6.5 188.3 ± 6.1 301.0 ± 2.1 269.3 ± 3.7 14.3 ± 2.4 18.3 ± 0.6  7.7 ± 0.8  6.7 ± 1.2  
Mvusa ukunzi 
5000 22.7 ± 0.7 19.3 ± 0.3 163.0 ± 4.6 191.0 ± 6.6 306.3 ± 10.1 287.0 ± 1.2 12.0 ± 0.6 21.0 ± 4.5  7.0 ± 0.0 10.0 ± 0.5  
500 23.0 ± 0.3 21.0 ± 2.1 178.3 ± 11.4  191.0 ± 7.1 319.0 ± 13.3 257.0 ± 5.0 14.0 ± 0.6 21.3 ± 2.1  8.0 ± 1.0 10.0 ± 0.5  
50 25.0 ± 2.0 26.0 ± 4.4 200.3 ± 6.0 198.0 ± 0.6 320.0 ± 2.0 257.0 ± 2.1 17.7 ± 2.6 21.3 ± 0.8  7.7 ± 1.3  8.7 ± 0.3  
Umpatisa inkosi 
5000 23.3 ± 2.6 219.6 ± 16.3 180.7 ± 8.0 207.0 ± 2.6 281.3 ± 9.3 274.0 ± 1.5 17.0 ± 4.0 96.3 ± 1.7  6.3 ± 0.8  8.3 ± 0.6  
500 24.7 ± 0.9 70.6 ± 1.5 183.0 ± 7.6 198.3 ± 0.7 291.3 ± 7.7 264.3 ± 1.2 14.0 ± 0.6 71.0 ± 2.5  6.3 ± 1.4  7.7 ± 0.3  
50 25.7 ± 1.2 32.3 ± 4.1 195.3 ± 5.7 200.0 ± 2.1 289.3 ± 6.9 272.3 ± 7.9 15.7 ± 0.9 47.3 ± 2.0  5.7 ± 0.8  7.3 ± 0.3  
Imbiza 
ephuzwato 
5000 22.0 ± 0.9 227.7 ± 23.1 171.6 ± 10.1 230.7 ± 1.5 329.6 ± 19.7 256.3 ± 1.9 14.7 ± 1.5 52.0 ± 3.0 7.3 ± 0.3  8.0 ± 1.0 
500 24.0 ± 1.6 71.5 ± 5.5 173.7 ± 2.9 194.7 ± 1.8 320.7 ± 50.3 236.3 ± 3.9 15.3 ± 1.5 34.0 ± 1.5  5.0 ± 0.5  9.3 ± 0.3  
50 19.7 ± 1.2 45.3 ± 1.8 180.5 ± 4.4  203.7 ± 1.8 299.3 ± 7.2 231.7 ± 0.7 14.0 ± 0.6 22.0 ± 0.5  5.7 ± 0.6  9.7 ± 1.7  
Vusa umzimba  
5000 23.7 ± 2.7 217.0 ± 26.2 167.7 ± 3.2 191.0 ± 1.2 305.3 ± 1.7 320.3 ± 4.4 13.3 ± 0.9 41.3 ± 0.6  5.7 ± 0.3  8.0 ± 0.1 
500 19.3 ± 0.7 106.0 ± 18.0 173.6 ± 9.1 181.3 ± 14.8 314.3 ± 26.5 223.7 ± 1.2 17.0 ± 0.6 32.0 ± 0.5  7.0 ± 0.5  6.7 ± 0.3  





5000 25.0 ± 1.0 32.7 ± 5.2 197.0 ± 9.7 209.0 ± 3.2 350.3 ± 14.1 288.0 ± 0.6 10.3 ± 2.4 21.3 ± 1.2  7.3 ± 0.8  7.3 ± 0.3  
500 19.3 ± 1.7 24.0 ± 5.5 185.3 ± 7.2 200.7 ± 0.3 311.3 ±  6.1 269.7 ± 4.2 16.0 ± 4.5 20.7 ± 1.8  7.3 ± 1.2  9.7 ± 0.3  




5000 23.3 ± 1.3 36.0 ± 2.1 184.6 ± 6.4 179.3 ± 1.8 337.0 ± 7.1 301.3 ± 0.3 16.0 ± 2.5 27.0 ± 0.5  6.0 ± 0.5  7.7 ± 0.3  
500 23.0 ± 1.0 39.7 ± 2.7 177.0 ± 5.2 180.3 ± 14.8 319.3± 3.9 266.0 ± 6.1 13.7 ± 4.8 19.7 ± 1.7  6.0 ± 0.5  8.0 ± 0.5  
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    Number of His+ revertants             




























5000 28.0 ± 1.5 31.6 ± 6.7 178.0 ± 9.9 223.3 ± 1.5 388.7 ± 12.7 244.0 ± 5.8 12.3 ± 0.3  26.0 ± 0.5  8.0 ± 1.5  7.7 ± 0.8 
500 26.0 ± 3.2 31.3 ± 2.3 179.6 ± 11.4 213.3 ± 1.8 322.7 ± 13.3 219.3 ± 6.8 17.0 ± 0.5  25.3 ± 0.3  7.3 ± 0.3  7.3 ± 0.3  





5000 20.0 ± 0.7 23.3 ± 0.9 163.3 ± 25.4 211.7 ± 5.3 307.0 ± 19.4 277.7 ± 6.1 14.3 ± 0.6  25.0 ± 1.5  5.3 ± 0.8  8.3 ± 0.3  
500 22.0 ± 0.6 25.0 ± 3.5 155.7 ± 1.8 203.7 ± 0.3 302.3 ± 12.3 255.3 ± 5.8 14.0 ± 1.5  18.3 ± 0.8  5.0 ± 0.5  8.7 ± 1.3 





5000 22.7 ± 1.0 23.7 ± 0.9 177.7 ± 10.1 255.7 ± 4.9 319.0 ± 12.9 213.0 ± 0.5  24.3 ± 0.3  24.3 ± 0.3 7.0 ± 2.0 7.7 ± 0.6  
500 23.1 ± 1.7 25.3 ± 3.5 177.7 ± 13.3 235.7 ± 2.9 298.0 ± 13.2 216.0 ± 2.5  22.0 ± 1.5  22.0 ± 1.5 6.3 ±0.8 7.7 ± 0.8 







5000 22.0 ± 2.0 131.3 ± 6.9 172.6 ± 6.9 187.0 ± 15.0 395.3 ± 9.3 257.0 ± 5.5 13.0 ± 0.5  28.0 ± 1.5  6.3 ± 0.3  8.7 ± 0.3 
500 22.3 ± 2.0 48.0 ± 3.2 166.3 ± 1.9 135.0 ± 1.0 341.3 ± 10.1 259.0 ± 9.6 13.0 ± 0.5  24.0 ± 0.5  6.3 ± 0.8  8.7 ± 0.3 







5000 21.3 ± 0.3 23.6 ± 2.4 175.0 ± 5.7 173.3 ± 4.2 320.3 ± 6.9 262.0 ± 3.1 11.3 ± 0.3  19.0 ± 0.5  6.7 ± 0.8  10.3 ± 1.2  
500 19.0 ± 1.0 24.3 ± 1.9 188.3 ± 2.2 167.0 ± 1.2 344.3 ± 11.3 256.0 ± 6.4 16.0 ± 2.0 18.7 ± 1.4  7.3 ± 0.8  7.7 ± 0.3 





5000 22.0 ± 0.9 174.1 ± 3.4 191.3 ± 0.6 204.1 ± 1.2 319.7 ± 0.3 328.3 ± 12.2 26.7 ± 2.3 24.3 ± 2.4 8.7 ± 1.3 10.3 ± 0.2 
500 23.3 ± 0.3 65.7 ± 1.4 164.3 ± 0.3 190.3 ± 3.9 323.3 ± 17.2 311.7 ± 21.3 20.3 ± 4.3 21.7 ± 4.5 7.3 ± 2.2 11.7 ± 1.1 
50 19.3 ± 2.3 40.3 ± 2.2 190.1 ± 2.2 218.3 ± 1.9 295.3 ± 23.2 299.3 ± 10.3 21.5 ± 0.9 17.7 ± 1.4 8.3 ± 0.1 11.3 ± 1.8 
4NQO   2 208.0 ± 0.6   931.7 ± 145.2  
2436.3 ± 
120.1 
  1415.7 ± 62.3   65.0 ± 6.9    
2-AA  2  218.0 ± 13.4  985.3 ± 13.9  1659.0 ± 51.5  
162.3 ± 
4.0 
 128.7 ± 31.4 
Water (-ve cont)   22.0 ± 1.6 25.3  ± 1.0 199.6 ± 2.3 207.0 ± 4.9 296.0 ± 10.6 266.7 ± 7.6 18.7 ± 1.4 21.7 ± 1.4 6.7 ± 1.2 9.3 ± 0.8 
Number of His+ revertants/plate: mean values of three triplicates, the assay was repeated two times. S9- refers to the assay without metabolic 
activation; S9+ refers to the assay with metabolic activation. 4-NQO; 4-nitroquinoline-oxide was the positive control for the S9- assays. 2-AA; 2-
aminoathracene was the positive control for S9+ assays. 





In the present study, the fourteen herbal preparations showed promising 
pharmacological properties including antibacterial activity against two Gram-negative 
and two Gram-positive bacterial strains as well as antifungal properties against 
Candida albicans. The herbal preparations also exhibited potential use as 
anthelmintics. Besides activities in antimicrobial and anthelmintic bioassays, more 
than 50% of the herbal preparations showed high inhibitory effects against COX, 
HIV-1 RT and AChE. Most of the herbal preparations which showed poor and low 
activities in the antibacterial, antifungal, anthelmintic and inhibitory properties against 
COX, HIV-1 RT and AChE, exhibited higher antioxidant potentials. Imbiza 
ephuzwato, Sejeso herbal mixture and African potato extractTM showed consistently 
moderate to high activities in the bioassays used in this study. The observed activity 
therefore validates the use of these commercial herbal preparations in both urban 
and rural communities. However, further studies to investigate the botanical 
composition of the herbal preparations are urgently needed. 
 
The herbal preparations were all not mutagenic towards the Ames test when 
Salmonella typhimurium tester strains TA98, TA100, TA102, TA1535 and TA1537 
exposed to three dilutions without S9 metabolic activation were used. However, five 
of the fourteen herbal preparations showed indirect mutagenic effects towards the 
tester strain TA98 after metabolic activation but not in the other tester strains 
(TA100, TA102, TA1535 and TA1537).  
 
Table 3.12 summarizes the various activities observed for the herbal mixtures for all 
the bioassays used in this study. Based on the summarised results, Imbiza 
ephuzwato, IbhubeziTM, Sejeso herbal mixture, and African potato extractTM were the 
best mixtures for bacterial infections. Imbiza ephuzwato, Ingwe muthi mixture, 
Sejeso herbal mixture, Lion izifozonke and African potato extractTM were the best 
mixtures for fungal infections. For pain and other conditions related to inflammation 
and COX enzymes, it will be best to use herbal mixtures such as Imbiza ephuzwato, 
Vusa umzimba, Ingwe muthi mixture, IbhubeziTM, Sejeso herbal mixture, and African 
potato extractTM. For the use as antiretroviral medication, Imbiza  
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ephuzwato, Ingwe muthi mixture, Sejeso herbal mixture, and African potato extractTM 
will be the best herbal mixtures to take. Umpatisa inkosi, Vusa umzimba, IbhubeziTM, 
Sejeso herbal mixture, and African potato extractTM are the best herbal mixtures for 
psychosis and mental related conditions such as AD. Herbal mixtures that worked 
well as antioxidants include Umuthi wekukhwehlela ne zilonda, Mvusa ukunzi, 
Umpatisa inkosi, Ingwe muthi mixture, IbhubeziTM, Sejeso herbal mixture and Lion 
izifozonke. Overally, Imbiza ephuzwato, Ingwe muthi mixture, Sejeso herbal mixture 
and African potato extractTM are best mixtures to use. However, Imbiza ephuzwato 
and African potato extractTM showed mutagenic effects after bioactivation, therefore 
they cannot be recommended for prolonged use until the sources of the toxins are 










Table 3.12: Summary of activities observed in bioassays for the fourteen herbal preparations 
 
 Efficacy Safety 
Herbal Antimicrobial bioassays Enzyme inhibition bioassays Antioxidants bioassays Cytotoxicity/mutagenicity 
preparations Antibacterial Antifungal Anthelmintic COX-1 COX-2 HIV-1 RT AChE DPPH FRAP CLASMS NRU Ames test 




– – ++ – + + – – ++++ + + – 
Mvusa ukunzi – – + ++ + ++ – ++ ++++ + – – 





++++ ++++ ++++ ++++ ++++ ++++ ++++ ++ ++ + + TA98 S9+ 
Vusa umzimba 
Ingwe®  
+ ++++ – ++++ ++++ + ++++ + – + – – 
Ingwe muthi 
mixture Ingwe®  
– ++ ++++ ++++ ++++ ++++ ++ + ++++ + – – 




– ++ ++ – + – – + – + – – 
Sejeso herbal 
mixture Ingwe®  
++++ ++++ ++++ ++ ++++ ++++ ++++ ++ ++++ + – – 
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 Efficacy Safety 
Herbal Antimicrobial bioassays Enzyme inhibition bioassays Antioxidants bioassays Cytotoxicity/mutagenicity 
preparations Antibacterial Antifungal Anthelmintic COX-1 COX-2 HIV-1 RT AChE DPPH FRAP CLASMS NRU Ames test 
Lion izifozonke 
Ingwe®  
++ ++++ ++++ ++++ ++ + ++ ++ ++++ + – – 
StametaTM 
BODicare® 
– – – ++ + + – ++ + + – – 
Ingwe special 
muti Ingwe® 
++ ++++ ++ ++ ++ + ++ + – – – – 
African potato 
extractTM 



















++++ = MIC values < 1 mg/ml 
++ = MIC values > 1 – 3.125 mg/ml 
+ = MIC values > 3.125- 6.25 mg/ml 
– = MIC values > 6.25- >12.5 mg/ml    
Enzyme inhibition/DPPH bioassays 
++++ = % inhibition 70-100 
++ = % inhibition 40-69 
+ = % inhibition 20-39 
– = % inhibition 0-19 
 
FRAP (Ferric reducing assay) 
++++ = Absorbance above 1.5 
++ = Absorbance between 1.0-1.5 
+ = Absorbance between 0.5-1.0 
– = Absorbance between 0 – 0.5 
 
CLAMS (β-caroten-linoleic acid model) 
++++ = Absorbance above 0.2 
++ = Absorbance between 0.15- 0.2 
+ = Absorbance between 0.10- 0.15 
– = Absorbance between 0 – 0.1 
 
NRU (Neutral red uptake assay) 
++++ = NI50 values < 0.5 mg/ml 
++ = NI50 values between 0.5 – 1.0 mg/ml 
+ = NI50 values between 1.0 – 1.5 mg/ml 
– = NI50 values > 1.5 mg/ml 
 
NT = Not tested 
 
Table 3.12: continued 
 
++++ = High activity  
++ = Moderate activity 
+ = Low activity 





Plant Composition and Pharmacological Properties 




Imbiza ephuzwato is a traditional herbal tonic containing extracts of roots, bulbs, 
rhizomes and leaves of 21 medicinal plants. The herbal mixture is prepared using 
plants that has been used by the Zulu people for decades. The herbal tonic is 
manufactured by a Pietermaritzburg herbalist trading as „KwaNyanga Yezizwe‟ which 
translate „a place of a great herbalist, for all nations‟. The herbal tonic is sold in muthi 
shops around Pietermaritzburg, KwaZulu-Natal. Imbiza ephuzwato is a detoxifying 
and energising tonic used to increase sexual prowess, relieve constipation, reduce 
stress, reduce high blood pressure, clear skin conditions, boost energy, boost vitality, 
prevent arthritis, cure kidney problems and relieve general body pains. Imbiza 
ephuzwato showed consistent bioactivities in all the assays reported in Chapter 3, 
therefore the mixture was ideal for further studies. This chapter will examine the 
botanical constituents of Imbiza ephuzwato as well as their pharmacological efficacy 
and significance in the herbal mixture. 
 
The dried materials (chopped) of the 21 plant species are mixed in equal portions 
and extracted with water by boiling for 1 h. The mixture is then cooled and 
subsequently sieved through a cloth. The cold brew is then packaged into 1 litre 
labelled plastic containers (Figure 4.1). Figure 4.1C shows the final stage of the 
production line, where the labels are put on to the containers while Figure 4.1B 
represents the label of Imbiza ephuzwato and Figure 4.1A presents the packaged 
Imbiza ephuzwato product, ready for sale. The label is written in isiZulu and lists 16 
medical conditions Imbiza ephuzwato is claimed to improve together with the 

































Figure 4.1: (A) Packaged product. (B) Imbiza ephuzwato label with 16 conditions the 
product is claimed to cure as well as directions for use. (C) Final step in the 
production line of Imbiza ephuzwato where labels are put on to the containers and 
then placed onto the shelf for sale. 
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The herbal tonic‟s name, Imbiza ephuzwato- ichathe ilapha lezizifo, gives a brief 
description of how the tonic is taken. The translation of the herbal tonic‟s name is: 
Imbiza (herbal pot) ephuzwato (to drink) – ichathe (to use as an enema) ilapha 
lezizipho (cures many diseases). 
 
4.1.1. Plant constituents of Imbiza ephuzwato 
 
The number of plant species in Imbiza ephuzwato, and the level of knowledge of 
plant choice and time needed to collect the plants represent a complicated and 
sophisticated process. Amongst the Zulu people, the ability to recognize medicinal 
plants seems to be an innate gift. The herbalists, Inyangas and Sangomas who are 
gifted in terms of traditional medicine form an integral part of the society. This 
explains the extraordinary ability amongst such herbalists to select plant medicines 
and the degree to which they can match them as well as understanding their ability 
to cure diseases (PUJOL, 1990).  
 
The mixture consists of 21 plant species, belonging to 17 families. Table 4.1 lists the 
plant constituents of Imbiza ephuzwato according to their families. The information 
about the plant constituents was provided by the manufacturer through an oral 
informal interview. Voucher specimens were collected and deposited in the 
Herbarium of the University of KwaZulu-Natal. The medicinal, aromatic and toxic wild 
plants that make up Imbiza ephuzwato are collected by the rural population and 
professional herbalists, who in turn sell them to the manufacturer. The plants are 
also sold in the herbal shops and markets of KwaZulu-Natal. 
 
Hyacinthaceae is the most represented family (three species) in the herbal tonic, 
followed by Amaryllidaceae and Asteraceae (two species each) and the rest had one 
species each. We can speculate that the high species representation of the 
Hyacinthaceae family may be due to either the fact that the species in the family are 
abundant in KwaZulu-Natal or the bulbous plants are highly utilized in ATM (PUJOL, 




The plant parts used to prepare the mixture are mostly roots (ten species). The other 
plant parts include bulbs (four species), leaves (three species), corms (one species), 
rhizomes (one species), stems (one species) and whole plant (one species). 
 
The plant species in the mixture represents a broad range of therapeutical uses 
(Table 4.1), giving Imbiza ephuzwato a variety of medicinal uses (PUJOL, 1990; 
HUTCHINGS et al., 1996; NEUWINGER, 1996; VAN WYK et al., 1997). According 
to the ethnobotanical records of the plant species listed in Table 4.1, the uses are 
consistent with the medicinal claims on the label of Imbiza ephuzwato. However, 
several questions still remains as to whether the extracts retain their therapeutical 
strength after a rigorous extraction process involving boiling for 1 h and after mixing 
extracts of several plant species to make a tonic. A lot of chemical changes and 
alterations are likely to take place during the manufacturing process of herbal 
mixtures. It should also be noted that beneficial effects related to synergism, 
combinational and additive effects of active compounds could also result. However, 
antagonistic actions amongst different compounds resulting in minimised therapeutic 
effects of the mixture are also possible. 
 
According to the National Red List of South African Plants, Imbiza ephuzwato 
contains 14 plant species listed as „least concern‟ (LC), one species listed as 
„declining‟ and one species listed as „data deficient-taxonomy problems‟ (DDT) 
(NATIONAL RED LIST OF SOUTH AFRICAN PLANTS, 2001). Despite the fact that 
most of the species used to make up the herbal mixture are listed as LC, implying 
that the taxa are widespread and abundant, conservation strategies still need to be 
implemented i.e. substitution of bulbs, roots and/or rhizomes with aerial parts. 
 
Despite the widespread use of Imbiza ephuzwato to treat these conditions, no 
scientific evidence exists to support its uses. The aims and objectives of this study 
were to investigate the bioactivity of the plant species used in the preparation of 
Imbiza ephuzwato herbal tonic. A compilation of the therapeutic validations for each 
single plant component could help to demonstrate the medicinal benefits from Imbiza 




Table 4.1: Information on the 21 plant species used to manufacture Imbiza ephuzwato herbal mixture 
 
Family name Botanical name 
Plant parts used 
Red Data List Status 
Voucher specimen number  
Traditional medicinal uses 
Amaryllidaceae Scadoxus puniceus (L.) Friis & Nordal 
Bulbs 
LC 
AR NDHLALA 06 
Traditionally used to treat coughs and gastro-
intestinal problems. Used to ensure easy birth. 
Also used for wound therapy, asthma and ulcers. 
(VAN WYK et al., 1997). 
Amaryllidaceae Cyrtanthus obliquus (L.f.) Aiton 
Bulbs 
Declining 
AR NDHLALA 28 
Used to treat chronic coughs and the dried bulb 
scales are used as a snuff for the relief of 
headaches (HUTCHINGS et al., 1996). 




Root decoction used to treat headache, toothache, 
anthrax, colds and as antidotes to snake bites 
(VAN WYK et al., 1997).  
Asclepiadaeceae Asclepias fruticose L. 
Roots 
NODL 
AR NDHLALA 29 
Used for chest infections including tuberculosis 
and can be used as an emetic to strengthen the 
body. Relieves stomach pain and general body 
pains (VAN WYK et al., 1997).  
Asteraceae Aster bakeranus Burtt Davy ex C.A. Sim. 
Roots 
LC 
AR NDHLALA 05 
Powdered roots are used as a snuff for relieving 
headache and may be mixed with water to clean 
the nostrils (PUJOL, 1990). Used also as an 
antidote for snake bites. Used for venereal 
diseases and can be administered as an enema to 
treat severe stomach pain and intestinal parasites 
(VAN WYK et al., 1997). 
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Family name Botanical name 
Plant parts used 
Red Data List Status 
Voucher specimen number  
Traditional medicinal uses 
Asteraceae Hypericum aethiopicum Thunb. 
Leaves and stems 
LC 
- 
Applied to cuts, swellings, burns and sores to 
promote healing. Treating of skin eruptions, 
swollen gums and chest pains (PUJOL, 1990).  
Cucurbitaceae Momordica balsamina L.  
Leaves 
LC 
AR NDHLALA 10 
Purgative, for worms, fever, syphilis, skin diseases, 
anti-inflammation, liver diseases, jaundice, 
gonorrhoea, arthritis, skin allergies, measles, 
chicken pox, scabies and anti-malaria 
(NEUWINGER, 1996). 
Fabaceae Eriosema cordatum E.Mey. 
Roots 
LC 
AR NDHLALA 22 
Roots used for infertility and as an aphrodisiac 
when mixed with Corchorus asplenifolius Burch. 
 (HUTCHINGS et al., 1996). 
Gunneraceae Gunnera perpensa L. 
Rhizomes 
Declining 
AR NDHLALA 02 
To induce or augment labour, antenatal medication 
to tone the uterus, used to assist the expulsion of 
the uterus, treats stomach pains, rheumatic fever, 
swellings, menstrual pain and stomach bleeding 
(PUJOL, 1990; HUTCHINGS et al., 1996). 
Hyacinthaceae Ledebouria sp. 
Bulbs 
NODL 
AR NDHLALA 01 
Used for the treatment of diarrhoea, flu and 
headache (POOLEY, 1998). 
Hyacinthaceae Drimia robusta Bak. 
Bulbs 
DDT 
AR NDHLALA 08 
Treat diseases of the uterus and to clean the 
bladder (PUJOL, 1990).  
   
   
Table 4.1: continued 
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Family name Botanical name 
Plant parts used 
Red Data List Status 
Voucher specimen number  
Traditional medicinal uses 
Hyacinthaceae Urginea physodes (Jacq.) Baker 
Bulbs 
NODL 
AR NDHLALA 23 
Bulbs are used as some of the ingredients to make 
infusions known in isiZulu as isihlambezo and 
inembe which are taken during pregnancy to 
facilitate easy delivery (HUTCHINGS et al., 1996). 
Iridaceae Watsonia densiflora Bak. 
Corms 
LC 
AR NDHLALA 07 
Corms are used for treatment of diarrhoea 
(HUTCHINGS et al., 1996). 
Lamiaceae Tetradenia riparia (Hochst.) Codd 
Leaves 
LC 
AR NDHLALA 27 
Leaves are used for treating respiratory ailments 
(Coughs, colds, sore throat), mouth ulcers, 
stomach ache, diarrhoea, influenza, fever, malaria, 
swollen legs and headaches (PUJOL, 1990; 
HUTCHINGS et al., 1996). 
Lycopodiaceae Lycopodium clavatum L. 
Whole plant 
LC 
AR NDHLALA 13 
The whole plant is used for magical purposes, 
smoked for the treatment of headache and 
infusions are taken to treat diseases of the urinary 
tract (HUTCHINGS et al., 1996). 




Decoction of the chopped root, mixed with 
Momordica foetida Schum. are used for treatment 
of boils. The root infusions are also used as 
enemas for children. The plant is used as a 
protective charm (HUTCHINGS et al., 1996).  
Rubiaceae Rubia cordifolia L. 
Roots 
LC 
AR NDHLALA 24 
The roots are used to lower the blood pressure, 
used internally in the treatment of abnormal uterine 
bleeding, internal and external haemorrhage, 
bronchitis, rheumatism, stones in the kidney, 
bladder and gall and dysentery. Roots are made 
into paste for ulcers, inflammations and skin 
Table 4.1: continued 
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Family name Botanical name 
Plant parts used 
Red Data List Status 
Voucher specimen number  
Traditional medicinal uses 
conditions (HUTCHINGS et al., 1996). 
 
Rutaceae 
Zanthoxylum capense (Thunb.) Harv. 
Roots 
LC 
AR NDHLALA 26 
Used to relieve flatulent colic, stomach ache and 
fever. Also used for treating toothache and for 
general mouth wash (VAN WYK et al., 1997). 
Sapotaceae Vitellariopsis marginata (N.E. Br.) Aubrév 
Roots  
LC 
AR NDHLALA 16 
Roots are used for the treatment of indigestion and 
blood cleansing (PUJOL, 1990). Root infusion is 
taken twice daily for idliso (poisoning caused by 
sorcery) (HUTCHINGS et al., 1996). 
Thymelaeaceae Gnidia kraussiana Meisn. var. kraussiana  
Roots 
LC 
AR NDHLALA 25 
Treatment of burns, snake bites, stomach 
complaints, used to ensure easy birth 
(HUTCHINGS et al., 1996).  
Tilliaceae Corchorus asplenifolius Burch. 
Roots 
LC 
AR NDHLALA 21 
Roots used for infertility and as an aphrodisiac 
when mixed with Eriosema cordatum 
(HUTCHINGS et al., 1996). 
LC-least concerned (the taxa are widespread and abundant). 
 
Declining- species not endangered or threatened but there are threatening processes causing a continuing decline in the 
population. 
 
DDT- A taxon is DDT when taxonomical problems hinder its distribution range and habitat from being well defined, so that an 
assessment of risk of extinction is not possible. 
 
NODL- Not on data list. 
Status on red data list taken from the NATIONAL RED LIST OF SOUTH AFRICAN PLANTS (2001). 
 
Table 4.1: continued 
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4.2. Materials and methods 
 
4.2.1. Sample procurement 
 
Plant materials were obtained from the herbal shop where Imbiza ephuzwato is 
manufactured. Voucher specimens were collected and deposited in the Herbarium of 
the University of KwaZulu-Natal, Pietermaritzburg. The plant materials were 
completely dried in an oven at 50 °C. After the materials were completely dry, they 
were ground and stored in airtight containers at 10 °C in the dark.  
 
4.2.2. Sample preparation 
 
Dried, ground plant parts were extracted sequentially with 20 ml/g of petroleum ether 
(PE), dichloromethane (DCM), 80% ethanol (EtOH) and water using a sonication 
bath for 1 h, the temperature being kept low by adding ice to the water bath. The 
crude extracts were then filtered through Whatman No. 1 filter paper. PE, DCM and 
EtOH were concentrated in vacuo at 40 °C using a rotary evaporator. The 
concentrated extracts were then dried under a stream of cold air. Water extracts 
were freeze dried and kept in airtight containers at 10 °C in the dark. 
 
4.2.3. Antibacterial microdilution bioassay 
 
Minimum inhibitory concentration (MIC) values for antibacterial activity of the plant 
extracts was determined using the microdilution bioassay in 96-well (Greiner Bio-one 
GmbH, Germany) microtitre plates (ELOFF, 1998) as described in section 3.2.2.1 
(Chapter 3) except that PE, DCM and EtOH extracts were resuspended in 80% 
ethanol and wells consisting of 80% ethanol as solvent control were included in the 
microtitre plate. 
 
4.2.4. Antifungal microdilution bioassay 
 
The antifungal activity of the plant extracts was evaluated against Candida albicans 
using the micro-dilution assay (ELOFF, 1998) modified for an antifungal assay 
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(MASOKO et al., 2007) as described in section 3.2.2.2 (Chapter 3) except that PE, 
DCM and EtOH extracts were resuspended in 80% ethanol and wells consisting of 
80% ethanol as solvent control were included on the microtitre plate. 
 
4.2.5. Cyclooxygenase (COX-1 and COX-2) inhibitory bioassays 
 
The COX-1 and -2 bioassays were performed as described by JÄGER et al. (1996) 
and ZSCHOCKE and VAN STADEN (2000) as described in Sections 3.3.2.1 and 
3.3.2.2 (Chapter 3) respectively except that 2.5 µl of 10 mg/ml sample in 17.5 µl 
giving a final assay concentration of 250 µg/ml were used for PE, DCM and EtOH 
and 80% ethanol was used for the background and solvent blanks. 
 
4.2.6. Acetylcholinesterase (AChE) inhibitory bioassay 
 
The microtiter plate assay for the inhibition of AChE by the water extracts of the 
plants used to make Imbiza ephuzwato was done as described by ELLMAN et al. 
(1961) with some modifications, as outlined in Section 3.3.2.4 (Chapter 3).  
 
4.2.7. In vitro mutagenic evaluation 
 
4.2.7.1. Ames test 
 
Mutagenic properties of the plant extracts were tested using the Salmonella 
microsome assay based on the plate-incorporation procedure with Salmonella 
typhimurium tester strains TA98 with and without metabolic activation (MARON and 
AMES, 1983; MORTELMANS and ZEIGER, 2000) as outlined in Section 3.6.2.2 
(Chapter 3). 
 
4.3. Results and discussion 
 
The antibacterial activity (MIC values) for the extracts of the 21 plant species used to 
manufacture Imbiza ephuzwato are presented in Table 4.2. The plant extracts with 
high antibacterial activity (< 1 mg/ml) are highlighted in bold. Out of the 21 plants 
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used to manufacture Imbiza ephuzwato, 13 species had at least one extract active 
against Bacillus subtilis; 7 against Escherichia coli; 9 against Klebsiella pneumoniae 
and Staphylococcus aureus respectively.  
 
Extracts of Corchorus asplenifolius (PE), Eriosema cordatum (DCM), Tetradenia 
riparia (PE and EtOH) and Zanthoxylum capense (PE, DCM and EtOH) showed the 
best antibacterial activity against Bacillus subtilis with MIC values of 0.195 mg/ml 
each. Corchorus asplenifolius (PE) and Tetradenia riparia (PE) also had MIC values 
of 0.195 mg/ml each against Klebsiella pneumoniae. Corchorus asplenifolius (PE), 
Eriosema cordatum (DCM), Gunnera perpensa (EtOH) and Tetradenia riparia (DCM) 
and Zanthoxylum capense (DCM) also exhibited good activity with MIC values of 
0.195 mg/ml each against Staphylococcus aureus. The best activity against 
Escherichia coli was exhibited by Lycopodium clavatum (EtOH) extract. 
 
Gunnera perpensa and Rubia cordifolia were the only plant species used to 
manufacture Imbiza ephuzwato that had water extracts which showed good 
antibacterial activity with MIC values of 0.78 mg/ml against some of the bacterial 
strains tested. The rest of the water extracts from the other plants showed poor 
activity. The MIC values (0.78 mg/ml) exhibited by the water extracts of Gunnera 
perpensa were comparable to the MIC values (0.78 mg/ml) shown by Imbiza 
ephuzwato against Bacillus subtilis, Escherichia coli and Staphylococcus aureus. 
Rubia cordifolia water extracts showed MIC values (0.78 mg/ml) comparable to 
Imbiza ephuzwato herbal mixture‟s MIC values only for Bacillus subtilis and 
Staphylococcus aureus. However, the water extract of Gunnera perpensa was more 
active (0.78 mg/ml) against Klebsiella pneumoniae than to Imbiza ephuzwato  
(1.56 mg/ml). This could probably be due to a dilution effect in Imbiza ephuzwato on 
the compounds that inhibits growth of Klebsiella pneumoniae. Apart from synergistic 
effects, interaction of secondary metabolites due to mixing of different plant species 
may also result in compounds with lower pharmacological effects compared to 
individual plant species. 
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Table 4.2: Antibacterial activity (MIC) of different extracts of the plant species 
used to manufacture Imbiza ephuzwato herbal mixture 
 Plant  
Part 
 Bacterial MIC (mg/ml) 
Plant name Extract B.s. E.c. K.p. S.a. 
Acokanthera venenata R 
PE 3.125 3.125 3.125 3.125 
DCM 1.56 1.56 3.125 1.56 
EtOH 3.125 3.125 1.56 3.125 
Water 12.5 12.5 12.5 12.5 
Asclepias fruticosa R 
PE 1.56 1.56 1.56 1.56 
DCM 1.56 1.56 3.125 1.56 
EtOH 1.56 1.56 1.56 3.125 
Water 12.5 12.5 12.5 12.5 
Aster bakeranus R 
PE 0.78 3.125 6.25 6.25 
DCM 0.78 3.125 3.125 0.78 
EtOH 1.56 3.125 3.125 3.125 
Water >12.5 >12.5 6.25 6.25 
Corchorus asplenifolius R 
PE 0.195 0.39 0.195 0.195 
DCM 0.78 0.78 0.78 0.78 
EtOH 1.56 1.56 3.125 1.56 
Water 1.56 6.25 3.125 >12.5 
Cyrtanthus obliquus B 
PE 0.39 6.25 3.125 0.39 
DCM 0.39 1.56 1.56 0.78 
EtOH 0.78 1.56 1.56 0.78 
Water 12.5 6.25 3.125 3.125 
Drimia robusta B 
PE 3.125 3.125 0.78 12.5 
DCM 3.125 3.125 3.125 6.25 
EtOH 3.125 3.125 3.125 3.125 
Water >12.5 6.25 3.125 6.25 
Eriosema cordatum R 
PE 6.25 1.56 1.56 6.25 
DCM 0.195 0.39 0.39 0.195 
EtOH 0.39 0.39 0.39 0.39 
Water 1.56 3.125 6.25 1.56 
Gnidia kraussiana  R 
PE 1.56 1.56 3.125 3.125 
DCM 1.56 1.56 1.56 3.125 
EtOH 3.125 6.25 6.25 3.125 
Water 1.56 1.56 1.56 3.125 
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 Plant  
Part 
 Bacterial MIC (mg/ml) 
Plant name Extract B.s. E.c. K.p. S.a. 
Gunnera perpensa Rh 
PE 6.25 3.125 6.25 12.5 
DCM 3.125 3.125 3.125 6.25 
EtOH 0.39 0.39 0.39 0.195 
Water 0.78 0.78 0.78 0.78 
Hypericum aethiopicum L 
PE 0.78 3.125 3.125 1.56 
DCM 0.78 1.56 1.56 1.56 
EtOH 0.39 3.125 0.78 1.56 
Water 6.25 >12.5 >12.5 6.25 
Ledeboria sp B 
PE 1.56 3.125 3.125 3.125 
DCM 0.78 3.125 1.56 1.56 
EtOH 1.56 3.125 3.125 1.56 
Water 6.25 6.25 12.5 6.25 
Lycopodium clavatum WP 
PE 0.78 1.56 0.78 0.39 
DCM 0.39 0.78 1.56 0.78 
EtOH 0.39 0.195 0.39 0.39 
Water 1.56 3.125 6.25 6.25 
Momordica balsamina L 
PE 3.125 6.25 3.125 12.5 
DCM 0.78 3.125 1.56 12.5 
EtOH 0.78 1.56 1.56 3.125 
Water 3.125 6.25 12.5 12.5 
Rubia cordifolia R 
PE 3.125 0.78 0.78 3.125 
DCM 1.56 0.78 0.39 3.125 
EtOH 0.39 1.56 0.78 0.39 
Water 0.78 1.56 3.125 0.78 
Scadoxus puniceus B 
PE 6.25 3.125 3.125 3.125 
DCM 3.125 3.125 1.56 3.125 
EtOH 6.25 6.25 6.25 6.25 
Water 6.25 6.25 6.25 6.25 
Stephania abyssinica R 
PE 3.125 3.125 3.125 6.25 
DCM 6.25 1.56 3.125 6.25 
EtOH 3.125 3.125 6.25 6.25 
Water >12.5 >12.5 >12.5 >12.5 
       
  
     
     
Table 4.2: Continued 
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 Plant  
Part 
 Bacterial MIC (mg/ml) 
Plant name Extract B.s. E.c. K.p. S.a. 
Tetradenia riparia L 
PE 0.195 0.39 0.195 0.39 
DCM 0.39 0.39 0.39 0.195 
EtOH 0.195 0.78 0.78 0.78 
Water >12.5 6.25 6.25 3.125 
Urginea physodes B 
PE 1.56 3.125 3.125 3.125 
DCM 6.25 3.125 1.56 6.25 
EtOH 1.56 3.125 6.25 1.56 
Water >12.5 12.5 12.5 12.5 
Vitellariopsis marginata R 
PE 6.25 6.25 3.125 >12.5 
DCM 1.56 1.56 1.56 1.56 
EtOH 0.78 6.25 1.56 3.125 
Water 1.56 6.25 6.25 3.125 
Watsonia densiflora C 
PE 1.56 3.125 3.125 3.125 
DCM 1.56 1.56 1.56 1.56 
EtOH 1.56 3.125 1.56 1.56 
Water 12.5 12.5 12.5 12.5 
Zanthoxylum capense R 
PE 0.195 1.56 1.56 1.56 
DCM 0.195 0.78 0.78 0.195 
EtOH 0.195 1.56 0.78 1.56 
Water 3.125 3.125 1.56 3.125 
Imbiza ephuzwato  Water 0.78 0.78 1.56 0.78 










B.s.=Bacillus subtilis; E.c.=Escherichia coli; K.p.=Klebsiella pneumoniae; 
S.a.=Staphylococcus aureus. 
 
B- bulbs; C- corms; L- leaves; R- roots; Rh- rhizomes; WP- whole plant; +ve- positive. 
 
Plant extracts with MIC values written in bold font are considered to be very active 
(MIC < 1 mg/ml). 
 
Table 4.2: Continued 
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The observed antibacterial activity of the water extracts of Gunnera perpensa and 
Rubia cordifolia justifies their inclusion in the makeup of Imbiza ephuzwato herbal 
drink. Besides possible synergistic effects of compounds within the heterogeneous 
mixture, Gunnera perpensa and Rubia cordifolia could be contributing a lot to the 
observed activity in Imbiza ephuzwato. However, further studies using techniques 
such as HPLC to ascertain the involvement of Gunnera perpensa and Rubia 
cordifolia are much needed. 
 
Gunnera perpensa contains a bioactive bitter principle, celastrin while several active 
compounds including anthraquinones, sistosterols, triterpenoids and fatty acids have 
been isolated from Rubia cordifolia (HUTCHINGS et al., 1996). These and other 
compounds could be responsible for the activity observed in the plant extracts as 
well as Imbiza ephuzwato herbal mixture. Further studies aimed at identifying the 
active compounds also needed. 
 
The PE, DCM and EtOH extracts of Tetradenia riparia exhibited high antibacterial 
activity. Tetradenia riparia contains diterpenoids which have antibiotic activity. 
However, the water extract did not show activity, suggesting that the active 
compounds were not extracted by the water phase. The other extracts (PE, DCM 
and EtOH) showing a wide range of activity amongst the test bacteria were from 
Lycopodium clavatum and Zanthoxylum capense which contains benzophenan-
thridine alkaloids which have various biological activities including antibiotic effects. 
The genus Hypericum contains flavonoids and a well known antibacterial compound 
called hyperforin (VAN WYK et al., 1997).  
 
Surprisingly, plant species such as Scadoxus puniceus and Watsonia densiflora 
which exhibited poor antibacterial activity in this study, have been reported to contain 
alkaloids with potent antibiotic activity (VAN WYK et al., 1997). However, several 
factors also contribute to loss of activity in plant extracts including storage conditions, 
geographical location of plant growth and environmental stress. 
 
Basing on the antibacterial results of the plant species investigated, Imbiza 
ephuzwato can be used against bacterial infections caused by both Gram-positive 
(Bacillus subtilis and Staphylococcus aureus) and Gram-negative (Escherichia coli 
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and Klebsiella pneumoniae) and possibly related bacteria. However, these results 
only offer supporting evidence for effective use of these extracts but still needs to be 
confirmed through other assays including in vivo tests. Such infections include 
stomach upsets due to Escherichia coli and food poisoning due to products of 
Bacillus subtilis. Although not included on the Imbiza ephuzwato label, it can be 
speculated that the mixture can also be used for wound healing. Wounds are mostly 
polymicrobial, involving numerous microorganisms that are potentially pathogenic 
(LUSEBA et al., 2007). The mixture can also be applied topically for skin infections, 
such as pimples and boils and, for to life-threatening diseases such as pneumonia, 
meningitis and osteomyelitis caused by Staphylococcus aureus. 
 
The antifungal activity (MIC and MFC values) for the extracts of the 21 plant species 
used to manufacture Imbiza ephuzwato are presented in Table 4.3. The plant 
extracts with high antifungal activity (< 1 mg/ml) are highlighted in bold. Out of the 21 
plants used to manufacture Imbiza ephuzwato, 13 species were highly active against 
Candida albicans. 
 
Just as in the antibacterial assay, the water extract of Gunnera perpensa showed 
good activity (0.78 mg/ml) which was comparable to that of Imbiza ephuzwato (0.78 
mg/ml). It can also be tentatively concluded that Gunnera perpensa could be 
contributing to the observed antifungal properties exhibited by Imbiza ephuzwato. 
The observed activity in Gunnera perpensa water extracts also justifies the inclusion 
of this plant species in the herbal mixture. The water extracts of the rest of the plant 
species exhibited poor activity. Water extracts have frequently been reported to have 
low antimicrobial activity (RABE and VAN STADEN, 1997; LUSEBA et al., 2007). 
 
A biologically active bitter principle, celastrin is reported to be present in Gunnera 
perpensa (VAN WYK et al., 1997). Celastrin could be the compound responsible for 
the observed activity in the water extract of Gunnera perpensa as well as in Imbiza 
ephuzwato. Interaction of the biological molecules in the mixture can also result in 
compounds or complexes with high biological activity. However, further research 




Table 4.3: Antifungal activity (MIC and MFC) of extracts from the plant species 
used to manufacture Imbiza ephuzwato herbal mixture 
 Plant  
Part 
 Candida albicans 
Plant name Extract MIC MFC 
Acokanthera venenata R 
PE 3.125 6.25 
DCM 0.195 1.56 
EtOH 0.78 6.25 
Water 3.125 6.25 
Asclepias fruticosa R 
PE 3.125 6.25 
DCM 3.125 >12.5 
EtOH 3.125 3.125 
Water 6.25 12.5 
Aster bakeranus R 
PE 3.125 6.25 
DCM 1.56 6.25 
EtOH 3.125 6.25 
Water 12.5 >12.5 
Corchorus asplenifolius R 
PE 3.125 3.125 
DCM 0.39 3.125 
EtOH 0.78 1.56 
Water 6.25 12.5 
Cyrtanthus obliquus B 
PE 1.56 6.25 
DCM 0.195 3.125 
EtOH 1.56 1.56 
Water 12.5 >12.5 
Drimia robusta B 
PE 6.25 12.5 
DCM 3.125 6.25 
EtOH 3.125 6.25 
Water 6.25 12.5 
Eriosema cordatum R 
PE 1.56 12.5 
DCM 1.56 12.5 
EtOH 3.125 6.25 
Water 12.5 >12.5 
Gnidia kraussiana  R 
PE 3.125 6.25 
DCM 3.125 6.25 
EtOH 3.125 6.25 
Water >12.5 >12.5 
135 
 
 Plant  
Part 
 Candida albicans 
Plant name Extract MIC MFC 
Gunnera perpensa Rh 
PE 3.125 6.25 
DCM 3.125 6.25 
EtOH 0.093 0.78 
Water 0.78 0.78 
Hypericum aethiopicum L 
PE 3.125 6.25 
DCM 0.093 0.78 
EtOH 3.125 6.25 
Water 12.5 12.5 
Ledeboria sp B 
PE 3.125 12.5 
DCM 6.25 12.5 
EtOH 1.56 1.56 
Water 12.5 >12.5 
Lycopodium clavatum WP 
PE 1.56 1.56 
DCM 1.56 1.56 
EtOH 0.195 1.56 
Water 12.5 >12.5 
Momordica balsamina L 
PE 3.125 3.125 
DCM 0.195 0.195 
EtOH 0.39 0.39 
Water 6.25 >12.5 
Rubia cordifolia R 
PE 1.56 3.125 
DCM 0.78 0.78 
EtOH 1.56 1.56 
Water 6.25 12.5 
Scadoxus puniceus B 
PE 3.125 6.25 
DCM 3.125 12.5 
EtOH 3.125 6.25 
Water 12.5 >12.5 
Stephania abyssinica R 
PE 3.125 6.25 
DCM 3.125 3.125 
EtOH 3.125 6.25 
Water 12.5 >12.5 
  
   
   
   
Table 4.3: Continued 
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 Plant  
Part 
 Candida albicans 
Plant name Extract MIC MFC 
Tetradenia riparia L 
PE 1.56 3.125 
DCM 0.78 0.78 
EtOH 3.125 3.125 
Water >12.5 >12.5 
Urginea physodes B 
PE 3.125 6.25 
DCM 1.56 >12.5 
EtOH 0.093 0.78 
Water 1.56 6.25 
Vitellariopsis marginata R 
PE 0.78 6.25 
DCM 1.56 6.25 
EtOH 3.125 3.125 
Water 12.5 >12.5 
Watsonia densiflora C 
PE 3.125 12.5 
DCM 3.125 12.5 
EtOH 0.78 0.78 
Water 0.78 3.125 
Zanthoxylum capense R 
PE 0.78 6.25 
DCM 0.78 1.56 
EtOH 0.39 0.78 
Water 3.125 6.25 
Imbiza ephuzwato  Water 0.78 1.56 
Amphotericin B (+ve control)   9.77 × 10
-3




B- bulbs; C- corms; L- leaves; R- roots; Rh- rhizomes; WP- whole plant; +ve- positive. 
 
Plant extracts with MIC and MFC values written in bold font are considered to be very 
active (MIC < 1 mg/ml). 
 
Table 4.3: Continued 
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The extracts of Gunnera perpensa (EtOH), Hypericum aethiopicum (DCM) and 
Urginea physodes (EtOH) showed the best antifungal activity with MIC values of 
0.093 mg/ml each. All the extracts of Asclepias fruticose, Aster bakeranus, Drimia 
robusta, Eriosema cordatum, Gnidia kraussiana, Ledeboria sp, Scadoxus puniceus 
and Stephania abyssinica showed poor activity. The rest of the plants had at least 
one extract active against Candida albicans. 
 
The antifungal assay was modified to test if the active extracts were fungistatic or 
fungicidal. As previously stated, there are certain conditions ideal for an extract or 
compound to be a good antifungal drug. The extract should be fungicidal rather than 
fungistatic (ZACCHINO et al., 2003). From the extracts which showed good 
antifungal activity (< 1 mg/ml), it was observed that the extracts of Gunnera 
perpensa (water), Momordica balsamina (DCM and EtOH), Rubia cordifolia (DCM), 
Tetradenia riparia (DCM) and Watsonia densiflora (EtOH) were fungicidal as there 
was no growth of fungal cells after addition of broth to the clear wells. 
 
Based on the results of the plant species investigated as well as the observed 
activity of Imbiza ephuzwato against Candida albicans, it is expected that the mixture 
can be successfully used for fungal infections including candidiasis (in blood, oral 
and genital) although these conditions are not listed on the label. Further studies 
aimed at investigating the effects of Imbiza ephuzwato against clinical strains of 
Candida albicans as well as isolating the active compounds are much needed. 
 
The inhibitory effects on COX-1 and COX-2 enzymes by extracts of the 21 plant 
used to manufacture Imbiza ephuzwato are presented in Figures 4.2 and 4.3 
respectively. As previously mentioned, four levels of activity are defined in the COX 
assay with activity below 20% being considered insignificant, 20– 40% low, 40–70% 
moderate and 70–100% high (TAYLOR and VAN STADEN, 2001). The level to 
which the plant extracts could inhibit the COX-1 enzyme can consequently be 
considered high for 5 PE, 7 DCM, 3 EtOH, 6 water extracts, moderate for 6 PE, 5 
DCM, 5 EtOH, 2 water extracts and low for 4 PE, 4 DCM, 5 EtOH and 2 water 






































































































































































Figure 4.2: Percentage inhibition of COX-1 enzyme by (A) PE, (B) DCM, (C) EtOH 
and (D) water extracts of the plants used to make Imbiza ephuzwato (250 µg/ml and 
2 mg/ml for organic and water extracts respectively); (1) Hypericum aethiopicum,  
(2) Gunnera perpensa, (3) Zanthoxylum capense, (4) Corchorus asplenifolius,  
(5) Drimia robusta, (6) Cyrtanthus obliquus, (7) Aster bakeranus, (8) Vitellariopsis 
marginata, (9) Asclepias fruticosa, (10) Scadoxus puniceus, (11) Watsonia 
densiflora, (12) Gnidia kraussiana, (13) Stephania abyssinica, (14) Urginea 
physodes, (15) Momordica balsamina, (16) Acokanthera venenata, (17) Ledeboria 
sp, (18) Tetradenia riparia, (19) Lycopodium clavatum, (20) Rubia cordifolia and  
(21) Eriosema cordatum. Percentage inhibition by Imbiza ephuzwato (2 mg/ml) and 
indomethacin (5 µM) was 82.23 ± 2.22 and 64.18 ± 3.10 respectively. Plant extracts 





The water extracts of Hypericum aethiopicum, Gunnera perpensa, Drimia robusta, 
Vitellariopsis marginata, Scadoxus puniceus and Momordica balsamina showed 
percentage inhibition of COX-1 that was over 70%. These plant species could have 
contributed to the COX-1 inhibition observed for Imbiza ephuzwato (82.23%) through 
additive or synergistic effects. 
 
The extent to which the plant extracts could inhibit the COX-2 enzyme can 
consequently be considered high for 6 PE, 5 DCM, 1 EtOH, 4 water extracts, 
moderate for 5 PE, 5 DCM, 4 EtOH, 2 water extracts and low for 4 PE, 3 DCM, 8 
EtOH and 2 water extracts. COX-2 enzyme inhibition activity was insignificant for 6 
PE, 6 DCM, 8 EtOH and 13 water extracts. 
 
The water extracts of Gunnera perpensa, Cyrtanthus obliquus, Momordica 
balsamina and Tetradenia riparia exhibited inhibitory activity above 70% against the 
COX-2 enzyme. Imbiza ephuzwato exhibited 84.10% inhibition against the COX-2 
enzyme. These four species could jointly have contributed to the observed COX-2 
inhibitory activity shown by Imbiza ephuzwato. 
 
The water extracts of Gunnera perpensa and Momordica balsamina showed higher 
inhibitory activity in the COX-2 bioassay when compared to the COX-1 bioassay 
which suggests that these extracts could be selective towards the COX-2 enzyme. It 
is unfeasible to have selective COX-1 inhibitory activity as the main criterion because 
of the side effects associated with COX-1 enzyme inhibition, including damage to the 
gastrointestinal tract, resulting in ulcers (KIM et al., 2005). 
 
The high COX-2 inhibitory activity of Gunnera perpensa and Momordica balsamina 
makes Imbiza ephuzwato a better product when treating inflammation related 
conditions. This is because it is desirable to have a product with higher COX-2 
inhibitory effects than for the COX-1 enzyme. The COX-2 enzyme is specific in 
treating inflamed tissue, resulting in less gastric irritation as is associated with COX-1 
inhibitors, hence decreased risk of gastric ulceration. However, the selectivity of 
COX-2 does not seem to negate other side-effects, such as increased risk of renal 
failure. There is evidence which indicates an increase in the risk for heart attack, 
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thrombosis, and stroke due to persistent use of COX-2 selective drugs (COPELAND, 
2005). 
 
As mentioned previously, the rhizome of Gunnera perpensa contains an active bitter 
principle, celastrin and other compounds that have been reported to show uterotonic 
activity (BROOKES and DUTTON, 2007). Such compounds could also have anti-
inflammatory activities, justifying the inclusion of Gunnera perpensa into Imbiza 
ephuzwato herbal mixture. The activity observed can also validate the use of 
Gunnera perpensa in ATM to treat stomach problems, fever, swelling, menstrual 
pain and for wound dressing. 
 
Tetradenia riparia has been reported to contain Ibozol, a diterpene diol and 
umuravumbolide (VAN WYK et al., 1997) which justifies the use of the leaf in ATM 
to treat stomach ache and swollen legs as well as its inhalation to treat headaches 
and its inclusion into Imbiza ephuzwato herbal mixture. 
 
The low inhibitory values in some of the extracts tested in the present study could be 
due to the impure form and/or low concentration of the active compound(s) in the 
crude extracts (RABE and VAN STADEN, 1997). Another important point to note is 
that enzyme inhibition assays involve specific mechanisms and if any compound 
acts by a mechanism not related to the enzyme being inhibited then the compound 
will be regarded as being not active (TAYLOR and VAN STADEN, 2001). Therefore, 
extracts showing low inhibitory activity in COX-1 and COX-2 bioassays can not 
conclusively be said to lack inhibitory activity as they may contain compounds that 
are active through other mechanisms linked to the processes of pain and 
inflammation (McGAW et al., 1997). 
 
Imbiza ephuzwato can therefore be used for treating inflammation related conditions 
listed on the label including back pain, swelling of the feet, menstrual pains, kidney 
inflammation, sore back and general body pain effectively. However, as mentioned 
above, persistent use of Imbiza ephuzwato may have negative effects associated 
with damage of the gastrointestinal tract because of the use of plants with high COX-
1 inhibitory effects. 
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Figure 4.3: Percentage inhibition of COX-2 enzyme by (A) PE, (B) DCM, (C) EtOH 
and (D) water extracts of the plants used to make Imbiza ephuzwato (250 µg/ml and 
2 mg/ml for organic and water extracts respectively); (1) Hypericum aethiopicum,  
(2) Gunnera perpensa, (3) Zanthoxylum capense, (4) Corchorus asplenifolius,  
(5) Drimia robusta, (6) Cyrtanthus obliquus, (7) Aster bakeranus, (8) Vitellariopsis 
marginata, (9) Asclepias fruticosa, (10) Scadoxus puniceus, (11) Watsonia 
densiflora, (12) Gnidia kraussiana, (13) Stephania abyssinica, (14) Urginea 
physodes, (15) Momordica balsamina, (16) Acokanthera venenata, (17) Ledeboria 
sp, (18) Tetradenia riparia, (19) Lycopodium clavatum, (20) Rubia cordifolia and  
(21) Eriosema cordatum. Percentage inhibition by Imbiza ephuzwato (2 mg/ml) and 
indomethacin (200 µM) was 84.10 ± 0.17 and 68.50 ± 2.57 respectively. Plant 






The results of the AChE enzyme inhibitory activity are presented in Figure 4.4. 
Fifteen out of the 20 water plant extracts showed inhibitory activity above 50%. 
Gunnera perpensa, Cyrtanthus obliquus, Vitellariopsis marginata, Asclepias fruticosa 
and Watsonia densiflora showed good AChE inhibitory activity (> 80%). Corchorus 
asplenifolius, Drimia robusta, Aster bakeranus, Scadoxus puniceus, Stephania 
abyssinica, Acokanthera venenata, Ledeboria sp, Lycopodium clavatum and 
Eriosema cordatum extracts exhibited moderate AChE enzyme inhibitory activity 
(between 50% and 80%). The rest of the plant extracts exhibited low activity  
(< 50%). 
 
The IC50 values for water extracts of the plant species used to make Imbiza 
ephuzwato herbal mixture are shown in Table 4.4. Four of the water extracts of the 
plant species (Aster bakeranus, Gnidia kraussiana, Ledeboria sp. and Urginea 
physodes) exhibited lower than 50% inhibitory activity at 1 mg/ml, making it 
impossible to calculate IC50 values. The order of potent activity with respect to IC50 
values for the plant extracts was: Gunnera perpensa > Zanthoxylum capense > 
Momordica balsamina > Lycopodium clavatum > Corchorus asplenifolius > 
Scadoxus puniceus > Asclepias fruticosa > Tetradenia riparia > Drimia robusta > 
Rubia cordifolia > Stephania abyssinica > Acokanthera venenata > Eriosema 
cordatum > Cyrtanthus obliquus > Watsonia densiflora > Vitellariopsis marginata > 
Hypericum aethiopicum. 
 
The family Amaryllidaceae (Scadoxus puniceus and Cyrtanthus obliquus) contains 
bioactive alkaloids such as epibuphanisine, epivittatine, haemathamine,  
1-O-acetyllycorine and cherylline. These alkaloids have been reported to have good 
AChE enzyme inhibitory effects (ELGORASHI et al., 2001). Some or all of these 
alkaloids in synergism or addition could be attributed to the AChE enzyme inhibitory 
activity exhibited by Scadoxus puniceus and Cyrtanthus obliquus in this study.  
 
Low activity observed in some extracts could be due to lower doses used in scientific 
studies. In ATM, healers seldom weigh plant materials when administering them to 
patients, resulting in consumption of larger doses of the medicine than may be 







































Figure 4.4: Percentage inhibition of the AChE enzyme by water extracts (1 mg/ml) 
of the plants used to make Imbiza ephuzwato; (1) Hypericum aethiopicum, (2) 
Gunnera perpensa, (3) Zanthoxylum capense, (4) Corchorus asplenifolius, (5) 
Drimia robusta, (6) Cyrtanthus obliquus, (7) Aster bakeranus, (8) Vitellariopsis 
marginata, (9) Asclepias fruticosa, (10) Scadoxus puniceus, (11) Watsonia 
densiflora,(12) Gnidia kraussiana, (13) Stephania abyssinica, (14) Urginea 
physodes, (15) Momordica balsamina, (16) Acokanthera venenata, (17) Ledeboria 
sp, (18) Tetradenia riparia, (19) Lycopodium clavatum, (20) Rubia cordifolia and  
(21) Eriosema cordatum. Plant extracts with inhibitory activity above 70% were 
considered to be highly active. Percentage inhibition by Imbiza ephuzwato herbal 







Table 4.4: AChE inhibitory activity (IC50 µg/ml) of water extracts of the plant 
species used to manufacture Imbiza ephuzwato herbal mixture 
Plant species 
Plant AChE inhibitory activity 
Part IC50 (µg/ml) 
Acokanthera venenata R 590.00 ± 10.22 
Asclepias fruticosa R 372.10 ± 3.44 
Aster bakeranus R NC 
Corchorus asplenifolius R 118.10 ± 2.65 
Cyrtanthus obliquus B 899.90 ± 4.34 
Drimia robusta B 487.40 ± 7.98 
Eriosema cordatum R 756.56 ± 9.12 
Gnidia kraussiana  R NC 
Gunnera perpensa Rh 3.249 ± 0.56 
Hypericum aethiopicum L 1218.0 ± 2.44 
Ledeboria sp B NC 
Lycopodium clavatum WP 98.23 ± 1.23 
Momordica balsamina L 61.34 ± 0.45 
Rubia cordifolia R 545.60 ± 12.47 
Scadoxus puniceus B 271.90 ± 10.87 
Stephania abyssinica R 560.90 ± 9.44 
Tetradenia riparia L 464.20 ± 16.33 
Urginea physodes B NC 
Vitellariopsis marginata R 959.10 ± 6.33 
Watsonia densiflora C 911.60 ± 18.55 
Zanthoxylum capense R 7.52 ± 0.01 
Imbiza ephuzwato  0.48 ± 0.01 
Galanthamine  1.6 ± 06 (µM) 
 
B- bulbs; C- corms; L- leaves; R- roots; Rh- rhizomes; WP- whole plant. 
 
Plant extracts with IC50 values in bold are considered potent inhibitors of AChE. 
 
NC- (Not calculated) IC50 could not be calculated because the activity was less than 
50% at highest concentration. 
 
Values in bold represents extracts with potent inhibitors of AChE enzymes. 
147 
 
A high activity against the AChE enzyme justifies the use of Imbiza ephuzwato for 
depression. Based on the inhibitory effects against AChE by most of these plant 
extracts, Imbiza ephuzwato can possibly also be used for treatment of Alzheimer‟s 
disease (AD) and short term memory lose. 
 
The standard plate incorporation method for the Ames test using Salmonella 
typhimurium tester strains TA98 exposed to three dilutions with and without S9 
metabolic activation of the water extracts of the 21 plant species used to make 
Imbiza ephuzwato was performed to investigate the observed mutagenicity observed 
in the herbal mixture. Ames test without S9 metabolic activation can only detect 
direct mutagens while the test with S9 metabolic activation allows the detection of 
indirect mutagens, as was observed in Imbiza ephuzwato.  
 
Table 4.5 presents the spontaneous reversion response of the Salmonella 
typhimurium tester strain to the different dilutions of the water extracts of the 21 plant 
species. The results revealed that all the extracts were non-mutagenic towards the 
Salmonella typhimurium strains TA98 for the assay with and without S9 metabolic 
activation. The average His+ revertant colonies observed for the tester strain caused 
by all the extracts at all the concentrations did not satisfy the criteria for mutagenicity. 
There were no notable dose-dependent increase in the number of revertants and the 
numbers of revertants were all not equal to or greater than two times that of the 
negative control (BULMER et al., 2007). There was also no decrease in the number 
of revertant colonies to levels far below the negative control (spontaneous reversion) 
which could also be classified as toxic. 
 
In view of the fact that no plant extract was found to be mutagenic, the mutagenicity 
observed against TA98 when Imbiza ephuzwato was exposed to S9 metabolic 
activation could therefore be as a result of interaction of biomolecules in the 
heterogeneous mixture, yielding compounds that are converted to mutagenic agents 
by xenobiotic metabolizing enzymes. As discussed in Section 3.6.3, such 
biomolecules includes various aromatic nitroso-derivatives of amine carcinogens that 
have been shown to cause a reversion of hisD3052 mutation in TA98 back to the 
wild-type state (MORTELMANS and ZEIGER, 2000). 
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Table 4.5: Number of revertant colonies of Salmonella typhimurium strain TA98 
induced by extracts of the plant species used to manufacture Imbiza 
ephuzwato herbal mixture with and without S9 metabolic activation 
Plant species 
Plant Concentration Number of His+ revertants 
part (µg/ml) S9- S9+ 
Acokanthera venenata R 
5000 20.3 ± 2.4 26.7 ± 2.2 
500 26.7 ± 0.2 28.3 ± 0.1 
50 22.3 ± 1.1 26.3 ± 1.1 
Asclepias fruticosa R 
5000 19.3 ± 4.2 20.7 ± 1.2 
500 26.7 ± 3.3 24.3 ± 0.2 
50 23.7 ± 4.1 22.7 ± 5.1 
Aster bakeranus R 
5000 19.3 ± 5.2 26.7 ± 2.2 
500 23.7 ± 3.3 29.3 ± 0.9 
50 24.7 ± 4.4 29.7 ± 1.2 
Corchorus asplenifolius R 
5000 26.3 ± 2.2 25.3 ± 3.3 
500 27.0 ± 0.0 29.3 ± 2.2 
50 28.7 ± 0.8 20.3 ± 2.2 
Cyrtanthus obliquus B 
5000 21.3 ± 2.1 23.7 ± 4.4 
500 24.3 ± 2.2 25.7 ± 0.9 
50 18.7 ± 3.1 27.3 ± 1.1 
Drimia robusta B 
5000 21.3 ± 3.3 22.7 ± 2.7 
500 17.7 ± 2.4 20.7 ± 3.3 
50 20.3 ± 4.4 20.7 ± 1.3 
Eriosema cordatum R 
5000 21.3 ± 3.3 25.3 ± 2.2 
500 18.7 ± 4.4 24.3 ± 1.1 
50 25.3 ± 3.3 26.7 ± 2.3 
Gnidia kraussiana  R 
5000 24.3 ± 4.2 27.3 ± 2.2 
500 25.7 ± 2.0 26.3 ± 1.3 
50 20.3 ± 2.5 27.7 ± 1.0 
Gunnera perpensa Rh 
5000 23.3 ± 2.3 24.7 ± 1.2 
500 24.7 ± 1.1 31.3 ± 2.2 




Plant Concentration Number of His+ revertants 
part (µg/ml) S9- S9+ 
Hypericum aethiopicum L 
5000 20.3 ± 1.3 27.3 ± 1.2 
500 26.7 ± 4.5 28.7 ± 2.7 
50 22.7 ± 3.3 23.3 ± 3.4 
Ledeboria sp B 
5000 20.3 ± 2.2 28.7 ± 0.2 
500 23.7 ± 3.4 29.3 ± 0.2 
50 31.3 ± 2.3 26.3 ± 1.2 
Lycopodium clavatum WP 
5000 27.7 ± 5.2 19.7 ± 3.3 
500 21.7 ± 2.9 18.7 ± 5.5 
50 26.3 ± 3.8 16.7 ± 4.5 
Momordica balsamina L 
5000 21.3 ± 2.9 23.3 ± 1.1 
500 28.7 ± 1.8 23.7 ± 0.9 
50 27.3 ± 0.2 28.3 ± 1.5 
Rubia cordifolia R 
5000 27.3 ± 1.1 19.7  ± 4.7 
500 20.7 ± 2.7 24.3 ± 3.3 
50 31.7 ± 3.9 23.7 ± 2.2 
Scadoxus puniceus B 
5000 24.3 ± 1.2 24.3 ± 2.8 
500 21.7 ± 3.4 23.3 ± 4.4 
50 24.3 ± 2.7 33.7 ± 3.5 
Stephania abyssinica R 
5000 20.7 ± 4.7 23.3 ± 1.0 
500 15.3 ± 2.3 24.7 ± 1.7 
50 22.3 ± 0.3 23.7 ± 3.3 
Tetradenia riparia L 
5000 21.7 ± 3.7 28.7 ± 1.7 
500 21.3 ± 5.1 28.3 ± 2.7 
50 23.3 ± 3.3 20.7 ± 5.4 
Urginea physodes B 
5000 20.3 ± 0.1 43.0 ± 0.0 
500 22.7 ± 1.3 26.3 ± 1.5 
50 23.3 ± 1.7 28.7 ± 3.3 
Vitellariopsis marginata R 
5000 19.7 ± 3.3 23.7 ± 2.7 
500 20.3 ± 1.7 25.3 ± 0.1 
50 20.3 ± 3.1 30.7 ± 0.7 




Plant Concentration Number of His+ revertants 
part (µg/ml) S9- S9+ 
Watsonia densiflora C 
5000 23.7 ± 1.9 29.7 ± 3.7 
500 20.3 ± 0.7 32.3 ± 2.3 
50 19.3 ± 3.7 33.3 ± 2.2 
Zanthoxylum capense R 
5000 19.7 ± 4.3 22.3 ± 3.3 
500 21.7 ± 3.3 30.7 ± 3.7 
50 21.3 ± 1.0 24.3 ± 1.2 
Imbiza ephuzwato  
5000 22.0 ± 0.9 227.7 ± 23.1 
500 24.0 ± 1.6 71.5 ± 5.5 
50 19.7 ± 1.2 45.3 ± 1.8 
4-NQO   2 208.0 ± 0.6  
2-AA  2 31.3 ± 1.7 218.0 ± 13.4 
Water   22.0 ± 1.6 25.3 ± 1.0 
 
B- bulbs; C- corms; L- leaves; R- roots; Rh- rhizomes; WP- whole plant. 
 
Number of His+ revertants/plate: mean values of three triplicates, the assay was 
repeated two times. 
 
S9- refers to assay without metabolic activation; S9+ refers to assay with metabolic 
activation. 
 
4-NQO; 4-nitroquinoline-oxide, positive control for the S9- assays. 2-AA;  
2-aminoathracene, positive control for S9+ assays and water was used as a negative 
control. 
 
Values in bold represents plant extracts/herbal mixture with mutagenic activity. 
 
Table 4.5: continued 
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The results obtained here offer supporting evidence for the safe use of these water 
extracts. However, more confirmatory tests using other assays and/or in vivo tests 
are still required. Studies aimed at investigating the effects of the interactions that 





The plant species used to make Imbiza ephuzwato were investigated for their 
individual pharmacological properties. Extracts (PE, DCM, EtOH and water) of the 
plants were evaluated against two Gram-positive and two Gram-negative bacteria, 
Candida albicans, inhibitory effects against COX-1 and -2 as well as AChE enzymes. 
Gunnera perpensa and Rubia cordifolia were the only plant species used to 
manufacture Imbiza ephuzwato that had water extracts which showed good 
antibacterial activity. The extracts of Gunnera perpensa (EtOH), Hypericum 
aethiopicum (DCM) and Urginea physodes (EtOH) showed the best antifungal 
activity. The water extracts of Hypericum aethiopicum, Gunnera perpensa, Drimia 
robusta, Vitellariopsis marginata, Scadoxus puniceus and Momordica balsamina 
showed percentage inhibition of COX-1 that was over 70%. For COX-2 enzyme, the 
water extracts of Gunnera perpensa, Cyrtanthus obliquus, Momordica balsamina 
and Tetradenia riparia exhibited inhibitory activity above 70%. Water extracts of 
Gunnera perpensa, Cyrtanthus obliquus, Vitellariopsis marginata, Asclepias fruticosa 
and Watsonia densiflora showed good AChE inhibitory activity (> 80%). The 
observed activities of the plant extracts (especially Gunnera perpensa water extract) 
justify their inclusion in the makeup of Imbiza ephuzwato herbal mixture as well as 
their use in ATM. The high activities in some of the plant species also validates the 
claimed medicinal properties listed on the Imbiza ephuzwato’s label. Several 
biological potent compounds have already been isolated from several of the 21 plant 
species used to manufacture Imbiza ephuzwato. Further studies aimed at 
investigating possible synergistic effects are much needed.  
 
The Ames test results revealed that all the water extracts of the 21 plant species 
used to make Imbiza ephuzwato were non-mutagenic towards the Salmonella 
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typhimurium strains TA98 for the assay with and without S9 metabolic activation. To 
the contrary, Imbiza ephuzwato showed mutagenic effects after exposure to the S9 
enzyme mix. The observed mutagenicity in Imbiza ephuzwato could be as a result of 
interaction of biomolecules in the heterogeneous mixture, yielding compounds that 
are converted to mutagenic agents by xenobiotic metabolizing enzymes. It is 
therefore important to carry out further studies aimed at identifying the mutagenic 
compounds in the heterogeneous mixture.  
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CHAPTER 5  
General Conclusions 
 
Humans have relied on plants for their basic needs including medicine, food, clothing 
and shelter for centuries. Plants are used for additional purposes such as poisons, 
ritualistic purposes associated with magic, religion and culture, stimulants for 
endurance and for appetite suppression. The plant chemicals responsible are mostly 
the secondary metabolites, which are classified into three major groups namely 
alkaloids, terpenoids and phenolics (SALIM et al., 2008). In South Africa, recent 
developments, most likely due to urbanisation, have resulted in a proliferation of 
commercial herbal preparations, most notable are the liquid preparations of plant 
material from several species that are sold in informal street markets, herbal (muthi) 
shops, supermarkets as well as some pharmacies. 
 
Fourteen herbal preparations commonly sold in Pietermaritzburg were tested for 
their pharmacological properties. The commercial preparations, regardless of their 
uses, were tested for antibacterial, antifungal and anthelmintic effects, the ability to 
inhibit two COX isoenzymes (COX-1 and -2), HIV-1 RT, AChE enzymes as well as 
for their antioxidant potentials. Apart from pharmacological tests, the fourteen herbal 
preparations were also subjected to phytochemical analysis to detect phenolic 
compounds including total phenolics, hydrolysable tannin, condensed tannin and 
flavonoids. TLC was used to profile the chemical composition of the fourteen herbal 
mixtures. Lastly, the fourteen herbal preparations were tested for their cytotoxic and 
mutagenic effects. 
 
Three of the fourteen herbal preparations (Imbiza ephuzwato, IbhubeziTM and Sejeso 
herbal mixture Ingwe®) showed good activity against the Bacillus subtilis, 
Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae strains tested. 
Hence these products can be successfully used to treat these bacterial infections. 
The rest of the preparations had moderate to low antibacterial activity. Seven 
products (Lion izifozonke, Imbiza ephuzwato, Ingwe® special muti, Sejeso herbal 
mixture, Vusa umzimba, IbhubeziTM and Supreme one hundred) of all those 
indicated for treating fungal infections and skin conditions showed good activity 
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against Candida albicans. These seven products also exhibited a fungistatic 
characteristic which is undesirable for good antifungal drugs. Sejeso herbal mixture 
Ingwe®, Imbiza ephuzwato, Ingwe® muthi mixture, Lion izifozonke Ingwe® and 
African potato extractTM exhibited good anthelmintic activity. The rest of the herbal 
preparations showed low activity against Candida albicans with Stameta™ 
BODicare® and Vusa umzimba showing poor activity. 
 
Based on IC50 values, Imbiza ephuzwato, Sejeso herbal mixture Ingwe
®, Lion 
izifozonke Ingwe®, Ingwe® muthi mixture and African potato extractTM showed 
consistent potent activities against the four enzymes (COX-1, COX-2, RT and AChE) 
used in this study. The observed activities, though they were mainly moderate 
especially for Lion izifozonke Ingwe® and Ingwe® muthi mixture, validates the use of 
these herbal preparations in treating pain related conditions, eradicating HIV/AIDS 
symptoms and easing mental conditions. 
 
Umzimba omubi, Umuthi wekukhwehlela ne zilonda, Mvusa ukunzi, Umpatisa inkosi, 
Imbiza ephuzwato, Vusa umzimba, Supreme one hundred, Sejeso herbal mixture 
Ingwe® and Ingwe® special muti exhibited high antioxidant properties. Phytochemical 
analysis revealed high total phenolic compounds, gallotannins and condensed 
tannins and lower levels of flavonoids in Ingwe® special muti, Ibhubezi™ and 
Stameta™ BODicare®. Surprisingly, these three herbal preparations were not active 
in most bioassays except for Ingwe® special muti which showed moderate activity 
against COX-1 and AChE. On the other hand, Imbiza ephuzwato exhibited high 
flavonoid concentrations and less total phenolic compounds, condensed tannin and 
gallotannin. This suggests that it is the quality rather than quantity of phenolic 
compounds that matters in terms of pharmacological properties. Thin layer 
chromatography (TLC) was used to investigate the chemical profiles of each of the 
fourteen herbal preparations. It was not surprising to note that Ingwe® muthi mixture, 
Sejeso herbal mixture Ingwe®, Lion izifozonke and Ingwe® special muti showed 
similar chemical profiles as shown by their TLC profiles. This implies that this 
particular manufacture is most likely using the same or similar combinations of plants 






The neutral red uptake inhibition bioassay in human liver (HepG2) cells was used to 
assess potential toxicity of the commercial herbal preparations. The results revealed 
that the most toxic herbal mixture was Umpatisa inkosi, with an NI50 value of 0.016 
mg/ml and a yield of 2.2 X 10-4 mg/ml residues which implies that 72.72 ml of the 
herbal mixture will result in the stated NI50 value. The least toxic herbal preparation 
was Stameta™ BODicare® with an NI50 value of 28.00 mg/ml and a yield of 1.8 x 10
-4 
mg/ml which implies that 115.56 litres of the mixture is required to reach the NI50 
value of the mixture. 
 
The standard plate incorporation test methods for the Ames test using Salmonella 
typhimurium tester strains TA98, TA100, TA102, TA1535 and TA1537 exposed to 
three dilutions with and without S9 metabolic activation of the herbal mixtures was 
performed to test for mutagenic effects of the fourteen herbal mixtures. The results 
revealed that all fourteen herbal preparations were non-mutagenic towards the 
Salmonella typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 without 
metabolic activation. However, five of the fourteen herbal mixtures (Umpatisa inkosi, 
Imbiza ephuzwato, Vusa umzimba, Stameta™ BODicare® and African potato 
extractTM) showed indirect mutagenic effect toward the tester strain TA98 after 
metabolic activation but not in the other tester strains (TA100, TA102, TA1535 and 
TA1537). The herbal mixtures could contain various aromatic nitroso-derivatives of 
amine carcinogens that have been shown to cause such a reversion of hisD3052 
mutation back to the wild-type state. Some carcinogenic compounds such as 
aromatic amines or polycyclic aromatic hydrocarbons like benzo-[a]-pyrene are 
biologically inactive unless they are metabolized to active forms. 
 
The observed activity exhibited by some of the herbal mixtures gives some credence 
to the manufacturers‟ claims and goes part of the way to validating their use against 
certain conditions such as microbial infections, pain and some mental conditions. 
Activity cannot be ruled out in the herbal preparations that showed poor/low activity 
as they could have different mechanisms of action that were not tested in this study. 
Furthermore, in traditional medicine, people seldom weigh the plant material when 
making decoctions or infusions and they may use more of the plant material which 
could result in consumption of higher doses of active compounds. Another point 
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which is often overlooked is that traditionally prepared decoctions are only crudely 
filtered, resulting in a considerable amount of particulate matter. This is often 
consumed by the user. However, in most laboratory tests extracts are general 
filtered to remove all solid materials. Little is know about the physiological 
contribution of ingested solids inconjuction with traditional herbal preparations. It can 
be assumed that these are partially or totally digested and absorbed and thus may 
elicit physiological responses. 
 
It is desirable to carry out further studies to determine the effects of mixing plant 
species/parts in one mixture as well as to try to isolate active constituents. The 
observed cytotoxic and mutagenic effects against TA98 after S9 metabolic activation 
of Umpatisa inkosi, Imbiza ephuzwato, African potato extractTM, Vusa umzimba and 
Stameta™ BODicare® raises concerns as to the safety of these herbal products. At 
present the contents of most of the mixture are not known. Further investigation and 
confirmation needs to be done with the objective of determining and hopefully 
eliminate the source of the observed cytotoxic and mutagenic effects. This will 
remain a challenge as it is difficult to convince the herbalist to reveal their ingredients 
as well as the recipes of their products. These herbal preparations are produced 
commercially by private entrepreneurs who guard their recipes in fear of competition 
and they consider themselves holding unofficial patents. 
 
The 21 plant species used to make Imbiza ephuzwato herbal mixture were each 
investigated for their pharmacological properties. PE, DCM, EtOH and water extracts 
of the 21 plants were evaluated against two Gram-positive and two Gram-negative 
bacteria, Candida albicans, inhibitory effects against COX-1 and -2 as well as AChE 
enzymes. Gunnera perpensa and Rubia cordifolia were the only plant species used 
to manufacture Imbiza ephuzwato that had water extracts which showed good 
antibacterial activity. The extracts of Gunnera perpensa (EtOH), Hypericum 
aethiopicum (DCM) and Urginea physodes (EtOH) showed the best antifungal 
activity. The water extracts of Hypericum aethiopicum, Gunnera perpensa, Drimia 
robusta, Vitellariopsis marginata, Scadoxus puniceus and Momordica balsamina 
showed percentage inhibition of COX-1 that was over 70%. For COX-2 enzyme, the 
water extracts of Gunnera perpensa, Cyrtanthus obliquus, Momordica balsamina 
and Tetradenia riparia exhibited inhibitory activity above 70%. Water extracts of 
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Gunnera perpensa, Cyrtanthus obliquus, Vitellariopsis marginata, Asclepias fruticosa 
and Watsonia densiflora showed good AChE inhibitory activity (> 80%). The 
observed activities of the plant extracts (especially Gunnera perpensa water extract) 
justify their inclusion in the makeup of Imbiza ephuzwato herbal mixture as well as 
their use in ATM. The high activities in some of the plant species also validates the 
claimed medicinal properties listed on Imbiza ephuzwato’s label. Several biologically 
potent compounds have already been isolated from several of the 21 plant species 
used to manufacture Imbiza ephuzwato. Further studies aimed at investigating 
possible synergistic effects as a result of mixing plant extracts are much needed.  
 
The Ames test results revealed that all the water extracts of the 21 plant species 
used to make Imbiza ephuzwato were non-mutagenic towards the Salmonella 
typhimurium strains TA98 for the assay with and without S9 metabolic activation. To 
the contrary, Imbiza ephuzwato showed mutagenic effects after exposure to S9 
enzyme mix. The observed mutagenicity in Imbiza ephuzwato could be as a result of 
interaction of biomolecules in the heterogeneous mixture, yielding compounds that 
are converted to mutagenic agents by xenobiotic metabolizing enzymes. It is 
therefore important to carry out further studies aimed at identifying and eliminating 
the sources of the mutagenic compounds in the heterogeneous mixture.  
 
The results obtained in this study reveal high levels of pharmacological activities by 
most of the herbal mixtures, in some cases providing scientific validation for their 
use. It can therefore be concluded that these herbal mixtures represents an 
important component of traditional medicine, not just a money making business. The 
results also offer a stepping stone towards the documentation of commercial herbal 
mixtures and information to policy makers on the way towards regulating the 
manufacturing and validation of herbal/natural products. The modernization and 
acceptance of herbal mixtures into mainstream medical practice will depend on the 
outputs of scientific research aimed at providing the rational for their usage. In this 







ALIGIANNIS, N., KALPOTZAKIS, E., MITAKU, S. and CHINOU, I.B. 2001. 
Composition and antimicrobial activity of the essential oils of two Origanum 
species. Journal of Agricultural and Food Chemistry 40, 4168-4170. 
AMAROWICZ, R., PEGG, R. B., RAHIMI-MOGHADDAM, P., BARL, B. and WEIL, 
J. A. 2004. Free radical scavenging capacity and antioxidant activity of 
selected plant species from the Canadian prairies. Food Chemistry 84: 551-
562.  
AMES, B.W. and GOLD, L.S. 2000. Paracelsus to parascience: The environmental 
cancer distribution. Mutation Research 447: 3-13. 
ASENSIO, V., KILLE, P., MORGAN, A.J., SOTO, M. and MARIGOMEZ, I. 2007. 
Metallothionein expression and Neutral Red uptake as biomarkers of metal 
exposure and effect in Eisenia fetida and Lumbricus terrestris exposed to Cd. 
European Journal of Soil Biology 43: 233-238. 
ASHAR, B.H. and DOBS, A.S. 2004. Clinical Trials for Herbal Extracts. In Packer, L, 
Ong, C.N. and Halliwell, B. (Eds.). Herbal and Traditional Medicine: Molecular 
aspects of health.  Marcel Decker, New York. 
ASHFORTH, A. 2005. Muthi, Medicine and Witchcraft: Regulating „African Science‟ 
in Post-Apartheid South Africa? Social Dynamics 31: 211-242 
BARILE, F.A. 1994. Introduction to in vitro Cytotoxicology. CRC Press, New York. 
BECKER, E.M., NISSEN, L.R. and SKIBSTED, L. 2004. Antioxidant evaluation 
protocols: Food quality or health effects. European Food Research 
Technology 219: 561-571. 
BEHNKE, J.M., BUTTLE, D.J., STEPEK, G., LOWE, A.E. and DUCE, I.R. 2008. 
Developing novel anthelmintics from plant cysteine proteinases. Parasite and 
Vectors 1: 29-32. 
BESSONG, P.O., OBI, C.L., ANDRÉOLA, M.L., ROJAS, L.B., POUYSEGU, L., 
IGUMBOR, E., MEYER, J.J.M., QUIDEAU, S. and LITVAK, S. 2005. 
Evaluation of selected South African medicinal plants for inhibitory properties 
against human immunodeficiency virus type 1 reverse transcriptase and 
integrase. Journal of Ethnopharmacology 99: 83-91. 
BEVERIDGE, T.J. and DAVIES, J.A. 1983. Cellular responses of Bacillus subtilis 
and Escherichia coli to the Gram stain. Journal of bacteriology 156: 846-58. 
159 
 
BODEKER, G. 2004. Integrating Traditional and Complementary Medicine into 
National Health Care: learning from the international experience. In Packer, 
L., Ong, C.N. and Halliwell, B. (Eds.). Herbal traditional medicine: Molecular 
aspects. Marcel Dekker, New York. 
BONORA, F. 2001. The Modernity/Traditional Interface amongst Urban Black South 
Africans: An Investigation of the Current Themes. MSc Thesis, University of 
South Africa, Johannesburg. 
BORENFREUND, E. and PUERNER, J.A. 1985. Toxicity determination in vitro by 
morphological alterations and neutral red absorption. Toxicology Letters 24: 
119-124. 
BRENDLER, T. and VAN WYK, B.-E. 2008. A historical, scientific and commercial 
perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). 
Journal of Ethnopharmacology 119: 420-433. 
BROOKES, K.B. and DUTTON, M.F. 2007. Bioactive components of the uteroactive 
medicinal plant, Gunnera perpensa (or Ugobo). South African Journal of 
Science 103: 187-189. 
BULMER, A.C., RIED, K., COOMBES, J.S., BLANCHFIELD, J.T., TOTH, I. and 
WAGNER, K.-H. 2007. The anti-mutagenic and antioxidant effects of bile 
pigments in the Ames Salmonella test. Mutation Research 629: 122-132. 
CANO, J.H. and VOLPATO, G. 2004. Herbal mixtures in the traditional medicine of 
Eastern Cuba. Journal of Ethnopharmacology 90: 293-316. 
CARIÑO-CORTÉS, R., HERNÁNDEZ-CERUELOS, A., TORRES-VALENCIA, J.M., 
GONZÁLEZ-AVILA, M., ARRIAGA-ALBA, M. and MADRIGAL-BUJAIDAR, 
E. 2007. Antimutagenicity of Stevia pilosa and Stevia eupatoria evaluated with 
the Ames test. Toxicology In Vitro 21: 691-697. 
CARMONA, M.D., LLORACH, R., OBON, C. and RIVERA, D. 2005. „Zahraa‟, a 
multicomponent herbal tea widely consumed in Syria: components of drug 
mixtures and alleged medicinal properties. Journal of Ethnopharmacology 
102: 244-350. 
CASTELL, J.V. and GÓMEZ-LECHÓN, M.J. 1996. In Vitro Methods in 
Pharmaceutical Research. Academic Press, London. 
CHAITOW, L. 1996. Candida albicans. Harper Collins Publishers. California. 
CHAVUNDUKA, G.L. 1994. Traditional Medicine in Morden Zimbabwe. University of 
Zimbabwe Press, Harare. 
160 
 
CHERDSHEWASART, W., SUTJIT, W., PULCHAROEN, K., PANRIANSAEN, R. 
and CHULASIRI, M. 2008. Antimutagenic potential of the Thai herb, Mucuna 
collettii Lace. Journal of Ethnopharmacology 115: 96-103. 
CHRISTENSEN, L.P. and BRANDT, K. 2006. Acetylenes and Psoralens. In Crozier, 
A., Clifford, M.N. and Ashihara, H. (Eds.). Plant Secondary Metabolites. 
Blackwell Publishing Ltd. Oxford. 
CHUKWUJEKWU, J.C., SMITH, P., COOMBES, P.H., MULHOLLAND, D.A. and 
VAN STADEN J. 2005. Antiplasmodial diterpenoid from the leaves of Hyptis 
suaveolens. Journal of Ethnopharmacology 102: 295-297. 
COPELAND, R.A. 2005. Evaluation of Enzyme Inhibitors in drug Discovery: A guide 
for medicinal chemists and pharmacologists. Wiley-Intescience, New Jersey. 
CROZIER, A., JAGANATH, I.B. and CLIFFORD, M.N. 2006. Phenols, polyphenols 
and Tannins: an overview. In Crozier, A., Clifford, M.N. and Ashihara, H. 
(Eds.). Plant Secondary Metabolites. Blackwell Publishing Ltd. Oxford. 
DAUSKARDT, R.P.A. 1990. The changing geography of traditional medicine: Urban 
herbalism on the Witwatersrand, South Africa. Geo-Journal 22: 275-283. 
DAVIES, J.A., ANDERSON, G.K., BEVERIDGE, T.J. and CLARK, H.C. 1983. 
Chemical mechanism of the Gram stain and synthesis of a new electron-
opaque marker for electron microscopy which replaces the iodine mordant of 
the stain. Journal of bacteriology 156: 837-45. 
DE JONG, J. 1991. Traditional Medicine in Sub-Saharan Africa: its importance and 
potential policy options. Report for Word Bank, Washington. 
DÉCIGA-CAMPOS, M., RIVERO-CRUZ, I., ARRIAGA-ALBA, M., CASTAÑEDA-
CORRAL, G., ANGELES-LÓPEZ, G.E., NAVARRETE, A. and MATA, R. 
2007. Acute toxicity and mutagenic activity of Mexican plants used in 
traditional medicine. Journal of Ethnopharmacology 110: 334-342. 
DE CLERCQ, E. 2009. Anti-HIV drugs: 25 compounds approved within 25 years 
after discovery of HIV. International Journal of Antimicrobial Agents 33: 307-
320. 
DEPARTMENT OF HEALTH. 1965 amended in 2002. Medicines and Related 
Substances Control Act 101 of 1965 after amendment by the Medicines and 
Related Substances Control Act. Pretoria. 
DOLD, A.P. and COCKS, M.L. 2002. The trade in medicinal plants in the Eastern 
Cape province, South Africa. South African Journal of Science 98: 589-597. 
161 
 
DOUGLAS, M. 1999. Sorcery accusations unleashed: The Lele revisited, 1987. 
Journal of the International African Institute 69: 177-193. 
DRAFT NATIONAL POLICY ON ATMSA. 2008. The Draft National Policy on 
African Traditional Medicine in South Africa. Government Gazette No. 31271: 
2-27. 
ELGORASHI, E.E., COOMBES, P.H., MULHOLLAND, D.A. and VAN STADEN, J. 
2007. Isoeugenitol, a cyclooxygenase-1 inhibitor from Gethyllis ciliaris. South 
African Journal of Botany 73: 156-158. 
ELGORASHI, E.E., DREWES, S.E. and VAN STADEN, J. 2001. Alkaloids from 
Crinum moorei. Phytochemistry 56: 637-640. 
ELGORASHI, E.E., TAYLOR, J.L.S., MAES, A., VAN STADEN, J., DE KIMPE, N. 
and VERSCHAEVE, L. 2003. Screening of medicinal plants used in South 
African traditional medicine for genotoxic effects. Toxicology Letters 143: 195-
207. 
ELLMAN, G.L., COUTNEY, D., ANDIES, V. and FEATHERSTONE, R.M. 1961. A 
new and rapid colourimetric determination of acetylcholinesterase activity. 
Biochemical Pharmacology 7: 88-95. 
ELOFF, J.N. 1998. A sensitive and quick microplate method to determine the 
minimal inhibitory concentration of plant extracts for bacteria. Planta Medica 
64: 711-713. 
ESQUIVEL, M., KNÜPFFER, H. and HAMMER, K. 1992. Inventory of the Cultivated 
Plants. In Hammer, K. Esquivel, M. and Knüpffer H. (Eds.). Origin, Evolution 
and Diversity of Cuban Plant Genetic Resources, Vol. 2, Institut für 
Pflanzengenetik und Kulturpflanzenforschung, Gatersleben, Germany. 
FARNSWORTH, N. R. 1993. Ethnopharmacology and future drug development: The 
North American experience. Journal of Ethnopharmacology 16: 63-97.  
FENNELL, C.W., LINDSEY, K.L., McGAW, L.J., SPARG, S.G., STAFFORD, G.I., 
ELGORASHI, E.E., GRACE, O.M. and VAN STADEN. J. 2004. Assessing 
African medicinal plants for efficacy and safety: pharmacological screening 
and toxicology. Journal of Ethnopharmacology 94: 205-217. 
FERREIRA, A., PROENÇA, C., SERRALHEIRO, M.L.M. and ARAÚJO, M.E.M. 
2006. The in vitro screening for acetylcholinesterase inhibition and antioxidant 




FRANKLIN, D. and LOWY, M.D. 1998. Staphylococcus aureus infections. The New 
England Journal of Medicine 339: 520-532. 
FRAWELY, D and LAD, V. 1986. The Yoga of Herbs: an ayurvedic guide to herbal 
medicine. Lotus Press, Twin Lakes. 
GILANI, A.H. and RAHMAN, A. 2005. Trends in ethnopharmacology. Journal of 
Ethnopharmacology 100: 43-49. 
GRAYBILL, J.R. 1996. The future of antifungal therapy. Clinical Infectious Diseases 
22: 166-178. 
HAGERMAN, A.E. 2002. Tannin Chemistry. Miami University, USA. 
HALLIWELL, B. 2004. Traditional Chinese Medicine: problems and drawbacks. In 
Packer, L., Ong, C.N. and Halliwell, B. (Eds.). Herbal traditional medicine: 
Molecular aspects. Marcel Dekker, New York. 
HANSEN, W.R., KEELAN, J.A., SKINNER, S.J.M., and MITCHELL, M.D. 1999. 
Key enzymes of prostaglandin biosynthesis and metabolism. Coordinate 
regulation of expression by cytokines in gestational tissues: A review. 
Prostaglandins and other Lipid Mediators 57: 243-257. 
HARBORNE, J. B. 1998. Phytochemical Methods: A guide to modern techniques of 
plant analysis, 3rd ed, Chapman and Hall, London. 
HARBORNE, J.B. 1994. The Flavonoids: Advances in Research since 1986. 
Chapman and Hall, London. 
HARDON, A., DESCLAUX, A., EGROT, M., SIMON, E., MICOLLIER, E. and 
KYAKUWA, M. 2008. Alternative medicines for AIDS in resource-poor 
settings: Insights from exploratory anthropological studies in Asia and Africa. 
Journal of Ethnobiology and Ethnomedicine 4: 16-16. 
HOUGHTON, P.J., HOWES, M.-J., LEE, C.C. and STEVENTON, G. 2007. Uses 
and abuses of in vitro tests in ethnopharmacology: Visualizing an elephant. 
Journal of Ethnopharmacology 110: 391-400. 
HUTCHINGS, A., SCOTT, A.H., LEWIS, G. and CUNNINGHAM, A. 1996. Zulu 
Medicinal Plants: An Inventory. University of Natal Press, Pietermaritzburg. 
JÄGER, A.K., HUTCHINGS, A. and VAN STADEN, J. 1996. Screening of Zulu 
medicinal plants for prostaglandins-synthesis inhibitors. Journal of 
Ethnopharmacology 52: 95-100. 
163 
 
JAMES, C. and DAVEY, M. 2007. A rapid colourimetric assay for the quantitation of 
the viability of free-living larvae of nematodes in vitro. Parasitology Research 
101: 975-980. 
JOHNS, T. 1990. The Origins of Human Diet and Medicine. Chemical Ecology. The 
University of Arizona Press, Arizona. 
JOVANOVIC, S.V., STEENKEN, S., TOSIC, M., MARJANOVIC, B. and SIMIC, 
M.G. 1994. Flavonoids as antioxidants. Journal of American Chemical Society 
116: 4846-4851. 
KAHN, L.P. and DIAZ-HERNANDEZ, A. 2000. Tannins with anthelmintic properties. 
In Brooker, J.D. (Ed.). Tannins in Livestock and Human Nutrition. Australian 
Centre for International Agricultural Research Proceedings 92: 130-139. 
KALE R. 1995. Traditional healers in South Africa: a parallel health care system. 
British Medical Journal 310: 1182-1185. 
KARIM, A.S.S., ZIQUBU-PAGE, T.T. and ARENDSE, R. 1994. Bridging the gap: 
Potential for health care partnership between African traditional healers and 
biomedical personnel in South Africa. Report of the South African Medical 
Research Council. South African Medical Journal Insert, December 1994. 
KARIOTI, A., HADJIPAVLOU-LITINA, D., MENSAH, M. L. K., FLEISCHER, T. C., 
and SALTSA, H. 2004. Composition and antioxidant activity of the essential 
oils of Xylopia aethiopica (Dun) A. Rich. (Annonaceae) leaves, stem bark, root 
bark, and fresh and dried fruits, growing in Ghana. Journal of Agricultural and 
Food Chemistry 52: 8094-8098. 
KATALINIC, V., MODUN, D., MUSIC, I. and BOBAN, M. 2005. Gender differences 
in antioxidant capacity of rat tissues determined by 2,2-azinobis  
(3-ethylbenzothiazoline 6-sulfonate; ABTS) and ferric reducing antioxidant 
power (FRAP) assays. Comparative Biochemistry and Physiology 140: 47-52. 
KEITH, C.T., BORISY, A.A. and STOCKWELL, B.R. 2005. Multicomponent 
therapeutics for networked systems. Nature Reviews Drug Discovery 4:  
71-78. 
KIM, J.H., RHEE, H.I., JUNG, I.H., RYU, K.H., JUNG, K., HAN, C.K., KWAK, W.J., 
CHO, Y.B. and JOO, H.J. 2005. SKI306X, an oriental herbal mixture, 
suppresses gastric leukotriene B4 synthesis without causing mucosal injury 
and the diclofenac-induced gastric lesions. Life Sciences 77: 1181-1193. 
164 
 
KING, R.A. 2000. The Role of Polyphenols in Human Health. In Brooker, J.D. (Ed.). 
Tannins in Live Stock and Human Nutrition. Proceedings of an International 
Workshop, Adelaide, Australia. Australian Centre for International Agricultural 
Research Proceedings 92: 75-81. 
KONG, D.E., LI, X.J. and Zhang, H.Y. 2009. Where is the hope for drug discovery? 
Let history tell the future. Drug discovery today 14: 115-119. 
KRISHNAN, A. 2009. Herbal remedy for A(H1N1) flu in China. URL 
http://www.thehindu.com/2009/07/24/stories/2009072455271300.htm, 
(27/07/09). 
KUDA, T., TSUNEKAWA, M., GOTO, H. and ARAKI, Y. 2005. Antioxidant 
properties of four edible algae harvested in the Noto Peninsula, Japan. 
Journal of Food Composition and Analysis 18: 625-633. 
LEE, N.J., CHOI, J.H., KOO, B.S., RYU, S.Y., HAN, Y.H., LEE, S.I. and LEE, D.U. 
2005. Antimutagenicity and cytotoxicity of the constituents from the aerial 
parts of Rumex acetosa. Biological and Pharmaceutical Bulletin 28: 2158-
2161. 
LEE, S.K.W., WONG, C.K., SUNG, R.Y.T., LEUNG, T.F., FUNG, K.P., LEUNG, 
P.C. and LAM, C.W.K. 2006. In vitro anti-allergic activities of a newly 
concocted traditional Chinese medicine- the Wheeze-relief formula. Journal of 
Ethnopharmacology 103: 406-412. 
LERNER, S.A. 1998. Clinical impact of antibiotic resistance. In Rosen, B.P. and 
Mobashery, S. (Eds.). Resolving the antibiotic paradox. Progress in 
understanding drug resistance and development of new antibiotics. Plenum 
Publishers, London. 
LEUNG, P.C. 2004. Can Traditional Medicine Coexist with Modern Medicine in the 
Same Health Care System? In Packer, L., Ong, C.N. and Halliwell, B. (Eds.). 
Herbal traditional medicine: Molecular aspects. Marcel Dekker, New York. 
LIM, T. Y., LIM, Y. Y. and YULE, C. M. 2009. Evaluation of antioxidant, antibacterial 
and anti-tyrosinase activities of four Macaranga species. Food Chemistry 114: 
594-599. 
LIN, H.Q., HO, M.T., LAU, L.S., WONG, K.K., SHAW, P.C. and WAN, D.C.C. 2008. 
Anti-acetylcholinesterase activities of traditional Chinese medicine for treating 
Alzheimer‟s disease. Chemico-Biological Interactions 175: 352-354. 
165 
 
LIU, H.-H. 2005. History of Application of Medicinal plants in China. In Yaniv, Z. and 
Bachrach, U. (Eds.). Handbook of Medicinal Plants. The Haworth press, Inc., 
New York. 
LUSEBA, D., ELGORASHI, E.E., NTLOEDIBE, D.T. and VAN STADEN, J. 2007. 
Antibacterial, anti-inflammatory and mutagenic effects of some medicinal 
plants used in South Africa for treatment of wounds and retained placenta in 
livestock. South African Journal of Botany 73: 378-383. 
MAKKAR, H.P.S. 1999. Quantification of Tannins in Tree Foliage: A laboratory 
manual for the FAO/IAEA Co-ordinated Research project on 'Use of nuclear 
and Related Techniques to Develop Simple Tannin Assay for Predicting and 
Improving the Safety and Efficiency of Feeding Ruminants on the 
Tanniniferous Tree Foliage. Joint FAO/IAEA Division of Nuclear Techniques 
in Food and Agriculture, Vienna. 
MAKKAR, H.P.S. 2003. Quantification of Tannins in Tree and Shrub Foliage: A 
laboratory manual. Kluwer Academic Publishers. Dordrecht. 
MAKKAR, H.P.S., SIDDHURAJU, P. and BECKER, K. 2007. Plant Secondary 
Metabolites. Humana Press, New Jersey. 
MANDER, M. 1998. Marketing of Indigenous Medicinal Plants in South Africa a Case 
Study in KwaZulu-Natal. Food and Agriculture Organization of the United 
Nations, Rome. 
MANDER, M., NTULI, L., DIEDERICHS, N. and MAVUNDLA, K. 2007. Economics 
of the Traditional Medicine Trade in South Africa. In Harrison, S., Bhana, R. 
and Ntuli, A. (Eds.). South African Health Review. Health Systems Trust, 
Pretoria. 
MARON, D.M. and AMES, B.N. 1983. Revised methods for the Salmonella 
mutagenicity test. Mutation Research 113: 173-215. 
MARSLAND, R. 2007. The Modern Traditional Healer: Locating 'Hybridity' in modern 
traditional medicine, southern Tanzania. Journal of Southern African Studies 
33: 751-765. 
MASOKO, P., PICARD, J. and ELOFF, J.N. 2007. The antifungal activity of twenty-
four southern Africa Combretum species (Combretaceae). South African 
Journal of Botany 73: 173-183. 
166 
 
MATHUR, N., BHATNAGAR, P., MOHAN, K., BAKRE, P., NAGAR, P. and 
BIJARNIA, M. 2007. Mutagenicity evaluation of industrial sludge from 
common effluent treatment plant. Chemosphere 67: 1229-1235. 
McGAW, L.J., JÄGER, A.K. and VAN STADEN, J. 1997. Prostaglandin synthesis 
inhibitory activity in Zulu, Xhosa and Sotho medicinal plants. Phytotherapy 
Research 11: 113-17. 
McINTYRE, M. 1998. Chinese herbs: risks, side effects, and poisoning: the case for 
objective reporting and analysis reveals serious misinterpretation. Journal of 
Alternative and Complementary Medicine 4: 15-17. 
MILLS, E., RACHLIS, B., WU, P., WONG, E. and WILSON, K. 2005. Media 
reporting of tenofovir trials in Cambodia and Cameroon. BioMed Central 
International Health and Human Rights 5: 6-6. 
MITHEN, R. 2006. Sulphur-containing Compounds. In Crozier, A., Clifford, M.N. and 
Ashihara, H. (Eds.). Plant Secondary Metabolites. Blackwell Publishing Ltd. 
Oxford. 
MORITA, I. 2002. Distinct functions of COX-1 and COX-2. Prostaglandins and other 
Lipid Mediators 69: 165-175. 
MORTELMANS, K. and ZEIGER, E. 2000. The Ames Salmonella/microsome 
mutagenicity assay. Mutation Research 455: 29-60. 
MUELLER-HARVEY, I. 2001. Analysis of hydrolysable tannins. Animal Feed 
Science and Technology 91: 3-20. 
NAKAMA, A., KURODA, K. and YAMADA, A. 1995. Induction of cytochrome p450-
dependent monooxygenase in serum-free cultured Hep G2 cells. Biochemical 
Pharmacology 50: 1407-1412. 
NATIONAL RED LIST OF SOUTH AFRICAN PLANTS. 2001. International Union 
for the Conservation of Nature and Natural Resources (IUCN) Categories and 
Criteria version 3.1. SANBI 2009. 
NCHIDA, T.C. 1976. Traditional and western medicine in Africa: collaboration or 
confrontation. Tropical Doctor 6: 133-133. 
NDHLALA, A.R., KASIYAMHURU, A., MUPURE, C., CHITINDINGU, K., 
BENHURA, M.A. and MUCHUWETI, M. 2007. Phenolic composition of 
Flacourtia indica, Opuntia megacantha and Sclerocarya birrea. Food 
Chemistry 103: 82-87. 
167 
 
NDHLALA, A.R., MUCHUWETI, M., MUPURE, C., CHITINDINGU, K., MURENJE, 
T., KASIYAMHURU, A. and BENHURA, M.A. 2008. Phenolic content and 
profiles of selected wild fruits of Zimbabwe: Ximenia caffra, Artobotrys 
brachypetalus and Syzygium cordatum. International Journal of Food Science 
and Technology 43: 1333-1337. 
NEUWINGER, H.D. 1996. African Ethnobotany: Poisons and Drugs: Chemistry, 
Pharmacology, Toxicology. Chapman and Hall, Germany. 
NOREEN, Y., RINGBORM, T., PERERA, P., DANIELSON, H. and BOHLIN, L. 
1998. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay 
for identification of natural products as inhibitors of prostaglandin 
biosynthesis. Journal of Natural Products 61: 2-7. 
OATES, J.F. 1978. Water-plant and soil consumption by guereza monkeys (Colobus 
guereza): A relationship with minerals and toxins in the diet. Biotropica 10: 
241-253. 
ONG, E.S., YONG, Y.L. and WOO, S.O. 1999. Determination of arsenic in traditional 
Chinese medicine by microwave digestion with flow injection-inductively 
coupled plasma mass spectrometry (FI-ICP-MS). Journal of American Oil 
Society 82: 903-937. 
ORHAN, I., KARTAL, M., ABU-ASAKER, SEZER, M., ŞENOL, F.S., YILMAZ, G. 
and ŞENER, B.S. 2009. Free radical scavenging properties and phenolic 
characterization of some edible plants. Food Chemistry 114: 276-281. 
PAGE, C.P., CURTIS, M.J., SUTTER, M.C., WALKER, M.J.A. and HOFFMAN, 
B.B. 1997. Integrated Pharmacology. Mosby. 
PATWARDHAN, B. 2005. Ethnopharmacology and drug discovery. Journal of 
Ethnopharmacology 100: 50-52. 
PEDERSEN, M.M., CHUKWUJEKWU, J.C., LATEGAN, C.A., VAN STADEN, J., 
SMITH, P.J. and STAERK, D. 2009. Antimalarial sesquiterpene lactones from 
Distephanus angulifolius. Phytochemistry 70: 601-607. 
POLAK, A. 1999. Past, present and future of antimycotic combination therapy. 
Mycoses 42: 355-370. 
POLYA, G. 2003. Biochemical Targets of Plant Bioactive Compounds: A 




POOLEY, E. 1998. A field guide to wild flowers of KwaZulu-Natal and the Eastern 
Region. Natal Flora Publications Trust, Durban.  
PORTER, L.J., HRSTICH, L.N. and CHAN, B.G. 1985. The conversion of 
procyanidins to cyaniding and delphinidin. Phytochemistry 25: 223-230. 
PRETORIUS, E., DE KLERK, G.W. and VAN RENSBURG, H.C.J. 1993. The 
Traditional Healer in South African Heath Care. Human Science Research 
Council, Pretoria. 
PUJOL, J. 1990. The Herbalist Handbook: African flora, medicinal plants. 
NaturAfrica, Durban. 
RABE, T. and VAN STADEN, J. 1997. Antibacterial activity of South African plants 
used for medicinal purposes. Journal of Ethnopharmacology 56: 81-87. 
RAJ, S.R., BLACK, B.K., BIAGGIONI, I., HARRIS AND P.A. and ROBERTSON, D. 
2005. Acetylcholinesterase inhibition improves tachycardia in Postural 
Tachycardia Syndrome. Journal of the American Heart Association 111: 2734-
2740. 
RAPPAPORT, H. 1980. The Integration of Scientific and Traditional Healing: the 
problem of demystification, in traditional health care delivery in contemporary 
Africa. In Ulin, P.R. and Segall, M.H. (Eds.). Traditional Health Care Delivery 
in Contemporary Africa. Foreighn and Comparative studies/Africa series xxxv. 
Maxwell, Syracuse University, New York. 
RATES, S.M.K. 2001. Plants as source of drugs. Toxicon 39: 603-613. 
REID, K.A., MAES, J., MAES, A., VAN STADEN, J., DE KIMPE, N., 
MULHOLLAND, D.A. and VERSCHAEVE, L. 2006. Evaluation of the 
mutagenic and antimutagenic effects of South African plants. Journal of 
Ethnopharmacology 106: 44-50. 
REPETTO, G., DEL PESO, A. and ZURITA, J.L. 2008. Neutral red uptake assay for 
the estimation of cell viability/cytotoxicity. Nature Protocols 3: 1125-1131. 
RIOS, J.L., RECIO, M.C. and VILLAR, A. 1988. Screening methods for natural 
products with antimicrobial activity: A review of the literature. Journal of 
Ethnopharmacology 23: 127-149. 
ROMANO, C.S., ABADI, K., REPETTO, V., VOJNOV, A.A. and MORENO, S. 2009. 
Synergistic antioxidant and antibacterial activity of rosemary plus butylated 
derivatives. Food Chemistry 115: 456-461. 
169 
 
RYAN, K.J. and RAY, C.G. 2004. Sherris Medical Microbiology 4th ed. McGraw Hill, 
London. 
SALIM, A.A., CHIN, Y.-W. and KINGHORN, A.D. 2008. Drug discovery from Plants. 
In Ramawat, K.G., Merillon, J.M. (Eds.). Bioactive molecules and medicinal 
plants. Spinger, Berlin. 
SERGEDIENE, E., JONSSON, K., SZYMUSIAK, H., TYRAKOWSKA, B., 
RIETJENS, I.M.C.M. and CENAS, N. 1999. Prooxidant toxicity of 
polyphenolic antioxidants to HL-60 cells: description of quantitative structure-
activity relationships. Federation of European Biochemical Societies (FEBS) 
letters 462: 392-396. 
SHEN, Z., CHAUSER-VOLFSON, E., HU, Z. and GUTTERMAN, Y. 2001. Leaf age, 
position and anatomical influences on the distribution of the secondary 
metabolites, homonataloin and three isomers of aloeresin in Aloe hereroensis 
(Aloaceae) leaves. South African Journal of Botany 67: 312-319. 
SHERIFFS, P. 1996. Truths and tradition. Femina 113: 62-65. 
SIDDHURAJU, P. and BECKER, K. 2007. The antioxidant and free radical 
scavenging activities of processed cowpea (Vigna unguiculata (L.) Walp.) 
seed extracts. Food Chemistry 101: 10-19. 
SLEIGH, J.D. and TIMBURY M.C. 1998. Medicinal Bacteriology. Churchill 
Livingstone, Edinburgh. 
SPALLAROSSA, A., CESARINI, S., RANISE, A., BRUNO, O., SCHENONE, S., 
COLLA, P.L., COLLU, G., SANNA, G., SECCI, B. and LODDO, R. 2009. 
Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted 
thiocarbamates and their ring opened congeners as non-nucleoside HIV-1 
reverse transcriptase inhibitors. European Journal of Medicinal Chemistry 44: 
1650-1663. 
SPANGENBURG, B. 2008. Derivatization, Detection (Quantification) and 
Identification of compounds online. In Waksmundzka-Hajnos, M., Sherma, J. 
and Kowalska, T. (Eds.). Thin layer chromatography in phytochemistry. 
Chromatographic Sciences Series 99. CRC Press, New York. 
STAFFORD, G.I., ALMQVIST, J.P., VANGSØE, S.A.K., OLSEN, H.T., 
CHRISTENSEN, S.B., ADSERSEN, A., JÄGER, A.K. and VAN STADEN, J. 
2007. Mild psychoactive constituents of Mentha aquatica L. South African 
Journal of Botany 74: 389. 
170 
 
STAFFORD, G.I., PEDERSEN, M.E., VAN STADEN, J. and JÄGER, A.K. 2008. 
Review on plants with CNS-effects used in traditional South African medicine 
against mental diseases. Journal of Ethnopharmacology 119: 513-537. 
STEENKAMP, P.A., HARDING, N.M., VAN HEERDEN, F.R. and VAN WYK, B.-E. 
2006. Identification of atractyloside by LC–ESI–MS in alleged herbal 
poisonings. Forensic Science International 163: 81-92. 
STREET, R.A., STIRK, W.A. and VAN STADEN, J. 2008. South African traditional 
medicinal plant trade- Challenges in regulating quality, safety and efficacy. 
Journal of Ethnopharmacology 119: 705-710. 
SUPPRESSION OF WITCHCRAFT ACT No. 3. 1957. Government Gazette 
GG05827 1957/02/22. 
TANKO, H., CARRIER, D.A., DUAN, L. and CLAUSEN, E. 2005. Pre- and post-
harvest processing of medicinal plants. Plant Genetic Resources 3: 304-313. 
TAYLOR, J.L.S. and VAN STADEN, J. 2001. COX-1 inhibitory activity in extracts 
from Eucomis L‟Herit. species. Journal of Ethnopharmacology 75: 257-265. 
TERREBLANCHE, C. 2003. HIV warning on African potato. Article originally 
published on page 4 of Daily News, July 15, 2003, South Africa. 
TINSLEY, J. 1999. The hazards of psychotropic herbs. Minnesota Medicine 82: 29-
31. 
VALLI, G. and GIARDINA, E.-G. 2002. Benefits, adverse effects and drug 
interactions of herbal therapies with cardiovascular effects. Journal of the 
American College of Cardiology 39: 1083-1095. 
VAN VUUREN, S.F. 2008. Antimicrobial activity of South African medicinal plants. 
Journal of Ethnopharmacology 119: 462-472. 
VAN VUUREN, S.F. SULIMAN, S. DHORAT, S. and VILJOEN, A.M. 2007. The 
pharmacological interaction of commercial essential oils in combination with 
conventional antimicrobials. South African Journal of Botany 73: 339-340. 
VAN WYK, B.-E., VAN OUDTSHOORN, B. and GERICKE, N. 1997. Medicinal 
Plants of South Africa. Briza Publications, Pretoria.  
VAN WYK, B.-E., VAN HEERDEN, F.R. and VAN OUDTSHOORN, B. 2002. 
Poisonous Plants of South Africa. Briza Publications, Pretoria. 
VERSCHAEVE, L. and VAN STADEN, J. 2008. Mutagenic and antimutagenic 
properties of extracts from South African traditional medicinal plants. Journal 
of Ethnopharmacology 119: 575-587. 
171 
 
VERSCHAEVE, L., KESTENS, V., TAYLOR, J.L. S., ELGORASHI, E.E., MAES, A., 
VAN PUYVELDE, L., DE KIMPE, N. and VAN STADEN, J. 2004. 
Investigation of the antimutagenic effects of selected South African medicinal 
plant extracts. Toxicology in Vitro 18: 29-35. 
VOET, D. and VOET, J.G. 1995. Biochemistry. 3rd ed. John Wiley and Sons, New 
York. 
WAFFO-TÉGUO, P., KRISA, S., RICHARD, T. and MÉRILLON, J. M. 2008. 
Bioactive Molecules and Medicinal plants. In Ramawat, K. G. and Mérillon, J. 
M. (Eds.). Springer-Verlag GmbH, Berlin. 
WAGNER, H., BLADT, S. and ZGAINSKI, E.M. 1984. Plant Drug Analysis: A Thin 
Layer Chromatoghraphy Atlas. Springer-Verlag, Berlin. 
WANG, Q., DING, Z.-H., LIU, J.-K. and ZHENG, Y.-T. 2004. Xanthohumol, a novel 
anti-HIV-1 agent purified from Hops Humulus lupulus. Antiviral Research 64: 
189-194. 
WHO. 2001. Legal Status of Traditional Medicine and Complementary/Alternative 
Medicine: A Worldwide Review. Geneva: World Health Organization, 2001. 
URL: http://whqlibdoc.who.int/hq/2001/WHO_EDM_TRM_2001.2.pdf.  
WOLSKI, T. and GLOWNIAK, K. 2003. Plant-Derived Extracts and Preparations as 
Antimycotics. In Rai, M. and Mares, D. (Eds.). Plant-Derived Antimycotics: 
Current trends and  future prospects. The Haworth Press, Inc. New York. 
YEH, S.L. and HU, M.L. 2001. Induction of oxidative DNA damage in human 
foreskin fibroblast Hs68 cells by oxidative β-carotene and lycopene. Free 
Radical Research 35: 203-213. 
YEH, P. and KISHONY, R. 2007. Networks from drug-drug surfaces. Molecular 
Systems Biology 3: 85-87. 
YONG, E.L. and LOH, Y.S. 2004. Herbal Medicine: Criteria for use in health and 
disease. In Packer, L., Ong, C.N. and Halliwell, B. (Eds.). Herbal traditional 
medicine: Molecular aspects. Marcel Dekker, New York. 
ZACCHINO, S.A., YUNES, R.A., FILHO, V.C. ENRIZ, R.D., KOUZNETSOV, V. and 
RIBAS, J.C. 2003. The Need for New Antifungal drugs: Screening for 
antifungal compounds with selective mode of action with emphasis on 
inhibitors of the fungal cell wall. In Rai, M. and Mares, D. (Eds.). Plant-Derived 




ZHANG, M.G. 1993. Brief History of Pharmaceutical Development. China Medico-
Pharmaceutical Science and Technology Publishing House, Beijing. 
ZSCHOCKE, S. and VAN STADEN, J. 2000. Cryptocarya species-substitute plants 
for Ocotea bullata? A pharmacological investigation in terms of 
cyclooxygenase-1 and -2 inhibitions. Journal of Ethnopharmacology 71:  
473-478. 
